Clinical trial NCT03078075
Conditions: Methamphetamine Use Disorder
Keywords: Methamphetamine Methamphetamine Use Disorder Naltrexone Bupropion Vivitrol®
Sponsor: University of Texas Southwestern Medical Center
Start date: 2017-05-05; Completion date: 2019-07-25
Enrollment: 403 participants; Allocation: RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.

Detailed description:
There will be 400 adults with moderate or severe methamphetamine use disorder randomized into this multi-site study. Eligibility will be determined during a maximum 21 day screening period. After screening is completed and eligibility is confirmed, including successful administration of a naloxone challenge, participants will begin the 12 week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release naltrexone (XR-NTX; as Vivitrol®) plus once-daily oral extended-release bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) arm and receive injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. During the course of the study, participants may be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. Injections will be administered every three weeks, in weeks 1, 4, 7, and 10. Take-home oral study medication (BUP-XL or oPLB) will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend the clinic twice weekly for observed oral medication dosing, assessments, collection of urine samples, and once-weekly medical management. On non-clinic days, participants will participate in smartphone app-based medication adherence activities. Participants will be asked to complete assessments as indicated on the schedule of assessments. Following the 12 week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during weeks 13 and 16.

Arms: arm 1: injectable extended release naltrexone plus once daily oral extended-release bupropion tablets arm 2: injectable matching placebo plus once-daily oral placebo tablets
Interventions: intervention 1: Naltrexone: Vivitrol® intervention 2: Placebo (PLB) Injectable intervention 3: Bupropion: Wellbutrin XL® intervention 4: Placebo (PLB) Oral
Intervention descriptions: intervention 1: Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks intervention 2: Placebo: 4 intramuscular injections administered every 3 weeks intervention 3: Bupropion: 450 mg oral dose daily intervention 4: Placebo: once-daily oral placebo tablets

Protocol documents:
ICF_002.pdf: 
 
 
NCT03078075 
 
INFORMED CONSENT FORM 
 
Title: NIDA CTN-0068 Accelerated Development of 
Additive Pharmacotherapy Treatment (ADAPT-2) for 
Methamphetamine Use Disorder 
IRB# STU062016-077 
Date: December 19, 2018 
 

















































Prot_000.pdf: 
 
 
NCT03078075 
 
PROTOCOL 
 
Title: NIDA CTN-0068 Accelerated Development of 
Additive Pharmacotherapy Treatment (ADAPT-2) for 
Methamphetamine Use Disorder 
Version 6.0 
Date: January 31, 2019 
 


 
 
NIDA CTN Protocol 0068 
Accelerated Development of Additive 
Pharmacotherapy Treatment (ADAPT-2) 
for Methamphetamine Use Disorder 
 
 
 
Lead Investigator (LI): Madhukar Trivedi, MD 
 
 
 
Version 6.0 
 
January 31, 2019 
 
 
Details regarding the timing of re-randomization and related statistical analysis (as it 
contains information about the timing of re-randomization) are omitted from the 
Protocol to protect the double blind. These details are contained in the confidential 
Statistical Analysis Plan. The Lead Team will provide the Statistical Analysis Plan 
directly to the site Institutional Review Board(s) or Independent Ethics Committee. 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
1 
 
PROTOCOL DEVELOPMENT TEAM 
 
 
Lead Investigator: 
Madhukar Trivedi, MD  
 
Texas Node 
 
University of Texas Southwestern Medical Center 
 
Co-Lead Investigator & 
Robrina Walker, PhD 
Project Director: 
Texas Node 
 
University of Texas Southwestern Medical Center 
 
Co-Investigators: 
Walter Ling, MD 
 
Adriane de la Cruz, MD, PhD 
 
Protocol Development Team: 
Linda Chang, MD 
 
Mora Kim, MPH 
 
CCTN Project Coordinators: 
Udi Ghitza, PhD 
 
National Institute on Drug Abuse 
 
 
Petra Jacobs, MD 
 
National Institute on Drug Abuse 
 
Clinical Coordinating Center: 
Robert Lindblad, MD 
 
CCC Principal Investigator 
 
 
Eve Jelstrom, CRNA, MBA 
 
CCC Co-Principal Investigator 
 
 
Prashanth Parmar, MS 
 
Protocol Specialist 
 
Data Coordinating Center:  
Paul Van Veldhuisen, PhD 
 
DSC Principal Investigator 
 
 
 
Gaurav Sharma, PhD 
 
DSC Statistician 
 
 
Lauren Yesko 
 
DSC Project Manager 
 
 
Ashley Case 
 
DSC Data Manager 
 
 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
3 
TABLE OF CONTENTS 
 
1.0 
LIST OF ABBREVIATIONS ............................................................................................ 7 
2.0 
SCHEMA ......................................................................................................................... 8 
3.0 
SYNOPSIS ...................................................................................................................... 9 
4.0 
BACKGROUND AND RATIONALE .............................................................................. 11 
4.1 
Background ............................................................................................................... 11 
4.1.1 
Treatment of Stimulant Use Disorder (Amphetamine-type) with Naltrexone ....... 11 
4.1.2 
Figure 1. Percentages of Urine Samples Negative for MA ................................. 12 
4.1.3 
Treatment of Stimulant Use Disorder (Amphetamine-type) with Bupropion ........ 13 
4.1.4 
Figure 2. Abstinence for the last two weeks among non-daily MA users ............ 15 
4.1.5 
Figure 3. Weekly Abstinence Rates for Light Users versus Heavy Users ........... 15 
4.2 
Study Rationale ......................................................................................................... 16 
4.3 
Significance of the Project to the Field ...................................................................... 17 
5.0 
OBJECTIVES ................................................................................................................ 18 
5.1 
Primary Objectives .................................................................................................... 18 
5.2 
Secondary Objectives ............................................................................................... 18 
6.0 
DESIGN ........................................................................................................................ 19 
6.1 
Overview of Study Design ......................................................................................... 19 
6.2 
Duration of Study and Clinic Visit Schedule............................................................... 19 
6.3 
Participant Selection ................................................................................................. 20 
6.3.1 
Inclusion Criteria ................................................................................................ 20 
6.3.2 
Exclusion Criteria ............................................................................................... 21 
6.4 
Site Selection ............................................................................................................ 22 
6.4.1 
Site Characteristics ............................................................................................ 22 
6.4.2 
Rationale for Site Selection ................................................................................ 23 
6.5 
Randomization Plan .................................................................................................. 23 
6.6 
Study Intervention ..................................................................................................... 23 
6.7 
Outcome Measures ................................................................................................... 24 
6.7.1 
Primary Efficacy Outcome Measure ................................................................... 24 
6.7.2 
Primary Safety Outcome Measure ..................................................................... 24 
6.7.3 
Secondary Outcome Measures .......................................................................... 24 
7.0 
PROCEDURES ............................................................................................................. 26 
7.1 
Screening and Baseline Phase ................................................................................. 26 
7.1.1 
Pre-screening Assessment ................................................................................ 26 
7.1.2 
Informed Consent .............................................................................................. 26 
7.1.3 
Screening and Baseline Assessments ............................................................... 26 
7.1.4 
Naltrexone Pre-Induction Strategy ..................................................................... 27 
7.1.5 
Final Confirmation of Eligibility ........................................................................... 28 
7.2 
Medication Phase...................................................................................................... 28 
7.2.1 
Randomization ................................................................................................... 28 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
4 
7.2.2 
Pharmacotherapy............................................................................................... 28 
7.2.3 
Medical Management ......................................................................................... 29 
7.2.4 
Medication Adherence ....................................................................................... 29 
7.2.5 
Participant Medication Withdrawal ..................................................................... 29 
7.2.6 
Medication Phase Visits ..................................................................................... 31 
7.3 
Follow-up Phase ....................................................................................................... 31 
7.3.1 
Oral Study Medication Taper.............................................................................. 31 
7.3.2 
Post-Medication Phase Follow-up Visits ............................................................ 31 
7.4 
Study Medication Management/Drug Accountability .................................................. 31 
7.4.1 
Documentation ................................................................................................... 31 
7.4.2 
Storage .............................................................................................................. 31 
7.4.3 
Packaging .......................................................................................................... 32 
7.4.4 
Ordering and Dispensing ................................................................................... 33 
7.4.5 
Used/Unused Medication ................................................................................... 33 
7.4.6 
Lost Medication .................................................................................................. 33 
7.4.7 
Maintaining and Breaking Blind .......................................................................... 33 
7.5 
Participant Compensation ......................................................................................... 34 
7.5.1 
Table 1. Compensation Schedule ...................................................................... 34 
8.0 
ASSESSMENTS ........................................................................................................... 36 
8.1 
Table 2. Schedule of Assessments ........................................................................... 37 
8.2 
Screening Measures ................................................................................................. 38 
8.2.1 
Pre-Screening Interview Form............................................................................ 38 
8.2.2 
Informed Consent .............................................................................................. 38 
8.2.3 
Demographics Form .......................................................................................... 38 
8.2.4 
Alcohol and Substance Use History ................................................................... 38 
8.2.5 
DSM-5 Checklist ................................................................................................ 38 
8.2.6 
Psychiatric Diagnostic Screening Questionnaire ................................................ 38 
8.2.7 
Self-Report of HIV Testing ................................................................................. 38 
8.2.8 
Medical and Psychiatric History ......................................................................... 39 
8.3 
Safety Measures ....................................................................................................... 39 
8.3.1 
Physical Examination ......................................................................................... 39 
8.3.2 
Electrocardiogram (ECG) ................................................................................... 39 
8.3.3 
Injection Site Examination .................................................................................. 39 
8.3.4 
Injection Site Abnormality Log ............................................................................ 39 
8.3.5 
Clinical Laboratory Tests .................................................................................... 39 
8.3.6 
Concise Health Risk Tracking - Participant Rated Module ................................. 40 
8.3.7 
Pregnancy and Birth Control Assessment .......................................................... 40 
8.3.8 
Vital Signs .......................................................................................................... 40 
8.3.9 
Prior and Concomitant Medications ................................................................... 40 
8.3.10 
Adverse Events (AEs) and Serious Adverse Events (SAEs) .............................. 40 
8.3.11 
Naloxone Challenge Form ................................................................................. 41 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
5 
8.4 
Efficacy Measures ..................................................................................................... 41 
8.4.1 
Urine Drug Screen ............................................................................................. 41 
8.4.2 
Timeline Followback .......................................................................................... 41 
8.4.3 
Visual Analog Craving Scale .............................................................................. 42 
8.4.4 
Patient Health Questionnaire-9 .......................................................................... 42 
8.4.5 
Treatment Effectiveness Assessment ................................................................ 42 
8.4.6 
Tobacco Use History .......................................................................................... 42 
8.4.7 
Quality of Life ..................................................................................................... 42 
8.4.8 
Sexual Risk Behaviors ....................................................................................... 42 
8.4.9 
Genetic Sampling............................................................................................... 42 
8.5 
Adherence Measures ................................................................................................ 43 
8.5.1 
Study Medication Dosing Logs ........................................................................... 43 
8.5.2 
Injection Administration Form ............................................................................. 43 
8.5.3 
Oral Medication Dispensation Form ................................................................... 43 
8.5.4 
Oral Study Medication Blood Levels................................................................... 43 
8.5.5 
Video Based Adherence to Oral Study Medication Database ............................. 43 
8.5.6 
End of Medication Form ..................................................................................... 43 
8.6 
Administrative and Other Forms ................................................................................ 44 
8.6.1 
Locator Form ..................................................................................................... 44 
8.6.2 
Eligibility - Randomization .................................................................................. 44 
8.6.3 
Missed Visit Form .............................................................................................. 44 
8.6.4 
Protocol Deviation Form ..................................................................................... 44 
8.6.5 
Protocol Satisfaction Surveys............................................................................. 44 
8.6.6 
Study Completion Form ..................................................................................... 44 
9.0 
TRAINING ..................................................................................................................... 45 
10.0 
STATISTICAL ANALYSES ........................................................................................... 46 
10.1 
General Design ......................................................................................................... 46 
10.1.1 
Study Hypothesis ............................................................................................... 46 
10.1.2 
Sample Size ....................................................................................................... 46 
10.1.3 
Primary Outcomes ............................................................................................. 46 
10.1.4 
Secondary Outcomes ........................................................................................ 46 
10.2 
Interim Analyses ....................................................................................................... 47 
10.2.1 
Sample Size Re-estimation ................................................................................ 47 
10.2.2 
Interim Monitoring of Primary Efficacy Endpoint ................................................. 48 
10.2.3 
Safety Interim Analyses ..................................................................................... 48 
10.2.4 
Conditional Power and Futility ............................................................................ 48 
10.3 
Demographic and Baseline Characteristics ............................................................... 49 
10.4 
Description of Plans to Conduct Analyses of Study Results by Sex and 
Race/Ethnicity ........................................................................................................... 49 
10.5 
Safety Analysis ......................................................................................................... 49 
11.0 
REGULATORY COMPLIANCE, REPORTING AND MONITORING ............................. 50 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
6 
11.1 
Statement of Compliance .......................................................................................... 50 
11.2 
Institutional Review Board Approval .......................................................................... 50 
11.3 
Research Advisory Panel of California (California sites only) .................................... 50 
11.4 
Informed Consent...................................................................................................... 50 
11.5 
Health Insurance Portability Accountability Act (HIPAA) ............................................ 51 
11.6 
Investigator Assurances ............................................................................................ 51 
11.7 
Financial Disclosure .................................................................................................. 51 
11.8 
Confidentiality ........................................................................................................... 52 
11.9 
IND Requirements ..................................................................................................... 52 
11.10 Regulatory Files ........................................................................................................ 52 
11.11 Study Documentation ................................................................................................ 53 
11.12 Records Retention and Requirements ....................................................................... 53 
11.13 Reporting to Sponsor ................................................................................................ 53 
11.14 Safety Monitoring ...................................................................................................... 53 
11.14.1 
Adverse Events (AEs) ........................................................................................ 53 
11.14.2 
Definitions of Adverse Events and Serious Adverse Events ............................... 54 
11.14.3 
Reportable Adverse Events and Serious Adverse Events .................................. 54 
11.14.4 
Data and Safety Monitoring Board (DSMB) ........................................................ 54 
11.14.5 
Medical Monitor ................................................................................................. 54 
11.15 Protocol Deviations: Reporting and Management...................................................... 55 
11.16 Audits ........................................................................................................................ 55 
11.17 Quality Assurance Monitoring ................................................................................... 55 
12.0 
DATA MANAGEMENT AND PROCEDURES ............................................................... 57 
12.1 
Design and Development .......................................................................................... 57 
12.2 
Site Responsibilities .................................................................................................. 57 
12.3 
Data and Statistics Center Responsibilities ............................................................... 57 
12.4 
Data Collection and Entry .......................................................................................... 57 
12.5 
Data Monitoring, Cleaning, and Editing ..................................................................... 57 
12.6 
Database Transfer and Lock ..................................................................................... 58 
13.0 
PUBLICATIONS AND OTHER RIGHTS ....................................................................... 59 
14.0 
SIGNATURES ............................................................................................................... 60 
15.0 
REFERENCES .............................................................................................................. 61 
16.0 
APPENDIX A - Adverse Event Reporting Definitions and Procedures .................... 67 
17.0 
APPENDIX B - Data and Safety Monitoring Plan ....................................................... 71 
18.0 
APPENDIX C - Smartphone App-based Medication Adherence Procedures .......... 76 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
7 
1.0 
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse Event 
AMC 
Active Medication Combination 
ALP 
Alkaline Phosphatase 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Aminotransferase 
BL 
Blood levels of bupropion and/or metabolite 
BUP-XL 
Extended-release Bupropion  
CAP 
College of American Pathologists 
CCC 
Clinical Coordinating Center 
CCTN 
Center for the Clinical Trials Network 
CHRT 
Concise Health Risk Tracking 
CLIA 
Clinical Laboratory Improvement Amendment of 1988 
CNS 
Central Nervous System 
CRF 
Case Report Form 
CTN 
Clinical Trials Network 
DSC 
Data and Statistics Center 
DSMB 
Data and Safety Monitoring Board 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
eCRF 
Electronic Case Report Form 
ECG 
Electrocardiogram 
EDC 
Electronic Data Capture system/Advantage eClinical 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GGT 
Gamma-Glutamyl Transpeptidase 
HIV 
Human Immunodeficiency Virus  
ICH 
International Council on Harmonisation 
IM 
Intramuscular 
IRB 
Institutional Review Board 
IND 
Investigational New Drug 
iPLB 
Injectable Placebo 
LFT 
Liver Function Test 
LN 
Lead Node 
MA 
Methamphetamine 
Mg 
Milligrams 
NAL 
Naloxone 
NDA 
New Drug Application 
NIDA 
National Institute on Drug Abuse 
NIH 
National Institutes of Health 
oPLB 
Oral Placebo 
PCM 
Prior and Concomitant Medications 
PDSQ 
Psychiatric Diagnostic Screening Questionnaire 
PI 
Principal Investigator 
PLB 
Placebo Medication Combination 
RAP-C 
Research Advisory Panel of California 
SRB 
Sexual Risk Behaviors  
SAE 
Serious Adverse Event 
SOP 
Standard Operating Procedure 
TEA 
Treatment Effectiveness Assessment 
TES 
Treatment Effectiveness Score 
TLFB 
Timeline Followback 
UDS 
Urine Drug Screen 
VAS 
Visual Analog Scale 
XR-NTX 
Extended-Release Naltrexone (as Vivitrol®) 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
8 
2.0 
SCHEMA 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
9 
3.0 
SYNOPSIS 
STUDY OBJECTIVE: The primary objective of this study is to evaluate the efficacy of extended-
release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use 
disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and 
determining the efficacy of the combination pharmacotherapy on other substance use outcomes, 
on depression symptom scores, and on quality of life ratings. 
STUDY DESIGN: This is a double-blind, placebo-controlled, adaptive randomized clinical trial in 
which 400 individuals with moderate or severe methamphetamine use disorder will be randomly 
assigned to the 1) active medication combination (AMC) arm in which injections of extended-
release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended-release bupropion (BUP-
XL) tablets will be provided or the 2) matching placebo (PLB) arm in which injections of placebo 
(iPLB) and once daily oral placebo (oPLB) tablets will be provided. During the course of the study, 
participants may or may not be switched to another arm, as determined by the a priori adaptive 
aspect of the study design. Participants appearing to respond well to their original treatment 
assignment will not be switched. Overall, approximately 50% of the participants will receive the 
AMC. After establishing eligibility during a maximum 21-day screening period, participants will 
begin the 12-week medication phase. Randomization will be stratified by site. At the end of the 
12-week medication phase, participants will complete a follow-up phase, including an oral 
medication taper. Post-medication phase follow-up visits will occur during Weeks 13 and 16.  
STUDY PARTICIPANTS: The study sample consists of 400 males and non-pregnant, non-
lactating females, ages 18 to 65 years old, who have met all eligibility criteria, including DSM-5 
criteria for moderate or severe stimulant use disorder (methamphetamine type), who report using 
methamphetamine 18 or more days during the 30 days prior to signing consent, and who provide 
at least 2 methamphetamine-positive urine specimens during screening. Potential participants 
have up to 3 weeks to meet eligibility criteria after signing consent.  
INTERVENTION: The study intervention consists of a 12-week medication phase. Participants 
randomized to the AMC arm will receive injections of extended-release naltrexone (Vivitrol®) plus 
450 mg of once-daily oral extended-release bupropion tablets while participants randomized to 
the PLB arm will receive placebo injections plus once-daily oral placebo tablets. Injectable study 
medication will be administered every three weeks (weeks 1, 4, 7, and 10). Take-home oral study 
medication will be dispensed once weekly for dosing on non-clinic days. Once weekly medical 
management sessions with the study medical clinician will be provided. Medication adherence 
procedures will include smartphone app-based videos of daily dosing. Participants will be asked 
to attend clinic twice weekly for observed oral study medication dosing, collection of urine drug 
screening samples, and self-report assessments. Compensation will be provided for visit 
attendance and dosing adherence.  
ASSESSMENTS: Screening/baseline assessments include safety and medical measures 
including a medical and psychiatric history, a physical examination, clinical lab tests (blood 
chemistry, hematology, and urinalysis), 12-lead electrocardiogram, vital signs, and pregnancy 
tests (for females). Screening/baseline assessments also include psychological and drug use 
measures. Methamphetamine use outcome assessments include Urine Drug Screens (UDS), 
self-reported use via the Timeline Followback (TLFB), and Visual Analog Scale (VAS) craving 
scores. Other outcome assessments include UDS and TLFB (i.e., alcohol, tobacco, and/or illicit 
drugs), depression (Patient Health Questionnaire-9), quality of life (QOL), functioning (Treatment 
Effectiveness Assessment), and clinic attendance. Safety measures include monitoring vital 
signs, adverse events (AEs), concomitant medications, clinical lab results, and assessments of 
suicidality. Oral study medication adherence will be assessed by self-report, quantitative blood 
levels of bupropion and its primary metabolite, and smartphone app-based dosing confirmation 
procedures. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
10 
A blood sample for genetic analysis will be collected from randomized participants who consent 
to this procedure and the de-identified sample will be sent to a cell and DNA repository. 
ANALYSES: The primary analysis will evaluate the impact of the AMC arm, relative to PLB, on 
methamphetamine use. The primary efficacy outcome is a measurement of treatment response 
based on MA-negative urine drug screen results obtained during weeks 5 to 6 and weeks 11 to 
12 of the medication phase. Outcome variables will be analyzed using appropriate statistical 
methods for the intention-to-treat (ITT) population and for the evaluable population.  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
11 
4.0 
BACKGROUND AND RATIONALE 
4.1 
Background 
Many years of concerted efforts have produced no effective medication to help initiate and 
maintain abstinence from methamphetamine (MA). Several promising candidates have shown 
preliminary clinical utility, including bupropion and naltrexone (Elkashef et al., 2008; Jayaram-
Lindström et al., 2008b). Development of a safe and effective pharmacotherapy is an important 
objective with considerable public health significance.  
For many medical conditions, combinations of medications may be routine in clinical practice but 
are emerging only recently for methamphetamine pharmacotherapy. Well-publicized combination 
pharmacotherapy studies have tested combination medications for depression (CO-MED, Zisook 
et al., 2011; STAR-D, Trivedi et al., 2006) made possible by the availability of a number of 
medications approved for depression. Two notable attempts within the National Institute on Drug 
Abuse National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) include the Cocaine 
Use Reduction with Buprenorphine (CTN-0048 CURB) trial, a Vivitrol+Suboxone combination trial 
for cocaine dependence (Ling et al., 2016; Mooney et al., 2013), and the Accelerated 
Development of Additive Pharmacotherapy Treatment (CTN-0054 ADAPT) pilot trial completed 
in early 2015 that examined the combination pharmacotherapy naltrexone plus bupropion for MA 
use disorder in an open-label design (Mooney et al., 2016). Findings from the ADAPT pilot study 
provided a signal sufficient to advise the development of a fully powered, placebo-controlled study 
to test the efficacy of the combination in producing sustained abstinence from methamphetamine 
at the end of the study (see below). 
4.1.1 
Treatment of Stimulant Use Disorder (Amphetamine-type) with 
Naltrexone 
There is modest research to support the individual constituents of the combination 
pharmacotherapy of naltrexone and bupropion as a putative treatment for MA use disorder. 
Naltrexone mechanism of action: An early human laboratory study provided some evidence for 
modulation of the opioid system as the mechanism of action of naltrexone in its ability to reduce 
reinforcing effects of amphetamine (Jayaram-Lindström et al., 2005). Although not completely 
clear, the action of naltrexone that may work to reduce the reinforcing effects of alcohol and other 
drugs appears to derive from a blockade of effects of endogenous opioid peptides by occupation 
and binding of opioid receptors. A retrospective pooled data analysis of three studies examining 
alcohol dependent participants with single nucleotide polymorphism (SNP) A118G (heterozygous 
or homozygous) found that participants treated with naltrexone were substantially less likely to 
relapse (Oslin et al., 2003). However, one small randomized trial showed no difference in 
outcomes along this SNP (A118A vs. A118G) when prospectively assigning individuals to open-
label injectable naltrexone treatment for methamphetamine dependence (Pal et al., 2015). More 
recent controlled human laboratory data show that compared to placebo, steady state naltrexone 
at 50 mg per day significantly blunted cue-induced craving for methamphetamine and attenuated 
several of the hedonic subjective effects of methamphetamine, including craving, during 
administration of 30 mg IV methamphetamine challenge. Specifically, naltrexone decreased 
subjective ratings of "crave drug," "stimulated," and "would like drug access," decreased the post 
methamphetamine administration time course of "anxious," and increased ratings of "bad drug 
effects," as compared to placebo (Ray et al., 2015). There is no aversive response to 
administration of opioids or alcohol while naltrexone is present at clinical dosages. 
Efficacy of naltrexone in treating stimulant use disorders: A study conducted in Sweden 
(Jayaram-Lindström, 2008b) indicated that naltrexone reduced amphetamine use among human 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
12 
subjects, though this efficacy was tested only for patients who could achieve two weeks of 
abstinence during the baseline screening period. Previously, efficacy of naltrexone for stimulant 
use disorder was found by Schmitz et al. (2001), reporting cocaine use decreased over time 
among cocaine-dependent patients taking 50 mg oral naltrexone compared to placebo. A 
question persists as to whether similar reductions can be expected among polydrug users, as the 
same authors subsequently found no effect on drug use among a sample of alcohol- and cocaine-
dependent individuals treated with 50 mg/day (Schmitz et al., 2004). In contrast, Comer et al. 
(2006), in a study of combination opioid and stimulant abusers, found that cocaine use was 
reduced among the portion of the sample randomized to 384 mg of sustained-release naltrexone, 
virtually the same dosage of the extended-release formulation to be used in this protocol.  
Efficacy of naltrexone in treating amphetamine dependent individuals: The clinical data 
emerging from research examining oral naltrexone in amphetamine dependent humans in 
Sweden provide convincing rationale for the exploration of naltrexone for MA dependence. 
Jayaram-Lindström and colleagues (2005) established tolerability and feasibility of naltrexone in 
an open-label trial, finding mild and transient side effects (nausea, headache, abdominal pains) 
and documenting reduced frequency and quantity of amphetamine use during treatment than 
before naltrexone treatment. Furthermore, in a double-blind trial, the same Swedish group 
(Jayaram-Lindström et al., 2008a) found that naltrexone reduced subjective effects of 
amphetamine. Subsequent work (Jayaram-Lindström et al., 2008b) found that oral naltrexone 
was effective in suppressing relapse to stimulant use among individuals meeting DSM-IV criteria 
for amphetamine dependence. While the current study protocol was being developed, a double-
blind, randomized, placebo-controlled trial (NCT01449565) of the injectable form of naltrexone 
was being conducted in San Francisco among methamphetamine dependent men who have sex 
with men (Coffin et al., 2017). Participants were assigned to extended-release injectable 
naltrexone (n=50) or matched placebo (n=50), administered every 4 weeks for a 12-week period. 
All participants reduced their methamphetamine use, as evidenced by urine drug screens, during 
the primary outcome evaluation period of intervention weeks 2 to 12; however, there were no 
significant differences by intervention arm. Therefore, this recent study does not provide support 
for the clinical benefit of the use of naltrexone alone as a treatment for methamphetamine 
dependence in men who have sex with men and who use methamphetamine during sex. Notably, 
study participants had excellent medication adherence, which lends support to the acceptability 
and tolerability of this medication in a methamphetamine dependent sample.  
Figure 1, from Jayaram-Lindström et al. (2008b), shows percentages of urine samples negative 
for MA, presented in the figure on the left in the intention-to-treat sample—for the naltrexone group 
(diamonds) versus the placebo group (circles)—and for the completer group in the right figure. 
4.1.2 
Figure 1. Percentages of Urine Samples Negative for MA 
 
The rationale for including extended-release injectable naltrexone (XR-NTX) in the original CTN-
0054 trial was based on preclinical and clinical pharmacology, as well as on results of clinical 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
13 
trials using oral naltrexone in the treatment of amphetamine dependent individuals. Opiate 
antagonists, particularly naltrexone, have been shown to reduce amphetamine-induced dopamine 
release and amphetamine-induced locomotor activity in rats (Hitzemann et al., 1982), attenuate 
amphetamine-induced locomotor sensitization in rats (Haggkvist et al., 2011a), reduce cue-
induced reinstatement for MA in rats (Anggadiredja et al., 2004), block amphetamine-induced 
reinstatement of amphetamine self-administration in rats (Haggkvist et al., 2009), reduce the 
subjective effects of amphetamine in amphetamine-dependent patients (Jayaram-Lindström et 
al., 2008a), and prevent relapse to amphetamine in a double-blind, placebo-controlled trial 
(Jayaram-Lindström et al., 2008b). The progression of work logically extends from research on 
preclinical effects of opiate antagonists, to a clinical pharmacology demonstration of attenuation 
of amphetamine by naltrexone, to an outpatient efficacy study, then to the CTN-0054 combination 
medication trial on which the present trial is based.  
4.1.3 
Treatment of Stimulant Use Disorder (Amphetamine-type) with 
Bupropion 
Bupropion is an antidepressant with stimulant properties that has been proven effective for the 
treatment of nicotine dependence (Richmond & Zwar, 2003). The antidepressant effects of 
bupropion may be related to its noradrenergic and dopaminergic mechanisms of action. 
Bupropion has a favorable side effect profile: it causes fewer anticholinergic, cardiovascular, 
sedative or adverse sexual effects than tricyclics and does not cause weight gain (Bryant, 
Guernsy, & Ingram, 1983). Bupropion has been studied as an attractive candidate medication for 
the treatment of stimulant use disorder, which is associated with dopaminergic dysregulation that 
may contribute to craving and drug seeking. Restoration of dopamine deficit states, combined 
with bupropion’s ability to alleviate dysphoria observed in early abstinence from stimulants 
(Newton et al., 2004), may in turn reduce craving and help prevent relapse. 
Bupropion has been investigated as a treatment for cocaine use disorder. In a pilot study, Margolin 
et al. (1991) found that 300 mg/day bupropion substantially reduced cocaine use in four of the 
five cocaine-dependent, methadone-maintained patients, was well tolerated, and reduced self-
reported craving for cocaine. A multicenter placebo-controlled double-blind clinical trial of 
bupropion for cocaine dependence in methadone-maintained patients indicated efficacy of 
bupropion for the subgroup of patients with depression at study entry (Margolin et al., 1995). 
The results of preclinical studies designed to test the effectiveness of bupropion to block effects 
of MA support clinical use for the treatment of MA dependence (Kim et al., 2000). Bupropion 
provides complete protection against MA-induced decrease in dopamine uptake in the striatum in 
an in vitro model of MA-induced dopamine nerve terminal toxicity. The combination of bupropion’s 
dopaminergic activity and antidepressant properties may enhance its efficacy in the treatment 
and relief of the signs and symptoms of MA withdrawal and for reduction of relapse.  
In a Phase 1 double-blind inpatient clinical laboratory study, 26 subjects with a DSM-IV diagnosis 
of MA dependence or abuse were randomized to receive either twice-daily bupropion XL (150 mg 
twice daily) or placebo control and a series of 3 infusions of saline or MA. The first and second 
infusions were randomized to be either 0 mg or 15 mg of either saline or MA, and the last infusion 
was always 30 mg of saline or MA (Newton et al., 2006). Of the 26 subjects enrolled, 20 completed 
the entire study, with 10 subjects in each of the bupropion and placebo control groups. Bupropion 
treatment 
was 
associated 
with 
reduced 
ratings 
of 
“any 
drug 
effect”  
(p = 0.02), and “high” (p = 0.02) as assessed with visual analog scales following MA 
administration. Bupropion also significantly reduced cue-induced craving [General Craving Scale 
total score (p = 0.002); Behavioral Intention subscale (p = 0.001)] (Newton et al., 2006). Bupropion 
treatment was well tolerated, with the bupropion- and placebo-treated groups reporting similar 
rates of adverse events. MA administration was associated with expected stimulant 
cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
14 
was a trend for bupropion to reduce MA-associated blood pressure increases and a statistically 
significant reduction in MA-associated heart rate increases (Newton et al., 2005). 
Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of MA 
and lowered plasma concentrations of the metabolite amphetamine in the plasma (Newton et al., 
2005). MA administration did not alter the peak and trough plasma concentrations of bupropion 
or its metabolites.  
A NIDA Phase 2 efficacy study showed that bupropion significantly decreased MA use in MA-
dependent participants who were using MA 18 days or less in the 30-day period prior to the start 
of screening (Elkashef et al., 2008). This study was a double-blind, placebo-controlled, 
randomized, two-arm, parallel-group design comparing 150 mg of bupropion to placebo 
administered twice daily to MA dependent outpatients. Of the 151 participants in the ITT sample, 
121 were considered evaluable. Conclusions regarding the efficacy of bupropion include: 
 
Results of analysis of the primary outcome measure (weekly proportion of participants 
with all urine specimens free of MA) showed a trend, albeit statistically non-significant, 
favoring bupropion over placebo for the entire population (GEE, p = 0.09). 
 
Bupropion showed a statistically significant effect for MA-free weeks in participants who 
used MA <18 days in the 30 days prior to the start of screening (GEE, p = 0.03). 
 
A higher percentage of participants in the bupropion group than the placebo group 
reduced their proportion of MA use days to 50% or less of their baseline rate based on 
self-report only (Chi-square test, p = 0.02).  
 
Bupropion showed a statistically significant effect for MA-free weeks in males  
(GEE, p = 0.04). 
 
Bupropion showed a trend toward significance favoring bupropion for MA-free weeks in 
non-depressed participants (GEE, p = 0.08). 
 
Bupropion showed a statistically significant effect for MA-free weeks in participants 
without attention-deficit disorder (GEE, p = 0.02). 
Participants were randomized to receive thrice-weekly CBT and either 150 mg twice daily 
bupropion SR or placebo. Randomization was balanced by frequency of self-reported MA use in 
the 30 days prior to the start of screening based on two rates of use: 1) low-rate users had 18 or 
fewer days of MA use; and 2) high-rate users had 19 or more days of MA use. Of the ITT sample, 
47% were low-rate users and 53% were high-rate users. A GEE analysis performed on the 
primary outcome measure for each of these two study subpopulations as well as for the entire 
ITT sample showed that the low-rate use group administered bupropion had a statistically 
significant increase (GEE, p<0.04) in the slope of weekly proportion of participants with MA-
negative urines compared to the low-rate use group administered placebo. The high rate of MA 
use appears to reduce the bupropion effect when examining the entire study population. 
Figure 2 illustrates the frequency of abstinence over the last two weeks in non-daily MA users in 
the bupropion study, in which 15 of 63 subjects (23.8%) achieved abstinence as compared to 3 
of 53 (5.7%) in the placebo group. This finding was shown to be statistically significant (Chi-
square, p=0.01). Although there was a fairly high dropout rate over the course of the study 
(approximately 50% of the participants completed the study), it is important to note that there were 
no significant differences in the rate of dropout between the two groups. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
15 
4.1.4 
Figure 2. Abstinence for the last two weeks among non-daily MA 
users 
 
Abstinence Last 2 Weeks 
Group 
Fail (%) 
Success (%) 
Total 
Bupropion 
48 (76.2%) 
15 (23.8%) 
63 
Placebo 
50 (94.3%) 
3 (5.7%) 
53 
 
98 
18 
116 
 
P = 0.01 (Chi-Square test) 
 
Bupropion was well tolerated in this study. The only significant treatment emergent adverse event 
was nausea. Participants receiving bupropion had a significant increase (Chi-square, p=0.019) in 
the incidence of nausea over the intervention period. One participant (a 31-year-old female) in 
the bupropion group temporarily discontinued taking bupropion during the study due to an adverse 
event four weeks after commencing study drug, but the investigator determined that the adverse 
event was not related to the study drug. 
 
Figure 3 is from Elkashef et al., 2008, showing the relative effects on MA use comparing 
participants who had reported 18 days or less of use per month at baseline (“light users”) against 
participants who had used more than 18 days per month (“heavy users”). 
4.1.5 
Figure 3. Weekly Abstinence Rates for Light Users versus 
Heavy Users 
 
To conclude, this study suggested efficacy of bupropion only in participants who had used 
methamphetamine relatively infrequently at baseline. However, in the Mooney et al. (2016) study, 
the medication combination of once-daily 450 mg bupropion XL and extended-release injectable 
naltrexone resulted in a clinically-meaningful outcome in terms of proportion of methamphetamine 
dependent participants who met “responder” criteria. Unlike in the Elkashef et al. (2008) study, 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
16 
these “responders” were participants who had used methamphetamine frequently, having self-
reported at least 20 days of MA use in the 30 days prior to consent, and having submitted 3 MA-
positive urine drug screens out of 4 collected during screening. Thus, the 450 mg dose of 
bupropion XL used in the Mooney et al. (2016) trial merits further evaluation in a sufficiently 
powered, randomized, placebo-controlled trial. 
4.2 
Study Rationale 
Interest in the combination of naltrexone with other medications, especially with cognitive 
enhancers and anti-depressants (e.g., methylphenidate, bupropion, modafinil, mirtazepine), has 
increased. For example, “a formulation that combines naltrexone with methylphenidate could be 
a useful pharmaceutical approach to alleviate abuse potential of methylphenidate and other 
stimulants” (Zhu et al., 2011). The efficacy of naltrexone in reducing stimulant use has been 
empirically documented (Jayaram-Lindström et al., 2008b). Still, the medication is not wholly 
effective (e.g., Coffin et al., 2017), which is also true of another medication—bupropion—which 
has been extensively studied in trials for MA dependence. Bupropion has been found to be 
somewhat successful at reducing MA use in dependent patients but demonstrates an uneven 
response across patient types (e.g., many patients did not complete protocols, and participants 
assessed at baseline as high-frequency users did less well than low-frequency users).  
The rationale for combining bupropion and naltrexone, as examined in CTN-0054, is predicated 
on their potentially complementary effects as shown in clinical research and as postulated in 
mechanistic arguments for naltrexone (e.g., Hanson, 2004), for bupropion, which may involve 
noradrenergic and/or dopaminergic effects (e.g., Ascher et al., 1995; Newton et al., 2006), and 
for the combination, which could regulate the mesolimbic reward pathways (Ornellas & Chavez, 
2011). Anecdotal reports derived from research involving opioid addicts who also use stimulants 
(e.g., Comer et al., 2006) also substantiate the utility of naltrexone for reducing MA use. The 
combination of naltrexone and bupropion had also been studied in research on the efficacy of the 
combination pharmacotherapy for controlling obesity (e.g., Greenway et al., 2010; Wadden et al., 
2011) leading to the marketing of Contrave® for weight management. In a small (n = 7) clinical 
pharmacology trial, however, steady state naltrexone (50 mg per day), bupropion (300 mg per 
day), and their combination showed no statistically significant effect on behavioral responses or 
subjective effects following 0 mg, 10 mg or 30 mg intranasal methamphetamine (Stoops, Hays, 
Glaser, & Rush, 2015). 
Combination pharmacotherapy, whereby medications exerting effects on different mechanisms 
of action may complement each other to help reduce stimulant use and to prevent relapse to 
stimulant use once abstinence has been attained, can be conceived in three ways: (1) one 
medication may act to enable the effects of other medication(s) as in CTN-0048 where the effect 
of Vivitrol® allowed buprenorphine to exert the hypothesized therapeutic effect under 
investigation; (2) one medication may act to enhance therapeutic effects of another, including 
possibly reducing side effects, as in combining different opioids in clinical pain management; and 
(3) the two medications may synergistically exert their combined effects as a novel compound 
and be studied as a single test agent. In this protocol, bupropion may serve to ameliorate some 
of the anhedonia and dysphoria that characterize early-phase abstinence from MA, and it also 
may counteract some of the side effects associated with naltrexone.  
Some of the best evidence in support of this protocol is from the CTN-0054 pilot trial that was 
conducted as an open-label study of 49 participants at three sites in two CTN Nodes (Nexus 
Recovery Center, Inc., Texas Node; Integrated Substance Abuse Programs (ISAP) and University 
of Hawaii (UH), Pacific Region Node). Treatment-seeking, severe MA users (using an average of 
27 days out of the previous 30 prior to enrollment) were given bupropion XL (450 mg) daily and 
XR-NTX every 4 weeks for 8 weeks. Many procedures being proposed for this phase III RCT 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
17 
were developed and evaluated in the initial pilot trial, including collection of data regarding the 
tolerability and titration procedures for the 450 mg bupropion in the AMC condition. The intent-to-
treat (ITT) analysis in the pilot trial defined the primary efficacy endpoint as the number of 
responders, with responders defined as participants who provide at least 6 MA-negative UDS 
tests during the last four weeks of the active medication phase (weeks 5 – 8), including a MA-
negative UDS test at the last clinic visit in week 8. Out of 49 participants, 9 responders were 
required to indicate that the medication combination has sufficient potential efficacy to warrant a 
fully-powered phase III, placebo-controlled trial. Findings from the 49 participants included in the 
analysis of the primary efficacy endpoint indicated that 11 were responders, which met the a priori 
specified criterion requiring 9 or more responders (p = 0.0075). The unbiased estimate of the 
responder rate was 24%, and the 95% lower confidence limit was 13%. There were no significant 
site, sex, race or ethnicity differences by responder status. The responder rate was highest at the 
ISAP site (27.8%) and lowest at the Nexus site (15.8%). Seven (26.9%) males and 4 females 
(17.4%) were responders. Four (16.7%) whites and 7 others (4 multiracial and 3 others) were 
responders. Seven responders were not Hispanic or Latino, and 4 were Hispanic or Latino.  
These data were used to support development of the current phase III randomized, double-blind, 
placebo-controlled trial of this combination pharmacotherapy to produce abstinence for 
participants with methamphetamine use disorder. It is intended that participants randomized to 
the active medication arm receive the maximum safe dose of both bupropion and naltrexone to 
maximally enable them to become abstinent within the treatment phase of this study. The 
recommended dosing regimen of Vivitrol® is every four weeks; however, plasma levels of 
naltrexone and its metabolite are at a plateau during the first three weeks after administration but 
fall off in the fourth week. Replenishment of the depot supply of naltrexone at the beginning of the 
fourth week by re-injecting Vivitrol® should prevent that decline and allow evaluation of the 
maximum safe dose of the combination medication.  
4.3 
Significance of the Project to the Field 
Identifying an effective medication, or combination of medications, to help achieve abstinence 
and to prevent relapse to MA use is an important objective with considerable public health 
significance. The proposed placebo-controlled trial, based on preliminary evidence established in 
the CTN-0054 ADAPT pilot trial, will advance medication research and potentially confirm the 
naltrexone plus bupropion combination as the first effective pharmacotherapy for the treatment of 
stimulant use disorder involving MA. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
18 
5.0 
OBJECTIVES 
The objective of this study is to evaluate an active medication combination (AMC) that comprises 
extended-release naltrexone (XR-NTX) plus bupropion (BUP-XL) as a potential pharmacotherapy 
for methamphetamine use disorder. 
5.1 
Primary Objectives 
The primary objective of this study is to evaluate the efficacy of the AMC arm, compared to a 
matched placebo (PLB) arm, in reducing methamphetamine use in individuals with moderate or 
severe methamphetamine use disorder seeking to stop or reduce methamphetamine use. It is 
hypothesized that the AMC arm will be associated with a greater number of “responders,” defined 
as participants who provide a pre-specified number of MA-negative UDS tests obtained during 
the evaluation period (i.e., weeks 5 to 6 and weeks 11 to 12) of the 12-week long medication 
phase, relative to the PLB arm.  
5.2 
Secondary Objectives 
Secondary objectives include evaluating the effect of the AMC arm, compared to the PLB arm, 
on safety, other substance use outcomes, depression scores, quality of life, overall functioning, 
clinic attendance, and medication adherence. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
19 
6.0 
DESIGN 
6.1 
Overview of Study Design 
The primary objective of this study is to assess the efficacy of extended-release naltrexone plus 
bupropion as a combination pharmacotherapy for methamphetamine use disorder. There will be 
400 individuals randomized into the study across 7 -10 clinical sites. Eligibility will be determined 
during a maximum 21-day screening period. To document an appropriate level of current 
methamphetamine use, prospective participants must submit at least 2 urine samples positive for 
methamphetamine of a possible 3 tests to occur within a 10-day period during which clinic visits 
occur with at least 2 days between visits. In addition, participants must self-report MA use on 18 
or more days in the 30-day period prior to consent using the Timeline Followback (TLFB) and 
meet diagnostic criteria for moderate or severe methamphetamine use disorder per DSM-5 (4 or 
more criteria) at screening. After screening is completed and eligibility is confirmed, participants 
will begin the 12-week medication phase of the trial. Participants will be randomized to either the 
1) AMC arm and receive injections of extended release naltrexone (XR-NTX; as Vivitrol®) plus 
once-daily oral extended-release bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) 
arm and receive injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. This 
protocol will utilize a sequential parallel comparison design (SPCD), originally proposed by Fava 
et al. (2003), and later revised by Chen et al. (2011). A feature of this design is that it can reduce 
the overall placebo response rate. One advantage of the adaptive aspect of the design is that it 
requires a smaller sample size compared to a standard two group randomized trial design. During 
the course of the study, participants may or may not be switched to another arm, as determined 
by the a priori adaptive aspect of the study design. Participants appearing to respond well to their 
original treatment assignment will not be switched. Overall, approximately 50% of the participants 
will receive the AMC. Injections will be provided in weeks 1, 4, 7, and 10. Take-home oral study 
medication will be dispensed weekly for dosing on non-clinic days. Participants will be asked to 
attend the clinic twice weekly for observed oral medication dosing, assessments, collection of 
urine samples, and once-weekly medical management. On non-clinic days, participants will 
participate in smartphone app-based medication adherence activities. Participants will be asked 
to complete assessments as indicated on the schedule of assessments (see Section 8.0). 
Following the 12-week medication phase, participants will complete a follow-up phase, including 
a medication taper and post-medication phase follow-up visits during weeks 13 and 16. 
6.2 
Duration of Study and Clinic Visit Schedule 
Participants will be involved in the study for approximately 19 weeks, including a 
screening/baseline period of up to 3 weeks (i.e., 21 days), 12 weeks of medication, and a post-
medication follow-up phase. The screening phase may differ by participant in the length of time 
needed to complete preliminary eligibility assessments. Confirmation of opioid-free status (urine 
drug screen test(s) and optional naloxone challenge) before randomization and medication 
induction will take approximately 1.5 hours. Twice-weekly visits during the medication phase will 
range from about 20 to 90 minutes in length depending on scheduled assessments. Once-weekly 
medical management sessions will require an additional 20 minutes. Medication injection visits 
will take approximately 2 hours. The post-medication phase follow-up visits will take 
approximately 1 to 2 hours to complete. A 12-week medication period was selected based on 
expected time needed to observe clinical benefit and for pragmatic issues related to medication 
dosing.  
Enrollment is expected to take place over a period of approximately 18 months.  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
20 
6.3 
Participant Selection 
A total of 400 males and females who meet eligibility criteria will be randomized. Study participants 
will be recruited using a variety of methods including word-of-mouth, referral, advertising, and 
study announcement flyers posted in local treatment programs. The study sites should attract a 
diverse study population. Efforts will be made to recruit a study sample that reflects, or exceeds, 
the proportion of minorities in the community where the site is located. Recruitment procedures 
aiming to enhance enrollment of women and/or minorities will be conducted, including linkages 
with medical sites and/or treatment programs that serve a large number of women and/or 
minorities, and advertising in media outlets with high female/minority audience. Participants will 
not receive other formal addiction treatment services while they are participating in the study. 
Thus, at the time of randomization participants must be willing to have the study intervention serve 
as their sole treatment during study participation. Mutual help support group attendance will be 
encouraged throughout the trial. Upon study completion, participants may enroll in behavioral or 
pharmacological addiction treatment services.  
6.3.1 
Inclusion Criteria 
Study participants must: 
1. Be 18 to 65 years of age; 
2. Be interested in reducing or stopping methamphetamine use; 
3. Be able to speak English sufficiently to understand the study procedures and provide 
written informed consent to participate in the study; 
4. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder (4 or more 
criteria); 
5. Self-report methamphetamine use on 18 or more days in the 30-day period prior to 
consent using the Timeline Followback (TLFB); 
6. Provide at least 2 urine samples positive for methamphetamine out of a possible 3 tests 
to occur within a 10-day period during which clinic visits occur with at least 2 days 
between visits;  
7. If female, agree to use acceptable birth control methods and have periodic urine 
pregnancy testing done during participation in the study unless documentation of 
hysterectomy provided; 
8. Meet subjective and objective measures of being opioid-free prior to naltrexone induction 
per study medical clinician’s determination; 
9. Be willing to comply with all study procedures and medication instructions; 
10. Agree to use a smartphone app (downloaded for free to own device or on a study 
provided smartphone device) to take daily videos of medication dosing.  
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
21 
6.3.2 
Exclusion Criteria 
Study participants must not: 
1. Have an acute medical or psychiatric disorder that would, in the judgment of the study 
medical clinician, make participation difficult or unsafe;  
2. Have suicidal or homicidal ideation that requires immediate attention; 
3. Have a history of epilepsy, seizure disorder, or head trauma with neurological sequelae 
(e.g., loss of consciousness that required hospitalization); current anorexia nervosa or 
bulimia; or any other conditions that increase seizure risk in the opinion of the study 
medical clinician;  
4. Have evidence of second or third degree heart block, atrial fibrillation, atrial flutter, 
prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of 
the study medical clinician, would preclude safe participation in the study; 
5. Have Stage 2 hypertension as determined by the study medical clinician (e.g., greater 
than or equal to 160/100 in 2 out of 3 readings during screening); 
6. Have any elevated bilirubin test value per laboratory criteria OR any other liver function 
test (LFT) value > 5 times the upper limit of normal per laboratory criteria;  
7. Have a platelet count <100 x 103/μL; 
8. Have a body habitus that precludes gluteal intramuscular injection of XR-NTX in 
accordance with the administration equipment (needle) and procedures;  
9. Have a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactide-
co-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents; 
10. Have been in a prior study of pharmacological or behavioral treatment for 
methamphetamine use disorder within 6 months of study consent; 
11. Have taken an investigational drug in another study within 30 days of study consent; 
12. Have been prescribed and taken naltrexone or bupropion within 30 days of study 
consent;  
13. Be concurrently enrolled in formal behavioral or pharmacological addiction treatment 
services;  
14. Be receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., 
theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, 
chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), 
or any medication that, in the judgment of the study medical clinician, could interact 
adversely with study medications; 
15. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which 
would preclude safe participation in the study as determined by the study medical 
clinician; 
16. Require treatment with opioid-containing medications (e.g., opioid analgesics) during the 
study period; 
17. Have a surgery planned or scheduled during the study period; 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
22 
18. Are currently in jail, prison or any inpatient overnight facility as required by court of law or 
have pending legal action or other situation (e.g., unstable living arrangements) that 
could prevent participation in the study or in any study activities; 
19. If female, be currently pregnant, breastfeeding, or planning on conception. 
Although not targeted for recruitment, this study obtained authorization from the Office for Human 
Research Protections (OHRP) to follow-up with study participants who happen to become 
incarcerated during the trial, as needed and feasible at the individual study sites. Study staff may 
work with institutions to arrange research visits, and any needed assessments and procedures 
the institution will allow may be completed. Study medications will be discontinued during 
incarceration. 
6.4 
Site Selection 
The trial will include 7 -10 sites with each site randomizing approximately 30-70 participants.  
6.4.1 
Site Characteristics 
Participating sites must: 
1. Have a physician who can commit the time necessary to take a leadership role and 
oversee all medical aspects of the study, perform medical assessments, confirm 
participant eligibility, order and dispense or administer study medications, review 
adverse events, and appropriately evaluate and respond to adverse reactions that may 
occur during the course of the study. 
2. Have at least one other medical clinician (i.e., physician, physician’s assistant, or nurse 
practitioner) who can, in accordance with the regulations of the state where the site is 
located, make independent medical decisions and commit the time necessary to perform 
medical assessments, determine participant eligibility, order and dispense or administer 
study medications, review adverse events, and appropriately respond to adverse 
reactions that may occur during the course of the study. 
3. Have standard operating procedures in place for handling medical and psychiatric 
emergencies. 
4. Have a physician available to provide after-hours clinical back-up for study-related 
emergencies. 
5. Have access to a phlebotomist or other qualified personnel to complete blood draws. 
6. Have the ability to meet storage and dispensing requirements for all study medications, 
including access to adequate storage space, equipment, and appropriately qualified 
staff, as directed by the protocol and in accordance with local regulations and NIDA 
stipulations. 
7. Have access to, or the ability to contract with, a local laboratory to process biological 
specimens (e.g., blood and/or urine) in a timely manner during screening. 
8. Have adequate facility space available to conduct study procedures. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
23 
6.4.2 
Rationale for Site Selection 
The sites selected for participation in this trial will be selected, in part, based on the node’s interest 
in participating in the trial, the availability of a sufficient pool of potential study participants in the 
area, and the presence of an existing team of experienced personnel at the site knowledgeable 
in clinical trial operations and trained in core CTN assessments. Information on site readiness 
and capacity will be gathered via a site survey and a coordinated site/investigator selection 
process will confirm the following: 
1. An ability to recruit and randomize 3-4 eligible individuals with methamphetamine use 
disorder each month. 
2. Experienced regulatory personnel capable of the timely preparation of necessary 
regulatory documents and having the ability to facilitate an expeditious IRB submission, 
approval, modification, and continuing review processes. 
3. Medical staff who can commit the time necessary to oversee all medical aspects of the 
study, perform medical assessments, confirm participant eligibility, order and administer 
or dispense study medications, and appropriately respond to possible adverse reactions 
that may occur during the course of the study. 
4. Staff familiar with web-based Electronic Data Capture systems and who have the 
capacity and discipline to conform to protocol-required direct data entry procedures.  
5. Adequate and available space that is suitable for the performance of study procedures. 
6.5 
Randomization Plan 
Eligible participants will be randomized to the AMC and PLB treatment arms, stratifying by site. 
During the course of the medication phase, participants who provide sufficient UDS for evaluation 
of outcomes may or may not be switched to another arm. Switching, or re-randomization 
parameters, were determined a priori and are based on a combination of original treatment 
assignment, availability of data, and treatment response. Participants appearing to respond to 
their original treatment assignment will not be switched. Re-randomization will be implemented 
automatically by computer and will be stratified by site. Overall, approximately 50% of the 
participants will receive the AMC.  
 
The randomization process will be conducted centrally and electronically by the CTN Data and 
Statistics Center (DSC) via the Advantage eClinical Electronic Data Capture (EDC) system, and 
randomization assignments will not be conveyed to staff or participants to maintain the double 
blind. To ensure the lack of predictability while maintaining the designed randomization fraction, 
an urn scheme similar to one described in Wei and Lachin (1988) will be used. The DSC 
statistician will review randomization data on a regular basis to ensure that the scheme is being 
implemented according to plan. A randomization slot, once used, will not be re-allocated. 
6.6 
Study Intervention 
The study intervention consists of 12 weeks of pharmacotherapy, medical management, and 
medication adherence procedures. Participants randomized to the AMC treatment arm will 
receive an injection of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg of once-
daily oral extended-release bupropion tablets (BUP-XL). Participants randomized to the PLB 
treatment arm will receive matched placebo in the form of injections of placebo (iPLB) plus once-


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
24 
daily oral placebo (oPLB) tablets. Injections of study medications (XR-NTX or iPLB) will be 
administered in weeks 1, 4, 7, and 10. All randomized participants will receive weekly medical 
management sessions with the study medical clinician and will utilize smartphone app-based 
medication adherence procedures.  
6.7 
Outcome Measures 
The primary outcome measure, as described below, is based on urine drug screen (UDS) test 
results and is considered a clinically significant improvement in methamphetamine use in this 
study population. The primary outcome (UDS) has been chosen because it is an objective 
measure of methamphetamine use. Secondary outcome variables are intended to explore various 
aspects of response to this medication combination and to identify factors that may be associated 
with treatment response or non-response. Some of the secondary outcome variables add a 
measure of clinical relevance to the reduction of use by assessing sustained abstinence, reduced 
frequency of methamphetamine use, reduction in craving that may be a prelude to relapse, and 
improvements in mood, quality of life, and overall functioning.  
6.7.1 
Primary Efficacy Outcome Measure 
The primary efficacy outcome measure is a composite of MA-negative UDS test results obtained 
during weeks 5 to 6 and weeks 11 to 12 of the medication phase and will be compared by 
treatment group (AMC versus PLB).  
6.7.2 
Primary Safety Outcome Measure 
The safety and tolerability of the AMC arm, relative to the PLB arm, will be determined using 
participants’ reports of adverse events (serious and non-serious) collected at clinic visits or via 
other contact.  
6.7.3 
Secondary Outcome Measures 
Secondary outcome measures for the impact of the AMC, relative to the PLB arm, on other 
substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, 
and medication adherence will be evaluated as follows: 
1. Alternate measures and composites of methamphetamine use including: 
a) The Treatment Effectiveness Score (TES), as measured by UDS results, during the 
medication phase;  
b) Frequency of MA use, as measured by self-report, during the medication phase; 
c) Severity of MA craving, as measured by Visual Analog Craving Scales (VAS), during 
the medication phase; 
d) MA use, as measured by UDS and self-report, during the follow-up period. 
2. Quantity and frequency of alcohol, tobacco, and other drug use, as measured by self-
report, during the medication phase; 
3. Change in depressive symptoms, as measured by the PHQ-9, during the medication 
phase; 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
25 
4. Changes in quality of life, as measured by the Quality of Life (QoL), during the 
medication phase; 
5. Changes in overall functioning, as measured by the Treatment Effectiveness 
Assessment (TEA), during the medication phase; 
6. Percentage of participants retained in treatment during the medication phase; 
7. Ratings of participant and staff satisfaction with study procedures, including use of the 
medication adherence app, compensation, and medication. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
26 
7.0 
PROCEDURES  
7.1 
Screening and Baseline Phase  
Assessments administered during screening will determine whether participants meet eligibility 
criteria and will provide baseline measures of drug use and other important domains. Screening 
and baseline assessments will be conducted as shown in Table 2 in section 8.0. Participants who 
do not complete all screening/baseline assessments within 21 days of signing consent, including 
the naltrexone pre-induction strategy, or who are otherwise found to be ineligible for participation 
in the study, will be considered screen fails. With Lead Node approval, screen fails may be allowed 
to return at a later date to repeat the screening process. 
7.1.1 
Pre-screening Assessment 
Individuals responding to recruitment materials or otherwise referred to the study will be pre-
screened on the phone or in person to ascertain preliminary eligibility status. A series of questions 
(e.g., MA use history, interest in participating in research to investigate medications that have 
potential to reduce MA use, ability and willingness to participate for the duration of the trial) will 
determine preliminary eligibility. Full screening appointments will be scheduled for those who 
meet preliminary eligibility criteria. 
7.1.2 
Informed Consent  
At the start of the screening appointment and before any assessments are administered, qualified 
study personnel will conduct the informed consent process with prospective participants. The 
informed consent process will begin with a description of the study, including study procedures 
and study medications. Potential study participants will be given a copy of the IRB-approved 
consent form to review either on site or at home, in accordance with IRB requirements. Potential 
study participants who remain interested after review of the consent form will answer written 
comprehension questions to ascertain their understanding of the study, including its purpose, 
procedures involved, and the voluntary nature of participation. For participants who do not 
correctly answer all comprehension items, research staff will re-explain the study, with a focus on 
aspects candidates did not understand. Participants may attempt the consent comprehension 
questions a maximum of three times before they are deemed unable to comprehend the study. 
Any participant who cannot demonstrate appropriate understanding of the study to research 
personnel will be ineligible to participate and will be assisted in finding other treatment resources 
if desired. Study participants who demonstrate understanding of the study and who voluntarily 
agree to participate will be asked to sign the IRB-approved consent form and, if the consent form 
is signed, will proceed with the screening assessments. As part of the informed consent process, 
participants also will be asked if they consent to (1) be contacted for future studies and (2) provide 
a blood sample for genetic testing. 
7.1.3 
Screening and Baseline Assessments 
Upon signing the IRB-approved consent form, participants enter a maximum 21-day screening 
phase to complete assessments to determine eligibility and to collect baseline data. 
Screening/baseline assessment procedures must be completed across at least two screening visits. 
During the screening phase, participants must submit at least 2 urine samples positive for 
methamphetamine out of a possible 3 tests to occur within a 10-day period during which clinic 
visits occur with at least 2 days between visits. Therefore, all screening visits will have at least 2 
days elapse between visits. In addition, participants must self-report MA use on 18 or more days 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
27 
in the 30-day period prior to consent using the Timeline Followback. These criteria will be used to 
confirm current MA use and further substantiate a diagnosis of moderate or severe 
methamphetamine use disorder. 
Once the participant completes all screening and baseline assessments, submits 2 MA-positive 
UDS tests, and is found otherwise eligible for continued participation, the participant may begin 
the naltrexone pre-induction procedure (see below). All consented participants who do not 
complete all screening assessments within the 21-day screening period or who are otherwise 
found to be ineligible for study participation will be considered to be screen fails. Demographic 
data and the reasons for not meeting eligibility criteria must be documented for all screen fails. 
7.1.4 
Naltrexone Pre-Induction Strategy  
The screening/baseline phase includes a naltrexone pre-induction strategy to be conducted on 
the final screening visit after all other eligibility criteria have been met. The naltrexone pre-
induction strategy is designed to ensure participants meet subjective and objective measures of 
being opioid-free, per the study medical clinician’s determination, on the day of and prior to 
randomization and induction on the injectable study medication. Required and optional 
procedures are outlined below: 
1. Subjective measures of opioid-free status. Participants must self-report no clinically 
significant opioid use (i.e., at any level that could constitute a potential risk of 
precipitating opioid withdrawal upon naltrexone administration) in the 7-10 days prior to 
the day of randomization, as measured using the TLFB and the Prior and Concomitant 
Medications (PCM) assessment.  
2. Objective measures of opioid-free status. To objectively evaluate opioid-free status, a 
urine sample must be provided and tested on the day of anticipated randomization. 
Individuals must have negative results for opioids (on the OPI 2000 and the OPI 300 
tests) prior to randomization. Individuals with a positive opioid result on these tests may 
provide an additional urine sample on a subsequent day if the study medical clinician 
determines that a second screen is appropriate. The study medical clinician must 
determine suitability for continuing the pre-induction process for individuals positive for 
opioids on other opioid tests that may be conducted during Screening. 
3. Optional naloxone challenge. A naloxone challenge is not required but may be 
administered for definitive determination of opioid free status at the discretion of the 
medical clinician. If a naloxone challenge is administered, a minimum 0.8 mg bolus must 
be given before determining the outcome of the challenge. The study medical clinician 
will use clinical judgment to determine if the participant passes the naloxone challenge 
and is safe to continue on to randomization and subsequent XR-NTX or iPLB induction. 
Evidence of withdrawal signs or symptoms following naloxone administration will result 
in postponement of randomization until a negative naloxone challenge result is achieved. 
In other words, if a clinician opts to administer a naloxone challenge and withdrawal is 
precipitated, a second naloxone challenge must be administered, with no withdrawal 
observed immediately prior to randomization.  
Participants who experience withdrawal symptoms following a naloxone challenge may 
be treated with ancillary medications, observed until symptoms resolve, and given the 
opportunity to return another day and be re-challenged if clinically indicated. Participants 
who are not interested in continuing to participate, or who fail a repeat naloxone 
challenge, will not be eligible to participate in the study but will be given referrals to local 
treatment programs, as appropriate. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
28 
7.1.5 
Final Confirmation of Eligibility  
After completing all screening and baseline assessments, including the naltrexone pre-induction 
strategy, the study physician must review and approve safety and eligibility assessments in order 
to confirm participant eligibility prior to randomization. Randomization will occur on the day the 
naltrexone pre-induction strategy is completed (i.e., the participant is determined to be opioid-
free) after study eligibility has been confirmed and documented. 
7.2 
Medication Phase 
7.2.1 
Randomization 
Immediately following the naltrexone pre-induction strategy and final assessment and 
documentation of eligibility, eligible participants will be randomly assigned to the AMC arm or the 
matching PLB arm. The randomization procedure will be conducted electronically by the 
Advantage eClinical system. The switching or re-randomization procedure described previously 
will occur seamlessly by the electronic system, based on data routinely collected and entered. 
7.2.2 
Pharmacotherapy 
Participants will receive the first intramuscular gluteal injection of study medication (XR-NTX or 
iPLB) on the day of randomization (Day 1), following confirmation of opioid-free status and final 
confirmation of study eligibility by the study physician. Subsequent intramuscular gluteal injections 
(XR-NTX or iPLB) will be administered at the beginning of Weeks 4, 7, and 10 and shall be 
administered following guidelines in the XR-NTX package insert. Study medical clinicians will 
evaluate participants to ensure continued suitability for injectable study medication administration. 
Urine drug screening procedures will help clinicians evaluate participant opioid-free status at the 
time of study medication injection. A naloxone challenge may be administered prior to any study 
medication injection at the discretion of the study medical clinician. 
Take-home oral study medication will be dispensed weekly. The first dose of oral study medication 
(BUP-XL or oPLB) will be taken on the day of randomization (Day 1) immediately following 
administration of the injectable study medication. For each clinic visit, participants will be asked 
to refrain from taking their dose at home and to bring their oral study medication for in-clinic 
dosing. On the days in which injectable study medication is administered, oral study medication 
self-administration will occur immediately following the injection. All in-clinic self-administration of 
oral study medication will be observed by study staff. Participants will take a dosing video using 
the study app for all in-clinic and non-clinic self-administrations of oral study medication. 
If a participant reports intolerable symptoms or side effects at the full 450 mg dose, ancillary 
medications may be used and/or a dose reduction may occur if deemed appropriate by the study 
medical clinician. The study medical clinician, in collaboration with the study physician and site 
principal investigator, is encouraged to consult with the Lead Investigator(s) in making the 
decision to reduce a participant’s dose. The dose may be reduced to 300 mg daily. Medication 
packaging will allow for dose reductions without re-dispensing; participants will be instructed to 
take only the tablets in the first two wells for each day they are on a reduced dose. If intolerable 
adverse effects continue, the participant may be withdrawn from further medication 
administration. If intolerable adverse effects resolve after an initial dose reduction or are 
appropriately addressed with the use of ancillary medications, and if deemed appropriate by the 
study medical clinician, titration to the full 450 mg target dose may be attempted (i.e., participants 
will be instructed to take all three tablets for each day) on any visit except visits in which injectable 
study medication is administered. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
29 
7.2.3 
Medical Management 
Medical management procedures will be conducted as follows. Participants will meet with a study 
medical clinician once weekly for an individual medical management session that utilizes a 
structured adherence enhancement manual designed for pharmacotherapy trials with subjects 
with substance use disorder (adapted from Carroll et al., 1996). The goal of medical management 
sessions is to achieve high quality supportive treatment that reinforces adherence to study 
procedures and the study medication regimen. A session will be approximately 20 minutes and 
focus on: 
1. Setting abstinence from methamphetamine as a goal,  
2. Participant adherence with study medications and procedures,  
and  
3. Current functioning.  
Medical clinicians will also review adverse events, consider potential medication side effects, and 
discuss other pertinent issues in keeping with sound medical practice. Ancillary medications may 
be provided for study medication-related adverse events as clinically indicated. A range of 
prescription and over-the-counter ancillary medications may be used for symptoms such as 
anxiety, nausea, vomiting, diarrhea, muscle pain, and insomnia. At all medical management 
sessions, the medical clinician will remind participants about the importance of adhering to the 
study procedures, including attending scheduled clinic visits and complying with smartphone app-
based dosing confirmation procedures. Mutual help support group attendance will be encouraged. 
7.2.4 
Medication Adherence 
Medication adherence procedures will be conducted as follows. To encourage and monitor 
adherence to oral study medication, procedures include discussing adherence during medical 
management sessions and twice-weekly observed dosing in the clinic as described previously. 
Procedures also include the use of a smartphone app to take dosing videos to document oral 
study medication self-administration on non-clinic days and during clinic visits (while staff 
observe), including on the taper days in the post-medication follow-up phase. Participants will 
access the app on either a study provided smartphone device or by downloading the app to their 
personal device. Further details are outlined in Appendix C. Dosing will be assessed by 
automated visual recognition software during the video capture to ensure the videos clearly show 
dosing adherence based on assessment criteria. Participants will be compensated for dosing 
videos (see section 7.5). 
7.2.5 
Participant Medication Withdrawal 
Participants will be withdrawn from further study medication administration if it is clinically 
determined that continuation may be unsafe. For example, participants who develop uncontrolled 
hypertension (160/100 or higher on three consecutive visits) will be withdrawn from further study 
medication administration. Likewise, women who become pregnant during the medication period 
will be immediately withdrawn from study medication administration. Participants reporting use of 
medications that may interact with naltrexone or bupropion will be withdrawn based on clinical 
judgment. Participants who experience intolerable adverse effects or other physical or psychiatric 
conditions, regardless of relationship to the study medication, may also be withdrawn from further 
study medication administration. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
30 
The medical clinician may determine that a participant’s clinical condition has deteriorated during 
the course of the study to the extent that now taking study medication may be possibly unsafe or 
unwise. Examples of clinical deterioration that might trigger a decision to withdraw the participant 
from study medication include the following: 
 
New onset of psychiatric or medical conditions that would require intervention and 
preclude continued participation in the study (e.g., emergence of psychosis, suicide risk, 
severe cognitive impairment, or dangerous criminal behaviors); 
 
Worsening of a pre-existing psychiatric or medical condition that would preclude 
continued safe participation in the study; 
 
Worsening of substance use disorder or overdose such that a higher level of care is 
indicated; 
 
Increase in LFT or decrease in platelet test results at week 6 that may increase 
participant health risks. This includes any of the following: AST/ALT results > 5 times 
ULN, total bilirubin > 2 times ULN, or platelets below 75 x 103/μL.  
The study medical clinician, in collaboration with the study physician and site principal 
investigator, should consult with the Lead Investigator(s) and Study Medical Monitor in making 
the decision to withdraw a participant from study medications. Also, participants may decide at 
any time that they no longer wish to continue to receive medication or participate in the study. 
In most cases, a taper is not indicated if the study medical clinician determines medication 
discontinuation is warranted for medical or psychiatric reasons. Generally, a taper of bupropion 
is not medically necessary as there is no evidence of a physiological dependence or increased 
incidence of adverse events when this medication is discontinued. However, as down titration is 
common in clinical practice, clinicians are guided to follow this convention for the majority of study 
participants. If a taper is believed to be necessary based on clinical judgment, the study medical 
clinician, in collaboration with the study physician and site principal investigator, should consult 
with the Lead Investigator(s) and Study Medical Monitor on how to best proceed. 
In the event a participant becomes pregnant during the medication period, a taper is not indicated 
as bupropion is a pregnancy category C medication and the risks of taper outweigh the benefits 
in pregnant women. The pregnant participant will be immediately discontinued from further study 
medication administration, referred for medical care, and the pregnancy followed until an outcome 
is known. 
A taper is also not indicated for participants who become incarcerated or for participants who lose 
study medication during the medication phase of the study. Participants who lose study 
medication will resume their dosing schedule at the appropriate next study visit; no medication 
should be dispensed earlier than scheduled. 
As the primary aim of this study is to evaluate the efficacy of XR-NTX plus BUP-XL as a 
combination pharmacotherapy, withdrawal from either study medication will typically lead to 
discontinuation of the other medication. With Lead Node and Study Medical Monitor approval, 
participants may be allowed to continue on one medication if discontinued from the other. In the 
event a participant is withdrawn from further study medication administration, referrals to 
treatment programs or recommendations for medical care will be provided. Unless consent is 
officially withdrawn, study staff will encourage participants who are withdrawn from study 
medications or who opt out of study medications to continue attending twice weekly clinic visits 
and complete study assessments throughout the duration of the medication phase (weeks 1 – 12) 
and the follow up phase (weeks 13 and 16).  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
31 
7.2.6 
Medication Phase Visits 
Given the requirements across study visits (e.g., meeting with medical clinician, blood draws, 
injections, assignment of oral medication only after the participant arrives, physical exam, ECG, 
etc.), the study was designed with the expectation that all visits occur at the study site. However, 
there may be cases in which off-site visits may be possible with Lead Team approval.  
7.3 
Follow-up Phase 
7.3.1 
Oral Study Medication Taper 
A taper will occur during the first four days of Week 13 (Days 85 – 88) for participants continuing 
on oral study medication (BUP-XL or oPLB) through the end of the medication phase. The daily 
dose will be 300 mg for Days 85 and 86 and 150 mg for Days 87 and 88. This taper schedule will 
apply to all participants, including any participants already taking a reduced dose. 
7.3.2 
Post-Medication Phase Follow-up Visits 
All enrolled participants will be asked to complete post-medication phase follow-up visits in weeks 
13 and 16 according to the schedule of assessments (see Table 2, section 8.0). There may be 
cases in which off-site visits may be possible with Lead Team approval. Tracking and locating 
strategies will be used to ensure the highest possible follow-up rates.  
7.4 
Study Medication Management/Drug Accountability 
As set forth in the protocol agreement signed by each site principal investigator (see Section 14, 
Signatures), study sites are required to observe local, state, and federal regulations regarding 
receipt, custody, dispensing, administration, and associated documentation of all medications 
used in this study. Medications used in the study include extended-release bupropion, extended-
release injectable naltrexone, oral placebo, and injectable placebo provided by the NIDA 
contractor as well as naloxone purchased and maintained by each site.  
7.4.1 
Documentation 
Upon receipt, the investigator, pharmacist, or authorized designee at each site is responsible for 
maintaining written inventory of the investigational agents and naloxone obtained for the study. 
Appropriately trained and qualified personnel will maintain an accurate and real-time accounting 
of all medications, which will be available for verification by study monitors. Medication 
accountability records, including perpetual inventory, will document the amount of study 
medication ordered, received, transferred between areas of the study site (e.g., from pharmacy 
to clinic), and medications administered to or dispensed to and returned by an individual 
participant. Documentation will also record unused medications destroyed on site or returned to 
the NIDA contractor for destruction. As with all study documentation, medication accountability 
records must be maintained in accordance with Good Documentation Practices and must be 
attributable, legible, contemporaneous, original, accurate, and complete. 
7.4.2 
Storage 
All medication used in this study will be stored in compliance with federal, state, and local laws 
and institutional policy. Study medications will be stored in a locked, secure, limited-access 
location under the conditions specified by the package insert; XR-NTX and iPLB injectable kits 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
32 
will be stored in a secure, limited access refrigerator. Temperature logs will show a daily record 
of medication storage temperature for all medications. 
7.4.3 
Packaging 
Intramuscular gluteal injections (XR-NTX and iPLB) will be supplied in single use kits marked with 
medication kit numbers which will be used for tracking and inventory purposes. Each active 
injectable medication kit will contain one 380 mg vial of Vivitrol® microspheres, one vial containing 
4 mL (to deliver 3.4 mL) diluent for the suspension of Vivitrol®, one 5 mL prepackaged syringe, one 
1-inch 20-gauge needle, two 1.5-inch 20 gauge needles, and two 2-inch 20 gauge needles with 
needle protection devices. Each injectable placebo medication kit will be prepared to look identical 
and will contain the same contents as the active medication kits but with no active medication. 
Participants will receive once-daily oral study medication (BUP-XL or oPLB). BUP-XL blister cards 
will contain a daily dose of 300 mg for the up titration days and a daily dose of 450 mg for all other 
days in the medication phase. BUP-XL blister cards for the taper days (Days 85-88) will contain 
a daily dose of 300 mg (Days 85 and 86) and 150 mg (Days 87 and 88). 
Oral study medication (BUP-XL and oPLB) will be pre-packaged in weekly blister cards that 
contain 3 tablet wells for each day. The packaging will be designed such that participants will take 
all 3 tablets each day, including during the up titration and taper periods. 
There will be five types of blister cards manufactured to appear identical for both treatment arms. 
There will be three types of 7 day cards for use in weeks 1 to 12—one for up titration (for AMC 
only) and two for target dosing (AMC and PLB). Two types of cards will contain a 4-day supply 
for the week 13 taper period (AMC and PLB). 
The up titration AMC card will be dispensed twice during the study: in week 1 for participants 
randomized to AMC and again when some participants may be re-randomized and assigned to 
receive AMC. Therefore, the up titration card will be manufactured to contain 3 tablets for each 
day of the titration in order to appear identical to the target dosing card. The up titration card will 
contain two active and one placebo tablet each day for days 1 - 3, and it will contain three active 
tablets each day for days 4 - 7. Packaging the up titration card in this way will help protect the 
double-blind throughout the trial.  
The target dosing cards will contain either active medication or placebo. The AMC taper card will 
contain two active and one placebo tablet for the first two days and one active and two placebo 
tablets for the last two days. The PLB taper card will contain three placebo tablets for each of the 
four days.  
Weekly blister cards dispensed to participants will be labeled to include protocol number, study 
drug information, and blister card number. The label will also include blister card contents, 
“Caution: New Drug - Limited by Federal Law to Investigational Use. Store at Controlled Room 
Temperature (20-25°C or 68-77°F)” as well as the manufacturer and distributor information. 
Below, the medication packaging plan is summarized visually, whereby P indicates placebo tablet 
and A indicates active tablet. Weekly blister cards for each treatment arm by the dosing period 
(up titration, target dosing, and taper) will be dispensed as follows: 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
33 
 
Dosing Period during Medication Phase 
 
 
Day 
Up titration 
Target 
Taper 
  Treatment Arm 
 
 
 
PLB 
1 
2 
3 
4 
5 
6 
7 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
P P P 
 
P P P 
P P P 
P P P 
P P P 
 
 
 
 
 
 
 
 
AMC 
1 
2 
3 
4 
5 
6 
7 
 
A A P 
A A P 
A A P 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
A A A 
 
A A P 
A A P 
A P P 
A P P 
 
 
 
 
 
 
Key: A - Active medication tablet 
P - Placebo tablet 
7.4.4 
Ordering and Dispensing 
All study medications shall be ordered only by delegated licensed medical staff and dispensed by 
research staff appropriately trained to do so. Injectable medications will be administered by 
qualified staff during Weeks 1, 4, 7, and 10. Oral medications will be dispensed to the participant 
weekly in labeled blister cards that will include both in-clinic observed doses and self-administered 
doses for non-clinic days. 
7.4.5 
Used/Unused Medication 
Unused study medication will be returned and logged into a perpetual inventory. Returned, 
damaged, expired or otherwise unused study medications will be accurately labeled, securely 
stored, kept separately, and shall be accounted for prior to disposition. Any unused or expired 
investigational agent shall be accounted for at all times. Expired naloxone and other ancillary 
medications obtained for this study will be destroyed on site or sent for destruction per local 
institutional policies.  
7.4.6 
Lost Medication 
There will be no replacement of any dispensed study medications. 
7.4.7 
Maintaining and Breaking Blind 
This is a double-blind, placebo-controlled trial. With the exception of the data management group 
overseeing the random assignment schedule and the NIDA-contracted research pharmacist 
preparing study medications, all other study personnel and participants will remain blinded to 
medication status until nationwide completion of the trial. A Data and Safety Monitoring Board 
(DSMB) will review study data throughout the course of the trial. In rare cases, it may be 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
34 
necessary to break the blind for a particular study participant before completion of the trial (e.g., 
pregnancy or other medical necessity). A request to break the study blind for an individual 
participant must be made by the study physician after consultation with the Lead Investigator. 
Unblinding the participant should only be done in cases of medical emergency when knowledge 
of the treatment group assignment may be necessary for clinical management and decision 
making. The decision to break the blind for a participant will be made jointly by the CCC Medical 
Monitor and at least one of the Lead Investigators. Any requests for unblinding will be responded 
to within one business day or less. 
7.5 
Participant Compensation 
Study participants will be provided with study medications, medical management, and a study 
medication adherence app for use on his/her own device at no cost. Alternatively, a study 
smartphone device pre-loaded with the medication adherence app will be provided if needed. In 
addition, participants will receive gift cards or cash (based on local requirements) as 
compensation for time, travel, parking, and other costs borne by the participant. A total of up to 
$50 will be provided for completion of screening/baseline assessments (divided among at least 
two screening visits). Ten dollars ($10) will be provided for each additional eligibility phase clinic 
visit to provide a urine sample. During the medication phase, $10 will be provided for completion 
of assessments including a urine sample ($5 will be provided for assessments without a urine 
sample); $5 for bringing the study medication on clinic days and taking a self-dosing video via the 
smartphone app while staff observe; and $25 for each injection visit. Participants will be 
compensated an additional $40 per visit for completion of the mid-treatment visit (visit 602) and 
the end of treatment visit (visit 1202), and $30 for each follow-up visit in weeks 13 and 16. In 
addition, participants will be compensated $5 for each dosing video taken on non-clinic days, 
including the taper in week 13 (see Appendix C for details). Participants may earn a visit 
attendance bonus of $20 (received up to 6 times) when they attend each visit expected to occur 
within each 2-week block of the medication phase. For example, a participant could earn $20 for 
attending four visits in weeks 1-2, $20 for weeks 3-4, and so on until weeks 11-12. Participants 
may also receive up to $40 to offset the cost of additional data service needed for the dosing app 
on their personal device or for return of the study smartphone device (see Appendix C for details). 
Total compensation possible is $1,160 as outlined below.  
7.5.1 
Table 1. Compensation Schedule 
Visit/Assessment 
Amount 
# of Payments 
Total 
Screening Assessments 
$50 
1 
$50 
Eligibility Phase Clinic Visits 
$10 
4 
$40 
Injection Visits 
$25 
4 
$100 
Clinic Visits (12-week Medication Phase) 
$10 
23 
$230 
In-clinic dosing/med return (2x/wk) 
$5 
24 
$120 
Mid-Treatment Visit (visit 602) and End-of-
Treatment Visit (visit 1202)  
$40 
2 
$80 
Dosing video (5x/wk+4 taper days)  
$5 
64 
$320 
Attendance Bonus (attending all expected visits in 
each 2-week block) 
$20 
6 
$120 
Follow-up Visits (Weeks 13 and 16) 
$30 
2 
$60 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
35 
Visit/Assessment 
Amount 
# of Payments 
Total 
Additional data service for dosing app on personal 
device OR smartphone device return  
$40 
1 
$40 
 Maximum Compensation Possible 
$ 1,160 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
36 
8.0 
ASSESSMENTS 
Study measures were chosen to minimize the research burden on participants yet collect 
adequate data to support analyses and ensure safety. Importantly, many of the study measures 
were selected to record vital health information and are similar to other recent and ongoing studies 
of bupropion and extended-release naltrexone. Additional measures were also selected to obtain 
information typically assessed in medication studies, including assessments of drug abuse and 
dependence diagnoses, psychological status, and measures of craving. Safety is assessed at 
each visit. Additional forms will be used to collect and document information such as dosing and 
protocol satisfaction. The NIDA endorsed Substance Abuse and Addiction (SAA) common data 
elements from Core Tier 1 of the PhenX Toolkit (http://www.phenxtoolkit.org), which include 
demographic and other baseline information, will be captured directly or will be populated from 
the answers to questions from other assessments. Table 2 provides the schedule of study 
assessments. On average, screening and eligibility assessments will be completed in 6-8 hours. 
Twice-weekly assessments during the medication phase will be completed in approximately 30 
to 90 minutes. Once-weekly medical management sessions will require an additional 20 minutes. 
The post-medication phase follow-up visits will take approximately 1 to 2 hours. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
37 
8.1 
Table 2. Schedule of Assessments 
 
 
 
 
 
Study Phase
Screening/ 
Baseline
Study Week
0
1
2
3
4
5
6
7
8
9
10
11
12
13
16
Screening Measures
Pre-Screening Interview Form
X*
Informed Consent
X*
Demographics Form
X*
Alcohol and Substance Use History
X*
DSM-5 Checklist
X*
Psychiatric Diagnostic Screening Questionnaire
X*
Sexual Risk Behaviors
X*
X2
X2
Self-Report of HIV Testing
X*
Medical and Psychiatric History
X*
Safety Measures
Physical Examination
X*
X2
Electrocardiogram
X*
X
Injection Site Examination
X2
X2
X2
X2
Injection Site Abnormality LogA
Clinical Laboratory Tests
X*
X
     Liver function tests & platelet lab tests
X
Concise Health Risk Tracking
X*
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Urine Pregnancy Test 
XE
Pregnancy and Birth Control Assessment
X*
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs
XC
X
X
X
XC
X
X
XC
X
X
XC
X
X
Prior and Concomitant Medications
X+
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
X
X
Adverse Events and Serious Adverse Events
XD
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
X
X
Naloxone Challenge Form
XE
XE
XE
XE
Efficacy Measures
Urine Drug Screen
X+
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
X
X
     OPI 300 
X**
X**
X**
X**
Timeline Followback
X+
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
X
X
Visual Analog Craving Scale
X+
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Patient Health Questionnaire-9
X*
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Treatment Effectiveness Assessment
X*
X2
X2
Tobacco Use History
X*
 
X2
X2
Quality of Life
X*
X2
X2
Blood draw for genetic testing
XF
Adherence Measures
Study Medication Dosing Logs
XE
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
2X
X
Injection Administration Form
X
X
X
X
Oral Medication Dispensation Form
X
X
X
X
X
X
X
X
X
X
X
2X
XE
Bupropion Blood Levels
XB
XB
XB
X2
End of Medication FormE  
X
Administrative and Other Forms
Locator Form
X*
X
X
X
X
Eligibility - Randomization
X*
Missed Visit FormE
Protocol Deviation FormE
Protocol Satisfaction Surveys
X
Study Completion Form
X
 X2 = collected at the second visit of the week.
A Completed in the event an injection site reaction is reported by a participant or an abnormality is identified during an injection site examination.
B Collected according to schedule of assessments, but must be prior to administration of ANY medications (e.g., naloxone; injectable or oral study medication) in a given visit. 
D Collected at each visit after consent (i.e. SV02 through the final follow-up visit)
E Completed as applicable
F If consent is provided, collect genetic sample at the end of the day of randomization if possible. Otherwise, collect during any future visit in which a blood draw occurs.
NOTES:  X* = once during screening/baseline    
Follow-up
Medication Phase
C Collected according to schedule of assessments, including  BEFORE and AFTER administration of naloxone challenge(s) as well as BEFORE and AFTER administration of the 
study medication combination. 
X** = required prior to randomization and injectable study medication administration, may be collected at other times per Medical Clinician discretion.
X+ = at each screening/baseline visit
X= a procedure or assessment performed once per week and on the first visit of the week, unless otherwise noted.
2X= a procedure or assessment performed twice per week.


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
38 
8.2 
Screening Measures 
8.2.1 
Pre-Screening Interview Form  
Individuals responding to recruitment materials or otherwise referred to the study will be pre-
screened on the phone or in person to ascertain preliminary eligibility status. Prior to administering 
the IRB-approved Pre-Screening Interview, staff will provide a brief overview of the study and will 
obtain and document verbal consent. The Pre-Screening Interview consists of questions to 
assess essential information in determining potential eligibility.  
8.2.2 
Informed Consent 
Prior to beginning any study assessments, all participants will review and sign an IRB-approved 
consent form and any other related documents in accordance with IRB requirements. The date the 
IRB-approved consent form was signed will be entered into the electronic data capture system. 
8.2.3 
Demographics Form 
The Demographics Form will collect information about demographic characteristics of the 
participant at screening including sex, date of birth, ethnicity, race, education, employment 
pattern, and marital status.  
8.2.4 
Alcohol and Substance Use History 
The Alcohol and Substance Use History will be completed at screening to incorporate PhenX 
Core Tier 1 items. The participant will be asked whether he/she has ever used alcohol and/or 
various substances as well as his/her age when the substance was first used. The intent of this 
measure is to document any alcohol use, illicit drug use (e.g., illegal, more than prescribed, not 
prescribed), and any marijuana use. 
8.2.5 
DSM-5 Checklist 
The DSM-5 Checklist has been designed as a semi-structured interviewer-administered 
instrument that provides current diagnoses for substance use disorders based on DSM-5 
diagnostic criteria. The DSM-5 Checklist will be completed at screening. 
8.2.6 
 Psychiatric Diagnostic Screening Questionnaire  
The Psychiatric Diagnostic Screening Questionnaire (Zimmerman, 2002) is a self-report 
questionnaire used primarily as a psychiatric disorder screener administered in primary care. The 
Psychiatric Diagnostic Screening Questionnaire will evaluate symptoms of common psychiatric 
disorders and will be administered during the screening phase. 
8.2.7 
 Self-Report of HIV Testing 
HIV testing status will be assessed via self-report questionnaire using PhenX Core Tier 1 items. 
Items will assess whether the participant has ever had an HIV test, when the most recent test 
occurred, the test result, and, if the participant was not tested in the past 12 months, and the most 
important reason the participant was not tested. This will be administered during the screening 
phase.  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
39 
8.2.8 
Medical and Psychiatric History 
The medical and psychiatric history, collected at screening, will document participants’ past and 
present health conditions to help determine eligibility and to provide baseline information. 
8.3 
Safety Measures 
8.3.1 
Physical Examination 
A physical examination will be completed at screening to ensure there are no exclusionary 
medical conditions and to gather baseline information. The physical at screening will also include 
an examination of the participant’s body habitus and the planned injection site(s) to assess 
appropriateness for intramuscular gluteal injections. The physical examination will be repeated at 
the end of the medication phase (week 12 visit 2).  
8.3.2 
Electrocardiogram (ECG) 
A 12-lead ECG will be administered at screening to assist in determination of participant eligibility 
and again at study exit (i.e., week 12 visit 1) to assess safety at termination. The ECG tracings 
will be reviewed by a qualified medical clinician for accuracy and transmitted to be read by a 
central cardiologist. Results from the central cardiologist’s interpretation will be assessed by a 
qualified medical clinician at the site. 
8.3.3 
Injection Site Examination 
Appropriate medical personnel will examine the injection site on the visit following each 
intramuscular gluteal injection. These examinations will usually occur at visits 0102, 0402, 0702, 
and 1002 but should occur at the next attended visit if any of the aforementioned visits are missed. 
Additional monitoring may also be required. Well-developed precautionary procedures will be 
followed to avoid adverse events associated with injectable study medication administration. For 
example, body habitus will be assessed during the physical exam at screening to assure that 
intramuscular administration is feasible as an inadvertent subcutaneous injection may increase 
the likelihood of injection site reactions. Individuals whose body habitus precludes a gluteal 
intramuscular injection using the needles provided will be excluded from the study. 
8.3.4 
Injection Site Abnormality Log 
Participants will be asked to immediately report any injection site reactions to allow evaluation, 
monitoring, and possible referral, as needed. A log entry is completed in the event an injection 
site reaction is reported by a participant or an abnormality is identified during an injection site 
examination. All injection site reactions should be documented on the Injection Site Abnormality 
Log. If the abnormality results in a Serious Adverse Event (SAE), the Adverse Event forms must 
also be completed. 
8.3.5 
Clinical Laboratory Tests  
A comprehensive blood chemistry including liver function tests (LFTs: including AST, ALT, ALP, 
and bilirubin), hematology panel, and a standard urinalysis will be performed to help determine 
eligibility at screening. At week 6 visit 1, clinical lab tests to assess LFTs and platelet counts will 
be repeated for safety monitoring. Clinical labs completed at screening (chemistry, LFTs, 
hematology, and standard urinalysis) will be repeated during the final week of the medication 
phase (week 12 visit 1). An accredited local laboratory (College of American Pathologists or 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
40 
equivalent) that meets CLIA guidelines will perform testing, provide normal values, and provide 
proof of lab certifications.  
8.3.6 
Concise Health Risk Tracking - Participant Rated Module 
The Concise Health Risk Tracking measure will assess aspects of suicidal ideation and behavior 
using 16 questions scored on a 5-item Likert scale, including ideation frequency, duration and 
severity; identifiable deterrents to an attempt; reasons for living/dying; degree of specificity/planning; 
method availability/opportunity; expectancy of actual attempt; and actual preparation. The Concise 
Health Risk Tracking measure will be used at screening, every week during the medication phase, 
and at the week 13 and 16 follow-up visits. Participants who report a significant suicidal/homicidal 
risk will be assessed by a qualified clinician before leaving the clinic.  
8.3.7 
Pregnancy and Birth Control Assessment 
For females, urine pregnancy test administration, test results, and self-reports of birth control 
method(s) will be documented during screening unless documentation of hysterectomy is 
provided. A urine pregnancy test will be performed prior to the naltrexone pre-induction strategy 
in the screening/baseline phase and may be performed at any other time if clinically indicated or 
if a woman suspects she is pregnant. If a woman is found to be pregnant at any point during the 
study, she will be allowed to continue in the study but will be withdrawn from study medications, 
given an appropriate referral, and followed until resolution of the pregnancy. Self-reports of birth 
control method(s) will be documented every week during the medication phase.  
8.3.8 
Vital Signs 
Vital signs (e.g., body temperature, blood pressure, pulse, respiration rate) will be collected at 
least once during screening, as well as before and after any naloxone challenge conducted during 
the study. During study medication injection clinic visits, vitals will be collected before and after 
participants receive the combination of the study medications. On non-injection clinic visits, vitals 
will be collected weekly before oral medication self-dosing. Vital signs can be repeated to confirm 
the reading or on more frequent intervals, as clinically indicated. 
8.3.9 
Prior and Concomitant Medications 
At screening, the Prior and Concomitant Medications form will collect information about 
prescription and over-the-counter medications used by participants in the prior 30-day period. At 
other visits, the form will document medications taken since the previous data collection visit. 
Participants may be excluded based on medications reported during screening. Participants will 
be instructed to contact the study medical clinician before taking any non-study medications, 
including prescription medications, over-the-counter preparations, and herbal supplements, 
during the course of the study. 
8.3.10 
Adverse Events (AEs) and Serious Adverse Events (SAEs) 
Medical or psychiatric adverse events (AEs) will be collected by inquiring of participants: “How 
have you been feeling since your last visit?” AEs will be recorded at each visit after consent 
according to the adverse event reporting definitions and procedures. If an AE or abnormality 
suggests medical or psychological deterioration, it will be brought to the attention of the study 
medical clinician for further evaluation. All AEs and SAEs will be medically managed, reported, 
and followed in accordance with applicable regulatory requirements. Seizures will be reported to 
the DSMB. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
41 
8.3.11 
Naloxone Challenge Form  
The Naloxone Challenge Form will document the time of administration, total dose, route of 
administration, and result of each naloxone challenge administered during the study. A naloxone 
challenge may be conducted at the discretion of the medical clinician prior to any injection of study 
medication; the Naloxone Challenge Form will be completed for each naloxone challenge.  
8.4 
Efficacy Measures 
8.4.1 
Urine Drug Screen  
Urine samples will be collected at every clinic visit. Urine drug screen (UDS) testing will be 
performed on site using an FDA-cleared for use one-step urine drug dip card and/or dipstick 
following all the manufacturer's recommended procedures. 
The UDS will test for the presence of opiates, oxycodone, barbiturates, benzodiazepines, cocaine, 
amphetamines, methamphetamine, marijuana (THC), methadone, and ecstasy (MDMA). Prior to 
drug screening, a temperature and validity assessment will be performed on all urine samples 
collected. The validity assessment will be performed using a commercially available adulterant 
test strip that indicates normal ranges for creatinine, pH (at minimum), nitrate, glutaraldehyde, 
specific gravity, bleach and pyridinium chlorochromate. If the temperature or adulterant test falls 
outside the normal range, the first urine specimen will be considered adulterated and will not be 
screened. In this case, the first urine sample will be discarded, and the participant will be asked 
to provide another sample following oral hydration. If the only out of range value from the second 
sample is a high specific gravity on the adulterant test strip and there are no visible precipitants, 
this sample may be considered not adulterated and can be drug tested. Any other out of range 
value on either the temperature strip or adulterant test indicates adulteration and the second 
sample should not be tested. Study teams at each site may opt to observe the urine collection 
process either at each collection or as deemed necessary (e.g., recommend observing urine 
collection if specimen tampering is suspected) according to clinic standard operating procedures. 
Throughout the study, urine will be tested to evaluate urine opiate levels at 2000 ng/mL. At 
Screening/Baseline and prior to each injection of XR-NTX or iPLB, urine will be tested to evaluate 
urine opiate levels at 300 ng/mL. Additional onsite urine drug testing may occur at 
Screening/Baseline and during the medication phase to detect urine metabolites of other drugs 
that are not detected by the previously described tests. Results from any urine drug test intended 
for forensic use only, or otherwise not cleared by the FDA for use in clinical settings, may not be 
used in any clinical evaluation and is collected for data purposes only. 
8.4.2 
Timeline Followback  
The Timeline Followback (TLFB) procedure (Sobell & Sobell, 1992; Fals-Stewart, 2000) will be 
used to elicit the quantity and frequency of the participant’s self-reported use of cigarettes, e-
cigarettes, alcohol and illicit drug use. At screening, substance use reported by the participant in 
the 30-day period prior to consent will be assessed. The TLFB will be administered at each study 
visit throughout the screening phase, the medication phase and the post medication phase follow-
up visits to document the participant’s self-reported use of substances for each day since the 
previous TLFB assessment. Adherence to this procedure will ensure that self-reported substance 
use for the entire study period is documented without gaps. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
42 
8.4.3 
Visual Analog Craving Scale  
Participants’ craving for methamphetamine will be documented on a visual analog scale (VAS) 
that ranges from 0 (no craving) to 100 (most intense craving possible). The VAS will be completed 
at each screening visit, once weekly throughout the medication phase, and at the week 13 and 
16 follow-up visits.  
8.4.4 
Patient Health Questionnaire-9 
The Patient Health Questionniare-9 (Kroenke et al., 2001) is a well validated self-report tool that 
measures diagnostic criteria for major depression, severity and frequency of depressive 
symptoms, presence of suicidal ideation, and functional impairment related to depression. The 
Patient Health Questionniare-9 will be collected during screening, weekly during the medication 
phase, and at the week 13 and 16 follow-up visits. 
8.4.5 
Treatment Effectiveness Assessment 
The Treatment Effectiveness Assessment (Ling, 2012) is a 4-item self-administered assessment 
that uses a Likert scale (1-10) to document changes in four life domains: substance use, personal 
responsibilities, health, and community. The Treatment Effectiveness Assessment will be 
collected at screening, mid-treatment (week 6 visit 2) and end-of-treatment (week 12 visit 2). 
8.4.6 
Tobacco Use History 
The Tobacco Use History assessment will be administered at screening, mid-treatment (week 6 
visit 2), and end-of-treatment (week 12 visit 2) to incorporate PhenX Core Tier 1 items. Tobacco 
use items assessed include lifetime use, 30-day quantity and frequency, and age of first tobacco 
use. 
8.4.7 
Quality of Life 
Quality of Life will be assessed using items from the PhenX Core Tier 1. Participants will be asked 
to provide ratings of general health, physical health, and mental health during the past 30 days at 
screening, mid-treatment (week 6 visit 2), and end-of-treatment (week 12 visit 2). 
8.4.8 
Sexual Risk Behaviors  
The Sexual Risk Behaviors assessment will be administered at screening, mid-treatment (week 
6 visit 2), and end-of-treatment (week 12 visit 2) to assess engagement in risky sexual related 
behaviors in the 30 days prior to each assessment. Participants will answer questions about the 
number and sex of sexual partners, HIV status of partners, and use of condoms as well as the 
use of drugs and alcohol during sex.  
8.4.9 
Genetic Sampling 
The NIDA CCTN has requested that blood samples for genetic analysis be obtained for all new 
CTN pharmacotherapy trials. Randomized participants who consented to the optional genetic 
testing will have approximately 30 mL (2 tablespoons) of blood drawn at the end of the day of 
randomization, after all medication administration and monitoring has been completed. However, 
if the sample cannot be collected on the day of randomization, the sample may be collected at 
any subsequent visit, ideally at a visit in which a blood draw is scheduled to occur. The blood 
samples will be coded and only the local investigators will know the identity of the participant 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
43 
providing the sample. The blood sample will be sent to the Rutgers University Cell and DNA 
Repository for storage and future analysis. 
8.5 
Adherence Measures 
8.5.1 
Study Medication Dosing Logs 
Dosing logs will document medication administered in-clinic and dispensed for take-home dosing. 
Medications to be recorded on dosing logs include naloxone, injectable study medication, and 
oral study medication. A dosing log will also document return of oral medication blister cards and 
the participant’s self-report of doses taken. Logs will be completed at each visit when medications 
are dispensed or administered throughout the study. 
8.5.2 
Injection Administration Form 
The Injection Administration Form(s) will document whether injectable study medication is to be 
administered, it will automatically assign (in real time) an injection kit number for administration, 
and it will document information related to the administration of the medication (e.g., time of 
injection). The form is to be completed only after the participant appears in clinic. This form will 
be completed at each visit in which injectable study medication is administered (i.e., weeks 1, 4, 
7, and 10). 
8.5.3 
Oral Medication Dispensation Form 
The Oral Medication Dispensation Form(s) will document whether oral study medication is to be 
dispensed and it will automatically assign (in real time) a blister card number for dispensation. 
The first question on this form is to be completed only after the participant appears in clinic, even 
if oral study medication is not being dispensed.  
8.5.4 
Oral Study Medication Blood Levels 
One of the methods used to evaluate medication adherence requires collecting blood to test for 
bupropion and hydroxybupropion levels at a central bioanalytical laboratory. Blood will be 
collected for this purpose prior to study medication administration at visits 0401, 0701, and 1001 
and again at the final medication phase visit (week 12 visit 2).  
8.5.5 
Video Based Adherence to Oral Study Medication Database 
Dosing adherence will be assessed in part by automated visual recognition software during the 
video capture within the AiCure app. The software converts adherence information into data that 
is automatically entered and stored in the database maintained by AiCure for this study. This 
database will contain data indicating whether a video was submitted, whether the dosing was 
deemed valid (i.e., the study participant is clearly ingesting study medication), and whether the 
dosing was self-reported as opposed to documented via video. Study staff will help ensure 
information in the AiCure dashboard (the visual representation of the database) is accurate. No 
additional logs or forms are required for documenting video based adherence.  
8.5.6 
End of Medication Form 
An End of Medication Form will be completed any time a decision is made to discontinue a 
participant from further medication administration or at the post-medication phase follow-up 
assessment in Week 13. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
44 
8.6 
Administrative and Other Forms 
8.6.1 
Locator Form 
A locator form will be used to obtain information to assist in tracking participants during treatment 
and at follow-up. The locator form will collect information such as participants’ current address, 
email address, social media accounts, and phone numbers, as well as names, addresses, and 
phone numbers of family/friends who may know how to reach the participants if direct contact 
efforts are unsuccessful. This information will be collected at screening and updated in weeks 3, 
6, 9, and 12 and whenever the participant reports a change in locator information. No identifying 
information from this form will be used in data analyses. 
8.6.2 
Eligibility - Randomization 
The Enrollment form lists all the study inclusion and exclusion criteria and must be completed for 
every participant who has signed consent and entered the screening/baseline phase. Eligibility is 
assessed on an ongoing basis during the screening phase. Only participants who continue to 
meet study eligibility criteria will be allowed to continue in the screening phase, including the 
naltrexone pre-induction procedures (e.g., naloxone challenge). The Enrollment form is to be 
completed in the electronic data capture system after all screening and baseline procedures are 
complete. Eligible participants will be randomized; ineligible participants will be excluded and 
deemed screen failures. 
8.6.3 
Missed Visit Form 
This form is designed to capture the reason any study visit was missed. Once the visit window 
closes without completion of the visit, this Missed Visit Form will be completed directly in the 
electronic data capture system. Completing this form will remove the requirement for most 
assessments scheduled for that missed visit. Active tracking and follow-up should be performed 
for all missed visits.  
8.6.4 
Protocol Deviation Form 
This form should be entered into the electronic data capture system whenever a protocol deviation 
occurs. This form will document a description of the deviation, how it occurred, the corrective 
action taken to resolve the specific deviation, as well as a description of the plan implemented to 
prevent future occurrences of similar deviations.  
8.6.5 
Protocol Satisfaction Surveys 
Satisfaction with medication components, smartphone app, and other study procedures will be 
recorded on the Protocol Satisfaction Survey completed at the week 13 visit. A survey will be 
completed by both the participant and a study team member. These forms will be used in data 
analyses to evaluate secondary objectives including the acceptability of the combination 
medication and the usefulness of smartphone app-based technology for improving and monitoring 
medication adherence. 
8.6.6 
Study Completion Form 
Information regarding when and why study visits were stopped for each participant, including 
whether a participant completed the final follow-up visit in week 16, will be recorded on this form. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
45 
9.0 
TRAINING 
The study staff will be trained as specified in the Training Plan. Required training will include 
Human Subjects Protection (HSP) and Good Clinical Practice (GCP), as well as protocol-specific 
training as needed (e.g., assessments, study interventions, safety procedures, data management 
and collection). Support mechanisms will also be identified as part of the training (e.g., who to 
contact for aid, questions, resources). All study staff will also complete any additional training per 
their study site and IRB requirements. An Operations Manual will be provided for this study that 
will outline study procedures in more detail as necessary for the day-to-day conduct of the trial. 
The Operations Manual will be used to train study staff, to provide reference for study procedures, 
and to support quality management activities. 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
46 
10.0 STATISTICAL ANALYSES 
10.1 General Design 
10.1.1 
Study Hypothesis 
The primary hypothesis is that the combination of extended-release depot naltrexone plus 
extended-release bupropion medication (AMC), relative to the PLB, will be associated with greater 
MA non-use. Participants will be randomized to one of two conditions, PLB or AMC. 
Randomization will be stratified by site. 
10.1.2 
Sample Size 
A sample size of 400 is chosen for this study to detect the difference between the two treatment 
arms. A total of 7 - 10 sites will participate in the trial. It is anticipated that each site will randomize 
approximately 30 - 70 participants over the recruitment period.  
10.1.3 
Primary Outcomes  
The primary efficacy outcome measure is MA-negative urine drug screen (UDS) test results 
obtained during weeks 5 to 6 and weeks 11 to 12, which will be compared by treatment group 
(AMC versus PLB). Participants will be defined as a “responder” if there are at least 75% MA-
negative UDS tests during the pre-specified evaluation period. The treatment groups will be 
compared as to the proportion of responders using a Z test. All treatment comparisons will be 
performed under the Intent-to-Treat (ITT) criteria. 
10.1.4 
Secondary Outcomes 
Secondary outcomes include methamphetamine and other substance use outcomes in the pre-
evaluation period, in the evaluation period, at the follow-up assessment, and any combination of 
these periods, for responders, non-responders, and other sub-groups. Secondary outcomes also 
include depression scores, quality of life, overall functioning, clinic attendance, and ratings of 
participant and staff satisfaction with study procedures, including use of the smartphone app, 
compensation, and study medication. Secondary safety outcomes will be participants’ reports of 
treatment emergent adverse events including serious adverse events collected at scheduled clinic 
visits or via other contact.  
Drug use will be measured by several outcomes including but not limited to the Treatment 
Effectiveness Score (TES; Ling et al., 1997), days of self-reported drug use, number of 
consecutive negative UDS, and UDS as a binary outcome (positive or negative) across time. The 
TES is the percentage of the scheduled urine drug screens that were negative for each drug. 
Mixed-model analysis of repeated measures will be used to explore the presence of time-related 
medication effects, including severity of cravings. In the models, we will control for baseline MA 
use and other key demographic and participant variables. Additional analyses will include 
assessment of drug use in the pre-evaluation period, over the entire medication period and at the 
follow-up assessment. Changes occurring over the medication period in severity and type of drug-
related problems and in quality of life will be analyzed with parametric and nonparametric 
measures. Participant and staff satisfaction ratings will be summarized. A two-sided test of 
significance will be used with a p-value less than 0.05 indicating significance. 
Analyses of secondary outcomes will be primarily performed on all individuals who are 
randomized and inducted onto study medications. Secondary analyses will also be performed by 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
47 
examining responses in subgroups with varying characteristics. Adherence with oral study 
medication dosing will be measured by participant self-report, smartphone device app dosing 
videos, and in-clinic observation. A dosing adherent per-protocol analysis will be performed by 
evaluating response rates in the medication-adherent group. Because per-protocol analyses may 
be biased (Sheiner and Rubin, 1995) an unbiased complier-adjusted-causal-effects analysis (Jo 
and Stuart, 2009) may also be used to adjust for adherence. Multiple testing will not be adjusted 
for in the secondary analyses, since these are not part of the study’s primary objective. When 
multiple tests are conducted, the chance of finding a significant difference in one of the tests, 
when in fact no difference exists, is greater than the stated Type I error rate. The investigators 
are aware of the issues associated with multiple testing and will interpret results with caution. 
All the above mentioned secondary analyses (except staff satisfaction ratings) will be performed 
in a similar way as the primary analysis. For continuous outcomes, ordinary least squares and 
mixed effects model for repeated measures (MMRM) will be used and for binary outcomes, a 
logistic regression will be used. These will be described in the protocol Statistical Analysis Plan 
(SAP). 
10.2 Interim Analyses 
In coordination with the centralized Data and Statistics Center, a DSMB will monitor the progress 
of the trial. As requested by the DSMB, interim analyses of sample size re-estimation and 
monitoring of the efficacy and safety data will be performed. However, if ADAPT-2 has a rapid 
recruitment such that the proportion of Week 12 outcomes realized is small when recruitment is 
completed or nearly completed, discussion with the DSMB will take place about whether sample 
size re-estimation and interim analysis of efficacy data is warranted. 
10.2.1 
Sample Size Re-estimation 
Sample size re-estimation analysis will be conducted when approximately half of the participants 
have been enrolled. This analysis will not reveal the treatment effect observed in the trial at the 
time of this interim analysis. A sample size re-estimation will be performed to assess the adequacy 
of the projected study sample size and whether a sample size increase is warranted.  
The timing of the sample size re-estimation is based on a number of factors: recruitment rate, 
timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size 
re-estimation. The sample size re-estimation will be done only once, and done before any interim 
analysis of the primary outcome is performed. The results of the sample size re-estimation 
analysis would be presented in a closed session of the DSMB, who will then provide a 
recommendation to the NIDA CCTN regarding whether the target sample size should be modified. 
A decision regarding any such modification would be made subsequently by the CCTN, taking 
into consideration the recommendation of the DSMB. 
Update to the sample size: 
The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, 
prepared by the DSC. Based on the results, the DSMB and NIDA CCTN recommended increasing 
the originally planned sample size of 370 by 30 additional participants to maintain the targeted 
90% power. The CCTN approved the increase in sample size to 400 participants in a letter to the 
Lead Investigator dated August 13, 2018. 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
48 
10.2.2 
Interim Monitoring of Primary Efficacy Endpoint 
Interim monitoring for efficacy will be performed. There will be no interim efficacy monitoring 
before a sample size re-estimation is performed (or a determination that re-estimation is not 
needed) because sample size re-estimation could change the target sample size, affecting the 
alpha spending function used in the interim efficacy monitoring. After sample size re-estimation, 
interim efficacy monitoring will be performed only once during the recruitment period.  
All interim monitoring will use an O’Brien-Fleming-type boundary with information fraction equal 
to the proportion of the target sample size with primary outcome. This approach spends very little 
alpha at the interim look, therefore the impact of an interim monitoring on the sample size is 
negligible. The only criterion for early stopping for efficacy will be based on Z-scores and its 
relation to O’Brien-Fleming-type boundary. 
Before recommending early termination, the DSMB will consider: 
 
Internal consistency of primary and secondary results. 
 
Internal consistency of primary and secondary results by subgroups defined by baseline 
characteristics (e.g., severity of MA use, tobacco use history, treatment effectiveness 
assessment and visual analog craving scale). 
 
Distribution of baseline prognostic factors among the two groups. 
 
Consistency of primary and secondary results across clinical sites and among clinical 
sites enrolling larger numbers of participants. 
 
Possible impact of missing data from missed participant visits for assessment of the 
primary and secondary response variables. 
 
Possible differences in concomitant interventions or medications. 
10.2.3 
Safety Interim Analyses 
Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times 
per the DSMB’s request. These will include analysis of adverse events and narrative reports on 
serious adverse events. 
Simultaneous with primary interim efficacy monitoring analysis, a “poor efficacy” statistic will be 
calculated to assess whether the combination of extended-release depot naltrexone plus 
extended-release bupropion medication (AMC), relative to the PLB, is associated with greater MA 
use. This analysis will be conducted after the sample size re-estimation. If the “poor efficacy of 
AMC” statistic crosses its boundary, defined as the response rate for PLB minus AMC being 
greater than 10%, the DSMB will consider whether to stop the trial early because of poor efficacy 
of AMC relative to PLB.  
10.2.4 
Conditional Power and Futility 
Unless otherwise requested, a futility/conditional power calculation will be performed every time 
interim monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3, 
this will stimulate a discussion among the DSMB members about whether we should stop for 
futility. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
49 
10.3 Demographic and Baseline Characteristics 
Baseline demographic and clinical variables will be summarized for participants randomized and 
inducted on study medications. Descriptive summaries of the distribution of continuous baseline 
variables will be presented with percentiles (median, 25th and 75th percentiles), and with mean 
and standard deviation. Categorical variables will be summarized in terms of frequencies and 
percentages.  
10.4 Description of Plans to Conduct Analyses of Study Results by Sex 
and Race/Ethnicity 
The association between specific demographic characteristics and outcome will be studied. The 
demographic characteristics of potential importance include: age, sex, race, and ethnicity. In 
accordance with NIH guidelines, analyses will be completed to determine whether treatment 
response was significantly affected by participant minority/sex status using an interaction term for 
treatment, time and minority/sex as appropriate. 
10.5 Safety Analysis 
AEs, including SAEs, will be summarized by body system and preferred term using MedDRA 
codes (per The Medical Dictionary for Regulatory Activities). AEs will be presented as: (1) the 
number and proportion of participants experiencing at least one incidence of each event overall; 
and (2) the total number of each event overall in tabular form. Listings of SAEs will be sorted by 
body system, and preferred term. Detail in these listings will include severity, relationship to study 
drug(s), and action taken, as available. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
50 
11.0 REGULATORY COMPLIANCE, REPORTING AND MONITORING 
11.1 Statement of Compliance 
This study will be conducted in compliance with the current version of the study protocol, in 
accordance with the ethical principles outlined in the Declaration of Helsinki, consistent with 
current International Conference on Harmonization Good Clinical Practice (GCP) Guidelines, and 
all other applicable regulatory requirements.  
11.2 Institutional Review Board Approval 
Participating sites must obtain written approval of the study protocol, consent form(s), other 
supporting documents, any materials given to the participant, and any advertising for participant 
recruitment from their Institutional Review Board (IRB) of record or Independent Ethics Committee 
(IEC) to participate in the study. Prior to initiating the study, site investigators will obtain written 
IRB approval to conduct the study at their respective site. Any amendments to the protocol or 
consent must be approved by the Lead Investigator and IRB before implementation. Progress 
reports, and any required post-approval reports will be submitted to the IRBs either annually or at 
a frequency requested by each IRB so that continuous study approval is maintained without lapse. 
The Lead Investigator is responsible for maintaining copies of all performance site(s)’ current IRB 
approval notice(s) and IRB-approved consent document(s), including approvals for all protocol 
and consent modifications. These materials must be received by the Lead Investigator prior to 
the initiation of research activities at a given site, must be maintained by the Lead Investigator 
throughout the course of the trial, and must be available at any time for audit. 
11.3 Research Advisory Panel of California (California sites only) 
Prior to initiating the study, the sponsor or designee will obtain written approval from the Research 
Advisory Panel of California (RAP-C). Any planned research project to be conducted in California 
requiring the use of a Schedule I or Schedule II Controlled Substance as its main study drug as 
well as research for the treatment of controlled substance addiction or abuse utilizing any drug, 
scheduled or not, must be submitted to RAP-C for review and approval prior to study start-up. 
Study approval is based on review of the study protocol, consent form, and other pertinent study 
documents. Yearly reports will be provided to the RAP-C by the sponsor or designee to maintain 
continuing study approval. Protocol amendments must also be submitted, and it is required that 
the Panel be notified of any significant study drug related adverse events that may emerge during 
conduct of the study at the California sites only. 
11.4 Informed Consent 
All potential candidates for the study will be given a current IRB-approved consent form in English 
to read. In accordance with IRB policies, appropriately trained and qualified study personnel will 
explain all aspects of the study in lay language and answer all the study candidates’ questions. 
Participants who remain interested after receiving an explanation of the study will be given a short 
quiz to test their understanding of the project including the purpose, procedures involved, and the 
voluntary nature of participation. Those who cannot successfully answer all quiz items will have 
the study re-explained by research staff with a focus on aspects they did not understand. Anyone 
who cannot demonstrate appropriate understanding of the study will be ineligible to participate 
and will be assisted in finding other treatment resources. Those who demonstrate understanding 
of the study and voluntarily agree to participate will be asked to sign the IRB-approved consent 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
51 
form. Participants will not be administered any assessments or participate in study procedures in 
any way prior to signing and dating the IRB-approved consent form. 
Informed consent is a process and not just a document. The informed consent process is a means 
of providing study information to each prospective participant in understandable language and 
taking all the time needed to answer all questions to allow for an informed decision about study 
participation. The IRB-approved consent form must be revised whenever important new 
information becomes available including whenever the protocol is amended in any way that may 
affect a study participant’s willingness to continue participating in the trial. All study sites must 
have the study consent forms approved by their IRB(s). Sites must maintain the original signed 
IRB-approved consent forms for all study participants in a locked, secure location that is in 
compliance with IRB and institutional policies. Signed/dated IRB-approved consent forms must 
be accessible for quality assurance review and regulatory compliance at all times. Every study 
participant will be provided with a copy of the signed/dated consent form that can be used as 
continual reference for study information including procedures, possible risks and/or side effects, 
and contact information for questions and/or emergencies. California site participants will also be 
provided with a California Research Subjects’ Bill of Rights. Individuals who refuse to participate 
or who withdraw from the study will be treated without prejudice.  
11.5 Health Insurance Portability Accountability Act (HIPAA) 
Study sites may be required by their institutions to obtain authorization from participants for use 
of protected health information. Releases of participant identifying information that are permitted 
by the HIPAA regulations, but which are prohibited by other applicable federal regulations and/or 
state/Commonwealth laws and regulations, are prohibited. Sites will be responsible for 
communicating with their IRBs or Privacy Boards and obtaining the appropriate approvals or 
waivers to be in regulatory compliance. 
11.6 Investigator Assurances 
Each participating site must file (or have previously filed) a Federalwide Assurance (FWA) with 
the HHS Office for Human Research Protections setting forth the commitment of the organization 
to adhere to appropriate policies and procedures for the protection of human research subjects. 
The site’s FWA must be current at trial initiation and must be maintained throughout the duration 
of the study with documentation sent to NIDA or its designee, as requested. Research covered 
by these regulations cannot proceed in any manner prior to NIDA receipt of certification that the 
research has been reviewed and approved by the OHRP-registered IRB designated in the 
assurance (45 CFR 46.103(b) and (f)). Prior to initiating the study, the principal investigator and 
sub-investigators at each study site will sign a protocol signature page, providing assurances that 
the study will be performed according to the standards stipulated therein. 
11.7 Financial Disclosure 
All investigators will comply with the requirements of 42 CFR Part 50, Subpart F to ensure that 
the design, conduct, and reporting of the research will not be biased by any conflicting financial 
interest. All study personnel with decision-making responsibilities regarding the protocol must 
comply with their institution’s policy regarding conflict of interest. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
52 
11.8 Confidentiality 
Confidentiality will be maintained in accordance with all applicable federal regulations and/or state 
law and regulations. Particular attention is drawn to the regulations promulgated by the Food and 
Drug Administration (FDA) under the Freedom of Information Act providing, in part, that 
proprietary information furnished to investigators and Institutional Review Boards will be kept 
confidential by the FDA only if maintained in confidence by the clinical investigator and 
Institutional Review Board (IRB). By signing the protocol signature page, the investigator affirms 
that information furnished to the investigator by NIDA will be maintained in confidence and such 
information will be divulged to the IRB, Ethical Review Committee, or similar expert committee; 
affiliated institution; and employees only under an appropriate understanding of confidentiality 
with such board or committee, affiliated institution and employees.  
The Lead Investigator obtained a federal Certificate of Confidentiality (CoC) and distributed it to 
all sites when it was received. A CoC helps researchers protect the privacy of human research 
participants enrolled in biomedical, behavioral, clinical and other forms of sensitive health-
related research (e.g., drug use). Certificates protect against compulsory legal demands, such as 
court orders and subpoenas, for identifying information or identifying characteristics of a research 
participant. The department that issues the CoC will be advised of any changes in the CoC 
application information that may occur during the study, as required. Participating sites will be 
notified if CoC revision is necessary.  
Participant records will be kept confidential by using study codes for identifying participants on 
CRFs, secure separate storage of any documents that have participant identifiers, and secure 
computing procedures for entering and transferring electronic data. All laboratory specimens, 
eCRFs, reports, and other data records will be identified by the participant identification study 
code that includes the site number, node number, and participant number. Research records will 
be stored in a locked cabinet. Only authorized individuals will have access to the study records. 
Participant information will not be released without written permission, except as necessary for 
monitoring by the FDA, NIDA-contracted monitors, local node monitors, lead node staff, or NIDA. 
By signing the protocol signature page, the investigator agrees that within local regulatory 
restrictions and ethical considerations, NIDA or any regulatory agency may consult and/or copy 
study documents in order to verify eCRF data. 
11.9 IND Requirements 
A request for IND exemption was submitted to FDA for this protocol, as described in title 21 of the 
Code of Federal Regulations, part 312 (21 CFR 312) and the Agency determined that the ADAPT-
2 study was exempt from FDA IND regulations, as per Title 21 of the Code of Federal Regulations, 
Part 312.2. 
Though exempt from IND regulation, this study will be conducted in accordance with International 
Council on Harmonisation Good Clinical Practices (ICH GCPs), all applicable FDA and OHRP 
Guidance documents, and any state and institutional requirements applicable at the clinical site 
level. 
11.10 Regulatory Files 
Essential documents are those documents which individually and collectively permit evaluation of 
the conduct of a trial and the quality of the data produced. These documents serve to demonstrate 
the compliance of the investigator, sponsor and monitor with the standards of Good Clinical 
Practice and with all applicable regulatory requirements. Regulatory files should be maintained 
throughout the lifecycle of the trial and should contain all required regulatory documents, study-


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
53 
specific documents, and all important study-related communications. Regulatory files will be 
checked at each participating site for regulatory document compliance prior to study initiation, 
throughout the study, as well as at study closure.  
11.11 Study Documentation 
Study documentation includes, but is not limited to, all data-related forms, workbooks, source 
documents, monitoring logs and appointment schedules, sponsor-investigator correspondence, 
signed protocols including amendments, Ethics Review Committee or Institutional Review 
Board/Committee correspondence, approved current and previous consent forms, and signed 
participant consent forms. Source documents include all recordings of observations or notations 
of clinical activities and all reports and records necessary for the evaluation and reconstruction of 
the clinical research study. All clinical trial information should be recorded, handled, and stored in 
a way that allows its accurate reporting, interpretation, and verification. The original recording of 
an observation should be retained as the source document.  
11.12 Records Retention and Requirements 
Research records for all study participants (e.g., case report forms, source documents, signed 
consent forms, and regulatory files) are to be maintained by the investigator in a secure location 
for a minimum of 3 years after the study is completed and closed. These records are also to be 
maintained in compliance with IRB, state and federal requirements, whichever is longest. The 
sponsor and Lead Investigator must be notified in writing and acknowledgment must be received 
by the site prior to the destruction or relocation of research records. 
11.13 Reporting to Sponsor 
The site principal investigator agrees to submit accurate, complete, legible and timely reports to 
the sponsor, as required. These include, but are not limited to, reports of any changes that 
significantly affect the conduct or outcome of the trial or increase risk to study participants. 
Adverse Event reporting and Serious Adverse Event reporting will occur as described herein. At 
the completion of the trial, the Lead Investigator will provide a final report to the sponsor. 
11.14 Safety Monitoring 
11.14.1 
Adverse Events (AEs) 
All adverse events (medical and/or psychiatric) occurring during the course of the study will be 
assessed, documented, and reported. AEs occurring during the course of the clinical trial will be 
collected, documented, and reported by the principal investigator or sub-investigators according 
to the specific instructions detailed in this section of the protocol and Appendix A. Appropriately 
qualified and trained medical personnel will elicit participant reporting of AEs and SAEs at each 
study visit designated to collect AEs (i.e., the first visit following informed consent and at every 
visit thereafter). Study staff will follow-up on the status of any AEs that remain at the post-
medication phase follow-up visit assessment for up to 30 days post last study visit.  
An AE is defined as any reaction, side effect, or untoward event that occurs during the course of 
the clinical trial, whether or not the event is considered investigational product-related or clinically 
significant. For this study, AEs will include events reported by the participant, as well as clinically 
significant abnormal findings on physical examinations or laboratory evaluations. A new illness, 
symptom, sign or clinically significant clinical laboratory abnormality or worsening of a pre-existing 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
54 
condition or abnormality is considered an AE. Stable chronic conditions, such as arthritis, which 
are present prior to clinical trial entry and do not worsen are not considered AEs. All AEs must be 
recorded on the AE log and CRF. The AE log and CRF are also used to record follow-up 
information for unresolved events reported on previous visits. 
Each week, appropriately qualified and trained medical personnel must review the AE log and 
CRF completed for the previous week for any events that were reported as continuing. All AEs, 
including clinically significant abnormal findings on laboratory evaluations, regardless of severity, 
will be followed until satisfactory resolution.  
A study medical clinician (MD, DO, PA, or NP) will review or provide consultation for each adverse 
event. These reviews will include an assessment of the severity and causality to the study drug 
or study procedures. The study medical clinician, in collaboration with the study physician and 
site principal investigator, will also make decisions to exclude, refer, or withdraw participants as 
required. The study staff will be trained to monitor for and report adverse events and serious 
adverse events. 
Each participating site has established practices for managing medical and psychiatric 
emergencies, and the study staff will continue to utilize these procedures. Study medical clinicians 
at each site will be responsible for monitoring participants for possible clinical deterioration or 
other problems, and for implementing appropriate courses of action. 
11.14.2 
 Definitions of Adverse Events and Serious Adverse Events 
Full definitions of adverse events and serious adverse events, their identification, and 
characterization regarding severity and relationship to therapy and processing are described in 
Appendix A. 
11.14.3 
 Reportable Adverse Events and Serious Adverse Events 
For the purpose of this study, all AEs and SAEs will require reporting in the electronic data system. 
Reporting of AEs and SAEs is described in Appendix A. The local site is responsible for reporting 
all their local AEs and SAEs to their IRBs per IRB guidelines. 
11.14.4 
Data and Safety Monitoring Board (DSMB) 
This study will utilize the CTN DSMB to oversee ongoing trial progress. The purpose of this board 
is to determine whether risks emerge during the conduct of the trial that make continuation 
unethical. This process is intended to assure the IRBs, the sponsor, and investigators that 
participants are provided with an accurate and ongoing risk evaluation when participating in CTN 
research trials. Safety monitoring begins with the initial review of the protocol during the study 
development process. Reports of participant seizures will be provided to the DSMB as they occur. 
The DSMB will meet as necessary over the study duration. 
11.14.5 
Medical Monitor 
Under the supervision of the NIDA-assigned Medical Monitor, the study Safety Monitor will be 
responsible for overseeing safety and for evaluating all Adverse Events (AEs). The Safety Monitor 
will review all Serious Adverse Events (SAEs) within one business day of their reporting in 
eClinical and all other Adverse Events on a regular basis. The Medical Monitor will review events 
regularly and will be available at all times for consultation. It is the responsibility of the site principal 
investigator to provide this information to the Safety Monitor. It is also the site principal 
investigators’ responsibility to inform the IRBs per IRB guidelines. 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
55 
In addition, the Medical Monitor will independently review the safety data, present it to the DSMB 
for periodic review, and provide site principal investigators a “Safety Letter” when necessary. The 
Medical Monitor will determine which safety events require expedited reporting to NIDA, the 
DSMB, study drug manufacturers, and regulatory authorities. This will include all suspected 
adverse reactions that are serious and unexpected. Furthermore, in the event of participant 
seizures, reports will be submitted to the DSMB using the AE form with additional information 
about the event as deemed appropriate. 
11.15 Protocol Deviations: Reporting and Management 
Any divergence from procedures and requirements outlined in the protocol will be classified a 
protocol deviation. A protocol deviation is an action (or inaction) that alone may or may not affect 
the scientific soundness of the investigation or seriously affect the safety, rights, or welfare of a 
study participant. In some cases, a protocol deviation may compromise participant safety, 
participant rights, inclusion/exclusion criteria or the integrity of study data and is cause for 
corrective action to resolve the departure and to prevent re-occurrence. Protocol deviations will 
be monitored at each site for (1) significance, (2) frequency, and (3) impact on the study 
objectives, to ensure that site performance does not compromise the integrity of the trial. The 
decision about whether a deviation from the protocol will be designated as minor or major will be 
made by the protocol’s Lead Investigator(s) in conjunction with the Clinical Coordinating Center 
(CCC). The consequences will be specified and participating sites will be informed. 
All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the 
Protocol Deviation CRF. Additionally, each site is responsible for tracking and reporting protocol 
deviations to their IRB, as required. The CCC and the Data and Statistics Center (DSC) and the 
Lead Investigator must be contacted immediately if an unqualified/ineligible participant is entered 
into the study. 
11.16 Audits 
The Sponsor has an obligation to ensure that this trial is conducted according to good research 
practice guidelines and may perform quality assurance audits for protocol compliance. The Lead 
Investigator and authorized staff from the Texas Node; the National Institute on Drug Abuse 
Center for the Clinical Trials Network (NIDA CCTN, the study sponsor); NIDA’s contracted agents, 
monitors or auditors; and other agencies, such as the Department of Health and Human Services 
(HHS), the Food and Drug Administration (FDA), the Office for Human Research Protections 
(OHRP), and the sites’ Institutional Review Boards may inspect research records for verification 
of data, compliance with federal guidelines on human participant research, and to assess 
participant safety. 
11.17 Quality Assurance Monitoring 
Protection of the rights and welfare of study participants will be a vigilant process conducted by 
the research teams at all sites and at the Lead Node and by the sponsors of the research. 
Monitoring of the study sites will be conducted on a regular basis using a combination of NIDA- 
contracted monitors, local node monitors, and lead node staff.  
Site investigators will host periodic visits by monitors who will ensure all study procedures are 
appropriately conducted, and that study data are generated, documented and reported in 
compliance with the protocol, GCP, and applicable regulations. These monitors will audit, at 
mutually agreed upon times, regulatory documents, case report forms (CRFs), and corresponding 
source documents for each participant. NIDA-contracted monitors will assure that submitted data 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
56 
are accurate and in agreement with source documentation and will also review 
regulatory/essential documents such as correspondence with the IRB. 
Areas of particular concern will be participant signed/dated consents, eligibility for study 
participation, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory 
documents, participant records, study drug accountability, and principal investigator supervision 
and involvement in the trial. Reports will be prepared following the visits and forwarded to the site 
principal investigator, the Lead Investigator and NIDA CCTN. 
Qualified node personnel (Node Protocol Managers and/or QA monitors) will provide site 
management for each site during the trial to encourage and assess compliance with the study 
protocol, Good Clinical Practice guidelines, and to ensure the integrity of the trial progress. These 
visits will take place as specified by the local protocol team, Node PI or Lead Team, and visits will 
occur as often as needed to help prevent, detect, and correct problems at the study sites. Node 
staff will ensure that study procedures are properly followed and that site staff are trained and 
able to conduct the protocol appropriately. If the node staff’s review of study documentation 
indicates that additional training of study personnel is needed, node staff will undertake or arrange 
for that training.  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
57 
12.0 DATA MANAGEMENT AND PROCEDURES 
12.1 Design and Development 
This protocol will utilize a centralized Data and Statistics Center (DSC). The DSC will be 
responsible for the development of the Case Report Forms (CRFs) and Participant Reported 
Outcome (PRO) forms, development and validation of the clinical study database, ensuring data 
integrity, and training site and participating node staff on applicable data management 
procedures. A web-based distributed data entry model will be implemented. This electronic data 
capture system (Advantage eClinical) will be developed to ensure that guidelines and regulations 
surrounding the use of computerized systems used in clinical trials are upheld. The remainder of 
this section provides an overview of the data management plan associated with this protocol. 
12.2 Site Responsibilities 
The data management responsibilities of each site will be specified by the Lead Node and the 
DSC. 
12.3 Data and Statistics Center Responsibilities 
The DSC will 1) develop and apply data management procedures to ensure the collection of 
accurate and good-quality data, 2) provide Case Report Forms in electronic (eCRF) and paper 
(CRF) format, and Participant Reported Outcome forms in electronic (ePRO) and paper (PRO) 
format for the collection of all data required by the study, 3) develop data dictionaries for each 
CRF and PRO form that will comprehensively define each data element, 4) prepare instructions 
for the use of Advantage eClinical and for the completion of forms, 5) conduct ongoing data 
validation and cleaning activities on study data collected from all participating sites, and 6) perform 
data validation and cleaning activities prior to any interim analyses and prior to the final study 
database lock.  
12.4 Data Collection and Entry 
Data will be collected at the study sites on source documents and entered by the site on the form 
in Advantage eClinical, or will be collected via direct entry into the eCRF by the site or direct entry 
into the ePRO by the participant. In the event that Advantage eClinical is not available, the DSC 
will provide the sites with paper source documents and completion instructions. Data will be 
entered into Advantage eClinical in accordance with the instructions provided during protocol-
specific training and guidelines established by the DSC. Data entry into the forms shall be 
performed by authorized individuals. Selected eCRFs may also require the investigator’s 
electronic signature. 
The principal investigator at the site is responsible for maintaining accurate, complete and up-to-
date research records. In addition, the investigator is responsible for ensuring the timely 
completion of forms for each research participant.  
12.5 Data Monitoring, Cleaning, and Editing 
Data will be entered into the DSC automated data acquisition and management system 
(Advantage eClinical). Forms will be monitored for completeness and accuracy throughout the 
study. Dynamic reports listing missing values and forms are available to sites at all times in 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
58 
Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC 
will identify inconsistencies within forms and between forms and post data clarification requests 
or queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies 
and errors by entering all corrections and changes directly into Advantage eClinical. 
The CCC will conduct regular visits to sites, during which audits comparing source documents to 
the data entered will be performed. Any discrepancies identified between the source document 
and the eCRF or ePRO will be corrected by the site. 
Trial progress and data status reports, which provide information on recruitment, availability of 
primary outcome, treatment exposure, attendance at follow-up visits, regulatory status, and data 
quality, will be generated routinely and posted to a secure website. These reports will be available 
to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and 
NIDA, to monitor the sites’ progress on the study. 
12.6 Database Transfer and Lock 
At the conclusion of data collection for the study, the DSC will perform final data cleaning activities 
and will “lock” the study database from further modification. The final analysis dataset will be 
returned to the Lead Investigator and to NIDA, as requested, for storage and archive. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
59 
13.0 PUBLICATIONS AND OTHER RIGHTS 
Protocol development and implementation in the NIDA CTN is a collaborative process. The 
planning, preparation, and submission of publications will follow the policies of the CTN 
Publications Committee. Individuals making substantive contributions to the protocol 
development and implementation will have opportunities to participate in publications. Other 
contributors will also be acknowledged. Per NIH policy, the results of the trial are to be made 
available to the research community and to the public at large. The project will adhere to 
stipulations in accord with the NIH Public Access Policy (for any articles based on work supported 
by NIH funding) required for Applications, Proposals, or Reports Submitted After July 1, 2013, as 
set forth in: 
http://publicaccess.nih.gov/ 
http://publicaccess.nih.gov/FAQ.htm#792 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-119.html  
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
60 
14.0 SIGNATURES 
 
SPONSOR’S REPRESENTATIVE (CCTN DESIGNEE) 
 
 
 
 
 
Udi Ghitza, PhD 
 
 
 
 
Printed Name 
 
Signature 
 
Date 
 
ACKNOWLEDGEMENT BY INVESTIGATOR: 
 
 
I am in receipt of version 6.0 of the protocol and agree to conduct this clinical study in accordance 
with the design and provisions specified therein. 
 
I agree to follow the protocol as written except in cases where necessary to protect the safety, rights, 
or welfare of a participant, an alteration is required, and the sponsor and IRB have been notified prior 
to the action. 
 
I will ensure that the requirements relating to obtaining informed consent and institutional review 
board (IRB) review and approval in 45 CFR 46 are met. 
 
I agree to personally conduct or supervise this investigation at this site and to ensure that all site staff 
assisting in the conduct of this study are adequately and appropriately trained to implement this 
version of the protocol and that they are qualified to meet the responsibilities to which they have been 
assigned. 
 
I agree to comply with all the applicable federal, state, and local regulations regarding the obligations 
of clinical investigators as required by the Department of Health and Human Services (DHHS), the 
state, and the IRB. 
 
SITE’S PRINCIPAL INVESTIGATOR 
 
 
 
 
 
      
 
 
 
 
Printed Name 
 
Signature 
 
Date 
 
Site Name  
 
      
Node Affiliation  
 
      
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
61 
15.0 REFERENCES 
Anderson, A. L., Li, S. H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., . . . Elkashef, A. M. 
(2015). Bupropion for the treatment of methamphetamine dependence in non-daily 
users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 150, 
170-174. doi:10.1016/j.drugalcdep.2015.01.036 
Anggadiredja, K., Sakimura, K., Hiranita, T., & Yamamoto, T. (2004). Naltrexone attenuates 
cue- but not drug-induced methamphetamine seeking: a possible mechanism for the 
dissociation of primary and secondary reward. Brain Res, 1021(2), 272-276. 
doi:10.1016/j.brainres.2004.06.051 
Aron, J. L., & Paulus, M. P. (2007). Location, location: using functional magnetic resonance 
imaging to pinpoint brain differences relevant to stimulant use. Addiction, 102(s1), 33-43.  
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., . . . et al. 
(1995). Bupropion: a review of its mechanism of antidepressant activity. J Clin 
Psychiatry, 56(9), 395-401.  
Brecht, M.-L., Greenwell, L., & Anglin, M. D. (2005). Methamphetamine treatment: Trends and 
predictors of retention and completion in a large state treatment system (1992-2002). 
Journal of Substance Abuse Treatment, 29(4), 295-306. doi:10.1016/j.jsat.2005.08.012 
Brensilver, M., Heinzerling, K. G., & Shoptaw, S. (2013). Pharmacotherapy of amphetamine-
type stimulant dependence: an update. Drug Alcohol Rev, 32(5), 449-460. 
doi:10.1111/dar.12048 
Brensilver, M., Heinzerling, K. G., Swanson, A. N., & Shoptaw, S. (2012). Placebo-group 
responders in methamphetamine pharmacotherapy trials: The role of immediate 
establishment of abstinence. Exp Clin Psychopharmacol, 20(5), 430-435. 
doi:doi:10.1037/a0029210 
Brensilver, M., Heinzerling, K. G., Swanson, A. N., Telesca, D., Furst, B. A., & Shoptaw, S. J. 
(2013). Cigarette smoking as a target for potentiating outcomes for methamphetamine 
abuse treatment. Drug Alcohol Rev, 32(1), 96-99. doi:10.1111/j.1465-3362.2012.00423.x 
Brensilver, M., Heinzerling, K. G., Swanson, A.-N., & Shoptaw, S. J. (2012). A retrospective 
analysis of two randomized trials of bupropion for methamphetamine dependence: 
Suggested guidelines for treatment discontinuation/augmentation. Drug and Alcohol 
Dependence, 125(1–2), 169-172. doi:10.1016/j.drugalcdep.2012.03.027 
Bryant, S. G., Guernsey, B. G., & Ingrim, N. B. (1983). Review of bupropion. Clin Pharm, 2(6), 
525-537.  
Carroll, C. C., & Trappe, T. A. (2006). Personal digital video: a method to monitor drug regimen 
adherence during human clinical investigations. Clin Exp Pharmacol Physiol, 33(12), 
1125-1127. doi:10.1111/j.1440-1681.2006.04503.x 
Carroll, K. M., O'Malley, S. S., & Nuro, K. F. (1996). Compliance Enhancement: A Manual for 
the Psychopharmacotherapy of Drug Abuse and Dependence. Retrieved from West 
Haven, CT:  
Chen, Y. F., Yang, Y., Hung, H. M., & Wang, S. J. (2011). Evaluation of performance of some 
enrichment designs dealing with high placebo response in psychiatric clinical trials. 
Contemp Clin Trials, 32(4), 592-604. doi:10.1016/j.cct.2011.04.006 
Cherner, M., Suarez, P., Casey, C., Deiss, R., Letendre, S., Marcotte, T., . . . Heaton, R. K. 
(2010). Methamphetamine use parameters do not predict neuropsychological 
impairment in currently abstinent dependent adults. Drug and Alcohol Dependence, 
106(2-3), 154-163.  
Coffin, P. O., Santos, G-M., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G., Batki, 
S. L. (2017). Extended-release naltrexone for methamphetamine dependence among 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
62 
men who have sex with men: a randomized placebo-controlled trial. Addiction, 
doi:10.1111/add.13950 
Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., . . . 
O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid 
dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry, 63(2), 210-
218. doi:10.1001/archpsyc.63.2.210 
Dean, A. C., London, E. D., Sugar, C. A., Kitchen, C. M., Swanson, A. N., Heinzerling, K. G., . . . 
Shoptaw, S. (2009). Predicting adherence to treatment for methamphetamine 
dependence from neuropsychological and drug use variables. Drug Alcohol Depend, 
105(1-2), 48-55. doi:10.1016/j.drugalcdep.2009.06.008 
Diez-Quevedo, C., Rangil, T., Sanchez-Planell, L., Kroenke, K., & Spitzer, R. L. (2001). 
Validation and utility of the patient health questionnaire in diagnosing mental disorders in 
1003 general hospital Spanish inpatients. Psychosom Med, 63(4), 679-686.  
Doros, G., Pencina, M., Rybin, D., Meisner, A., & Fava, M. (2013). A repeated measures model 
for analysis of continuous outcomes in sequential parallel comparison design studies. 
Stat Med, 32(16), 2767-2789. doi:10.1002/sim.5728 
Duarte, N. A., Woods, S. P., Rooney, A., Atkinson, J. H., & Grant, I. (2012). Working memory 
deficits affect risky decision-making in methamphetamine users with attention-
deficit/hyperactivity disorder. Journal of Psychiatric Research, 46(4), 492-499. 
doi:10.1016/j.jpsychires.2012.01.006 
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S. H., Holmes, T., Smith, E. V., . . . Weis, D. 
(2008). Bupropion for the treatment of methamphetamine dependence. 
Neuropsychopharmacology, 33(5), 1162-1170. doi:10.1038/sj.npp.1301481 
Fals-Stewart, W., O'Farrell, T. J., Freitas, T. T., McFarlin, S. K., & Rutigliano, P. (2000). The 
timeline followback reports of psychoactive substance use by drug-abusing patients: 
psychometric properties. J Consult Clin Psychol, 68(1), 134-144.  
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo 
response in clinical trials for psychiatric disorders: culprits, possible remedies, and a 
novel study design approach. Psychother Psychosom, 72(3), 115-127. doi:69738 
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., . . . Ehrich, 
E. (2016). Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment 
for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-
Controlled Trial. Am J Psychiatry, 173(5), 499-508. doi:10.1176/appi.ajp.2015.15070921 
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., . . . Pollack, M. (2012). 
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant 
therapy among depressed outpatients with inadequate response to prior antidepressant 
therapy (ADAPT-A Study). Psychother Psychosom, 81(2), 87-97. 
doi:10.1159/000332050 
Fernández-Serrano, M. J., Pérez-García, M., & Verdejo-García, A. (2011). What are the specific 
vs. generalized effects of drugs of abuse on neuropsychological performance? 
Neuroscience & Biobehavioral Reviews, 35(3), 377-406. 
doi:10.1016/j.neubiorev.2010.04.008 
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., . . . 
Group, C.-I. S. (2010). Effect of naltrexone plus bupropion on weight loss in overweight 
and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, 
phase 3 trial. Lancet, 376(9741), 595-605. doi:10.1016/S0140-6736(10)60888-4 
Haggkvist, J., Bjorkholm, C., Steensland, P., Lindholm, S., Franck, J., & Schilstrom, B. (2011). 
Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat. Addict 
Biol, 16(1), 20-29. doi:10.1111/j.1369-1600.2009.00199.x 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
63 
Haggkvist, J., Lindholm, S., & Franck, J. (2009). The opioid receptor antagonist naltrexone 
attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res, 
197(1), 219-224. doi:10.1016/j.bbr.2008.08.021 
Hanson, G. R., Sandoval, V., Riddle, E., & Fleckenstein, A. E. (2004). Psychostimulants and 
vesicle trafficking: a novel mechanism and therapeutic implications. Ann N Y Acad Sci, 
1025, 146-150. doi:10.1196/annals.1316.019 
Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J., & 
Shoptaw, S. (2013). Pilot randomized trial of bupropion for adolescent 
methamphetamine abuse/dependence. J Adolesc Health, 52(4), 502-505. 
doi:10.1016/j.jadohealth.2012.10.275 
Heinzerling, K. G., Swanson, A.-N., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014). 
Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent 
participants with less than daily methamphetamine use. Addiction, 109(11), 1878-1886. 
doi:10.1111/add.12636 
Hillhouse, M. P., Marinelli-Casey, P., Gonzales, R., Ang, A., Rawson, R. A., & Authors, M. T. P. 
C. (2007). Predicting in-treatment performance and post-treatment outcomes in 
methamphetamine users. Addiction, 102(Suppl. 1), 84-95.  
Hitzemann, R., Curell, J., Hom, D., & Loh, H. (1982). Effects of naloxone on d-amphetamine- 
and apomorphine-induced behavior. Neuropharmacology, 21(10), 1005-1011.  
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008b). Naltrexone for the 
Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. 
American Journal of Psychiatry, 165(11), 1442-1448. 
doi:doi:10.1176/appi.ajp.2008.08020304 
Jayaram-Lindstrom, N., Konstenius, M., Eksborg, S., Beck, O., Hammarberg, A., & Franck, J. 
(2008a). Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with 
Amphetamine Dependence. Neuropsychopharmacology, 33(8), 1856-1863.  
Jayaram-Lindstrom, N., Wennberg, P., Beck, O., & Franck, J. (2005). An open clinical trial of 
naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry, 
59(3), 167-171. doi:10.1080/08039480510023052 
Kim, S., Westphalen, R., Callahan, B., Hatzidimitriou, G., Yuan, J., & Ricaurte, G. A. (2000). 
Toward development of an in vitro model of methamphetamine-induced dopamine nerve 
terminal toxicity. J Pharmacol Exp Ther, 293(2), 625-633.  
Koffarnus, M. N., & Bickel, W. K. (2014). A 5-trial adjusting delay discounting task: accurate 
discount rates in less than one minute. Exp Clin Psychopharmacol, 22(3), 222-228. 
doi:10.1037/a0035973 
Ling, W., Farabee, D., Liepa, D., & Wu, L. T. (2012). The Treatment Effectiveness Assessment 
(TEA): an efficient, patient-centered instrument for evaluating progress in recovery from 
addiction. Subst Abuse Rehabil, 3(1), 129-136. doi:10.2147/SAR.S38902 
Ling, W., Hillhouse, M. P., Saxon, A. J., Mooney, L. J., Thomas, C. M., Ang, A., . . . Rotrosen, J. 
(2016). Buprenorphine + naloxone plus naltrexone for the treatment of cocaine 
dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction, 
111(8), 1416-1427. doi:10.1111/add.13375 
Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997). 
Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res 
Monogr, 175, 208-220.  
Loftis, J. M., & Sullivan, B. (2013). Cognitive impairments accompanying methamphetamine 
dependence: Pathologies, clinical implications, and treatment strategies. 
Margolin, A., Kosten, T., Petrakis, I., Avants, S. K., & Kosten, T. (1991). Bupropion reduces 
cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry, 48(1), 87.  


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
64 
Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., . . . et al. (1995). A 
multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. 
Drug Alcohol Depend, 40(2), 125-131.  
McCann, D. J., & Li, S. H. (2012). A novel, nonbinary evaluation of success and failure reveals 
bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. 
CNS Neurosci Ther, 18(5), 414-418. doi:10.1111/j.1755-5949.2011.00263.x 
Mi, M. Y., & Betensky, R. A. (2013). An analysis of adaptive design variations on the sequential 
parallel comparison design for clinical trials. Clin Trials, 10(2), 207-215. 
doi:10.1177/1740774512468806 
Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., . . . Ling, W. 
(2016). Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of 
Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine 
Use Disorder. J Addict Med. doi:10.1097/ADM.0000000000000218 
Mooney, L. J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., . . . Ling, W. 
(2013). Cocaine use reduction with buprenorphine (CURB): rationale, design, and 
methodology. Contemp Clin Trials, 34(2), 196-204. doi:10.1016/j.cct.2012.11.002 
Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N., & Ling, W. (2004). Methamphetamine 
abstinence syndrome: preliminary findings. Am J Addict, 13(3), 248-255. 
doi:10.1080/10550490490459915 
Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . 
Kahn, R. (2005). Safety of intravenous methamphetamine administration during 
treatment with bupropion. Psychopharmacology (Berl), 182(3), 426-435. 
doi:10.1007/s00213-005-0102-8 
Newton, T. F., Roache, J. D., De La Garza, R., 2nd, Fong, T., Wallace, C. L., Li, S. H., . . . 
Kahn, R. (2006). Bupropion reduces methamphetamine-induced subjective effects and 
cue-induced craving. Neuropsychopharmacology, 31(7), 1537-1544. 
doi:10.1038/sj.npp.1300979 
Ornellas, T., & Chavez, B. (2011). Naltrexone SR/Bupropion SR (Contrave): A New Approach to 
Weight Loss in Obese Adults. P T, 36(5), 255-262.  
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & 
O'Brien, C. P. (2003). A functional polymorphism of the mu-opioid receptor gene is 
associated with naltrexone response in alcohol-dependent patients. 
Neuropsychopharmacology, 28(8), 1546-1552. doi:10.1038/sj.npp.1300219 
Pal, R., Mendelson, J. E., Flower, K., Garrison, K., Yount, G., Coyle, J. R., & Galloway, G. P. 
(2015). Impact of prospectively determined A118G polymorphism on treatment response 
to injectable naltrexone among methamphetamine-dependent patients: an open-label, 
pilot study. J Addict Med, 9(2), 130-135. doi:10.1097/ADM.0000000000000107 
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., . . . Fava, M. 
(2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results 
of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry, 169(12), 
1267-1274. doi:10.1176/appi.ajp.2012.11071114 
Petry, N. M., Peirce, J. M., Stitzer, M. L., Blaine, J. D., Roll, J. M., Cohen, A. J., . . . Saladin, M. 
E. (2005). Effect of prize-based incentives on outcomes in stimulant abusers in 
outpatient psychosocial treatment programs. Archives of General Psychiatry, 62, 1148-
1156.  
Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use 
disorders: an update. Journal of Substance Abuse Treatment, 23(2), 145-150.  
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K., Roche, D., . . . Miotto, K. 
(2015). The Effects of Naltrexone on Subjective Response to Methamphetamine in a 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
65 
Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. 
Neuropsychopharmacology, 40(10), 2347-2356. doi:10.1038/npp.2015.83 
Richmond, R., & Zwar, N. (2003). Review of bupropion for smoking cessation. Drug Alcohol 
Rev, 22(2), 203-220. doi:10.1080/09595230100100642 
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., . . . Kellogg, 
S. (2006). Contingency management for the treatment of methamphetamine use 
disorders. American Journal of Psychiatry, 163(11), 1993-1999.  
Rose, M. E., & Grant, J. E. (2008). Pharmacotherapy for methamphetamine dependence: a 
review of the pathophysiology of methamphetamine addiction and the theoretical basis 
and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry, 20(3), 145-155. 
doi:10.1080/10401230802177656 
Salim, Z., Allen, J. S., Patterson, C., & Painter, K. (2007). Methamphetamine treatment 
program, Tarrant County, Texas: Final evaluation report, October 2004 - September 
2007. Retrieved from Fort Worth, Texas:  
Salo, R., Nordahl, T. E., Galloway, G. P., Moore, C. D., Waters, C., & Leamon, M. H. (2009). 
Drug abstinence and cognitive control in methamphetamine-dependent individuals. 
Journal of Substance Abuse Treatment, 37(3), 292-297.  
Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001). Naltrexone and relapse 
prevention treatment for cocaine-dependent patients. Addict Behav, 26(2), 167-180.  
Schmitz, J. M., Stotts, A. L., Sayre, S. L., DeLaune, K. A., & Grabowski, J. (2004). Treatment of 
cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J 
Addict, 13(4), 333-341. doi:10.1080/10550490490480982 
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, 
G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the 
development and validation of a structured diagnostic psychiatric interview for DSM-IV 
and ICD-10. J Clin Psychiatry, 59 Suppl 20, 22-33;quiz 34-57.  
Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A. N., . . 
. Ling, W. (2008). Randomized, placebo-controlled trial of bupropion for the treatment of 
methamphetamine dependence. Drug Alcohol Depend, 96(3), 222-232. 
doi:10.1016/j.drugalcdep.2008.03.010 
Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E., & Rush, C. R. (2015). Naltrexone and 
bupropion, alone or combined, do not alter the reinforcing effects of intranasal 
methamphetamine. Pharmacology Biochemistry and Behavior, 129, 45-50. 
doi:http://dx.doi.org/10.1016/j.pbb.2014.11.018 
Tamura, R. N., & Huang, X. (2007). An examination of the efficiency of the sequential parallel 
design in psychiatric clinical trials. Clin Trials, 4(4), 309-317. 
doi:10.1177/1740774507081217 
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., . . . Team, S. 
D. S. (2006). Medication augmentation after the failure of SSRIs for depression. N Engl J 
Med, 354(12), 1243-1252. doi:10.1056/NEJMoa052964 
van der Plas, E. A., Crone, E. A., van den Wildenberg, W. P., Tranel, D., & Bechara, A. (2009). 
Executive control deficits in substance-dependent individuals: a comparison of alcohol, 
cocaine, and methamphetamine and of men and women. J Clin Exp Neuropsychol, 
31(6), 706-719. doi:10.1080/13803390802484797 
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., . . . Dunayevich, 
E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an 
adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring), 19(1), 
110-120. doi:10.1038/oby.2010.147 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
66 
Wei, L. J., & Lachin, J. M. (1988). Properties of the urn randomization in clinical trials. Control 
Clin Trials, 9(4), 345-364.  
Winchell, C., Rappaport, B. A., Roca, R., & Rosebraugh, C. J. (2012). Reanalysis of 
methamphetamine dependence treatment trial. CNS Neurosci Ther, 18(5), 367-368. 
doi:10.1111/j.1755-5949.2011.00288.x 
Yurcel, M., Lubman, D. I., Solowij, N., & Brewer, W. J. (2007). Understanding drug addiction: a 
neuropsychological perspective. Australian & New Zealand Journal of Psychiatry, 
41(12), 957-968.  
Zhu, J., Spencer, T. J., Liu-Chen, L. Y., Biederman, J., & Bhide, P. G. (2011). Methylphenidate 
and mu opioid receptor interactions: a pharmacological target for prevention of stimulant 
abuse. Neuropharmacology, 61(1-2), 283-292. doi:10.1016/j.neuropharm.2011.04.015 
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2002). Symptom severity and exclusion 
from antidepressant efficacy trials. J Clin Psychopharmacol, 22(6), 610-614.  
Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., . . . 
Trivedi, M. H. (2011). Effect of antidepressant medication treatment on suicidal ideation 
and behavior in a randomized trial: an exploratory report from the Combining 
Medications to Enhance Depression Outcomes Study. J Clin Psychiatry, 72(10), 1322-
1332. doi:10.4088/JCP.10m06724 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
67 
16.0 APPENDIX A - ADVERSE EVENT REPORTING DEFINITIONS AND 
PROCEDURES 
Each participating site’s principal investigator is responsible for study oversight, including 
ensuring human research subject protection by designating appropriately qualified and trained 
study personnel to assess, report, and monitor adverse events. 
Definition of Adverse Events and Serious Adverse Events 
An adverse event (AE) is any untoward medical occurrence in humans, whether or not 
considered study drug/intervention related, which occurs during the conduct of a clinical trial. Any 
change from baseline clinical status, ECGs, lab results, x-rays, physical examinations, etc., that 
is considered clinically significant by the study medical clinician are considered AEs.  
Suspected adverse reaction is any adverse event for which there is a reasonable possibility that 
the study drug/intervention caused the adverse event. A reasonable possibility implies that there 
is evidence that the study drug/intervention caused the event. 
Adverse reaction is any adverse event caused by the study drug/intervention. 
An adverse event, suspected adverse reaction, or adverse reaction is considered “serious” 
(i.e., a serious adverse event, serious suspected adverse reaction or serious adverse reaction) if, 
in the view of either the study medical clinician or sponsor, it: 
1. Results in death: A death occurring during the study or which comes to the attention of 
the study staff during the protocol-defined follow-up period, whether or not considered 
caused by the study drug/intervention, must be reported. 
2. Is life-threatening: Life-threatening means that the study participant was, in the opinion 
of the medical clinician or sponsor, at immediate risk of death from the reaction as it 
occurred and required immediate intervention. 
3. Requires inpatient hospitalization or prolongation of existing hospitalization.  
4. Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
5. Is a congenital abnormality or birth defect. 
6. Seizure. 
7. Important medical event that may not result in one of the above outcomes, but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event. 
Definition of Expectedness 
Any adverse event is considered “unexpected” if it is not listed in the investigator brochure or the 
package insert or is not listed at the specificity or severity that has been observed. If neither is 
available then the protocol and consent are used to determine an unexpected adverse event. 
Pregnancy 
Any pregnancies that occur to a participant enrolled in the study will be captured on a pregnancy 
case report form (CRF) and not separately reported as an AE or SAE. Women who become 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
68 
pregnant during the medication period will be discontinued from further medication administration, 
referred for medical care, and the pregnancy followed until an outcome is known. 
Medical and Psychiatric History 
A thorough medical and psychiatric history during the screening/baseline phase should record 
any chronic, acute, or intermittent preexisting or current illnesses, diseases, symptoms, or 
laboratory signs of the participant, to avoid reporting pre-existing conditions as new AEs and to 
assist in the assessment of worsening in intensity or severity of these conditions that would 
indicate an AE. Stable chronic conditions, such as arthritis, which are present prior to clinical trial 
entry and do not worsen are not considered AEs. 
Site Staff’s Role in Eliciting and Reporting Adverse Events  
All adverse events (medical and/or psychiatric) occurring during the course of the study will be 
assessed, documented, and reported. Appropriately qualified and trained medical personnel will 
elicit participant reporting of AEs and SAEs at each study visit designated to collect AEs (i.e., the 
first visit following informed consent and at every visit thereafter). Study staff will follow-up on the 
status of any AEs that remain at the post-medication phase follow-up visit assessment for up to 
30 days post last study visit. Study personnel will obtain as much information as possible about 
the reported AE/SAE in order to complete AE/SAE documentation (i.e., log and CRFs) and will 
consult with medical clinicians and the Study Medical Monitor as necessary.  
Standard reporting, within 7 days of the site staff becoming aware of the event, is required for 
AEs. Expedited reporting, within 24 hours of their occurrence and/or site staff's knowledge of the 
event, is required for SAEs (including death and life-threatening events). Site staff is responsible 
for reporting SAEs to the IRB, per IRB’s guidelines. 
Site staff is required to enter AEs and SAEs in the eClinical system as soon as they become 
aware of the event. The AE log and CRF are used to capture AEs (as defined in the protocol). 
Additional information may need to be gathered to evaluate serious adverse events and to 
complete the appropriate CRFs and the summary. This process may include obtaining hospital 
discharge reports, medical records, autopsy records or any other type of records or information 
necessary to provide a complete and clear picture of the serious event and events preceding and 
following the event. If the SAE is not resolved or stable at the time of the initial report or if new 
information becomes available after the initial report, follow-up information must be submitted as 
soon as possible. 
Adverse events will be followed until resolution, stabilization or study end. Any serious adverse 
reactions will be followed until resolution or stabilization even beyond the end of the study.  
Site Staff’s Role in Assessing Severity and Causality of Adverse Events 
Appropriately qualified and trained medical personnel will conduct an initial assessment of 
seriousness, severity, and causality when eliciting participant reporting of adverse events. A study 
medical clinician will review AEs for seriousness, severity, and causality on at least a weekly 
basis. 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
69 
Guidelines for Assessing Severity  
The severity of an adverse event refers to the intensity of the event. 
Grade 1 
Mild 
Transient or mild discomfort (< 48 hours), no or minimal medical 
intervention/therapy 
required, 
hospitalization 
not 
necessary 
(non-prescription or single-use prescription therapy may be 
employed to relieve symptoms, e.g., aspirin for simple headache, 
acetaminophen for post-surgical pain) 
Grade 2 
Moderate 
Mild to moderate limitation in activity, some assistance may be 
needed; no or minimal intervention/therapy required, hospitalization 
possible. 
Grade 3 
Severe 
Marked limitation in activity, some assistance usually required; 
medical intervention/ therapy required, hospitalization possible. 
 
Guidelines for Determining Causality 
The study medical clinician will use the following question when assessing causality of an adverse 
event to study drug/intervention where an affirmative answer designates the event as a suspected 
adverse reaction: 
Is there a reasonable possibility that the study drug/intervention caused the event?  
Quality Assurance Staff’s Role in Monitoring Adverse Events 
Quality assurance monitors (from the node staff and the CRO contract monitor staff) will review 
safety documentation on a regular basis and will promptly advise site staff to report any previously 
unreported safety issues and ensure that the reportable safety-related events are being followed 
to resolution and reported appropriately. Staff education, re-training or appropriate corrective 
action plan will be implemented at the participating site when unreported or unidentified reportable 
AEs or serious events are discovered, to help ensure future identification and timely reporting. 
Sponsor’s Role in Safety Management Procedures of AEs/SAEs 
A NIDA-assigned Medical Monitor is responsible for reviewing all serious adverse event reports. 
All reported SAEs will generate an e-mail notification to the Medical Monitor, Lead Investigator, 
and designees. All SAEs will be reviewed by the Medical Monitor and, if needed, additional 
information will be requested. The Medical Monitor will also report events to the sponsor, the Data 
and Safety Monitoring Board (DSMB), study drug manufacturers, and regulatory authorities. The 
DSMB will receive summary reports of all adverse events annually, at a minimum. The DSMB or 
the NIDA assigned Medical Monitor may also request additional and updated information. Details 
regarding specific adverse events, their treatment and resolution, will be summarized by the 
Medical Monitor in writing for review by the sponsor and DSMB. Subsequent review by the 
Medical Monitor, DSMB, and ethics review committee or IRB, the sponsor, or relevant local 
regulatory authorities may also suspend further trial treatment at a site. The study sponsor and 
the DSMB retain the authority to suspend additional enrollment and treatments for the entire study 
as applicable. 
Reporting to the Data and Safety Monitoring Board 
The DSMB will receive a listing of AEs and summary reports of all SAEs at a frequency requested 
by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports 
of SAEs. 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
70 
Participant Withdrawal 
The study medical clinician must apply his/her clinical judgment to determine whether or not an 
adverse event is of sufficient severity to require that the participant is withdrawn from further study 
medication administration. The study medical clinician should consult with the study physician, 
site principal investigator, the Lead Investigator and/or Medical Monitor as needed. If necessary, 
a study medical clinician may suspend any trial treatments and institute the necessary medical 
therapy to protect a participant from any immediate danger. A participant may also voluntarily 
withdraw from treatment due to what he/she perceives as an intolerable adverse event or for any 
other reason. If voluntary withdrawal is requested, the participant will be asked to complete an 
end-of–medication visit to assure safety and to document end-of–medication outcomes and will 
be given recommendations for medical care and/or referrals to treatment, as necessary. Other 
reasons for the investigator or sponsor terminating a participant from the study may include, but 
are not limited to, the participant becoming a threat to self or others, lack of funding, or DSMB 
early termination of the study for safety or effectiveness reasons.  
 
AE Chart 
 
AEs Identified
Research staff documents AE 
information on AE Log. A Study 
Medical Clinician will review AEs for 
seriousness, severity, and causality.
Is the event a 
Serious AE?
(SAE)
Continue follow-up and reporting until 
event is resolved, stabilized or 
participant is lost to follow-up and/or 
terminated from the study.
Safety monitor reports event to 
sponsor and DSMB at the frequency 
requested by the DSMB.
Continue follow-up and reporting until 
event is resolved, stabilized or 
participant is lost to follow-up and/or 
terminated from the study.
No
Yes
Research staff completes AE eCRF.
Standard reporting within 7 days of 
knowledge of the event.
Site PI or designee submits AE & SAE 
eCRF with as much info as is available. 
Expedited initial reporting within 24 
hours of knowledge of the event. 
EDC system will automatically notify 
Safety Monitor, Lead Investigator(s). 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
71 
17.0 APPENDIX B - DATA AND SAFETY MONITORING PLAN 
BRIEF STUDY OVERVIEW 
This double-blind, placebo-controlled, randomized clinical trial will investigate a combination 
medication, extended-release injectable naltrexone plus extended-release bupropion, compared 
to placebo as a potential pharmacotherapy for MA dependence. Screening will occur over a 
maximum of 21 days. Study medications will be provided during a 12-week medication phase. 
Participants will be randomized to either the active medication combination (AMC) arm in which 
injections of extended-release naltrexone (XR-NTX; as Vivitrol®) plus 450 mg / day oral extended-
release bupropion (BUP-XL) tablets will be provided or the matching placebo (PLB) arm in which 
injections of placebo (iPLB) and once daily oral placebo (oPLB) tablets will be provided. Injections 
will be provided in weeks 1, 4, 7, and 10. Participants will be asked to attend clinic twice weekly 
for observed oral medication dosing and provision of take-home oral medication, collection of 
urine samples, assessments, and medical management. Following the 12-week medication 
phase, participants will complete a follow-up phase, including a medication taper and post-
medication phase follow-up visits during Weeks 13 and 16. 
Details for the definitions and reporting of safety events are found in Appendix A of the protocol. 
OVERSIGHT OF CLINICAL RESPONSIBILITIES 
A. Site Principal Investigator 
Each participating site’s PI is responsible for study oversight, including ensuring human research 
subject protection by designating appropriately qualified, trained research staff and medical 
clinicians to assess, report, and monitor adverse events.  
Regarding safety, all Adverse Events (AEs) occurring during the course of the clinical trial will be 
collected, documented, and reported by the investigator or sub-investigators according to the 
protocol. The assessment of Adverse Events (medical and/or psychiatric) will commence the visit 
after consent and will continue through all study visits. Study staff will follow-up on the status of 
any AEs that remain for up to 30 days after the last planned study visit in week 16. 
The occurrence of AEs and Serious Adverse Events (SAEs) will be assessed at each clinic visit 
after consent. All adverse events will be followed until resolution, stabilization or study end. 
Serious adverse events will be followed until resolved or considered stable, with reporting to the 
CCC Safety Monitor/Medical Monitor through the follow-up period. 
Standard reporting, within 7 days of the site becoming aware of the event, is required for AEs. 
Expedited reporting (within 24 hours of their occurrence and/or site's knowledge of the event) is 
required for reportable SAEs (including death and life-threatening events).  
B. Medical Monitor/Safety Monitor 
The NIDA Clinical Coordinating Center (CCC) Safety Monitor/Medical Monitor is responsible for 
reviewing all adverse events and serious adverse events reported. All SAEs will be reviewed at 
the time they are reported in eClinical. The Medical Monitor will also indicate concurrence or not 
with the details of the report provided by the site. Where further information is needed the Safety 
Monitor/Medical Monitor will discuss the event with the site. Reviews of SAEs will be conducted 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
72 
in the Advantage eClinical data system and will be a part of the safety database. All AEs will be 
reviewed on a regular basis to observe trends or unusual events. 
The CCC Safety Monitor/Medical Monitor will in turn report events to the sponsor, study drug 
manufacturers, and regulatory authorities if the event meets the definition of an expedited event. 
All SAEs that meet expedited reporting based on federal regulations will be reported to the DSMB 
in writing within 15 calendar days of notification of the CCC. If the SAE meets the criteria for death 
or is immediately life-threatening, the CCC will notify the DSMB electronically, by phone or by fax 
as soon as possible but no later than 7 calendar days of notification of the CCC, with a follow-up 
written report within 15 calendar days of notification of the CCC. The CCC will prepare an 
expedited report and copies will be distributed to site investigators. 
Reports will be generated and presented for Data and Safety Monitoring Board (DSMB) meetings. 
The DSMB will receive listings of AEs and summary reports of all SAEs at a frequency requested 
by the DSMB, but at least annually. Furthermore, the DSMB will be informed of expedited reports 
of SAEs. 
C. Data and Safety Monitoring Board (DSMB) 
The NIDA CTN DSMB affiliated with this trial will be responsible for conducting periodic reviews 
of accumulating safety, trial performance, and outcome data. The DSMB will make 
recommendations to NIDA as to whether there is sufficient support for continuation of the trial, 
that study procedures should be changed, or that the trial (or a specific site) should be halted for 
reasons relating to safety of the study participants or inadequate trial performance (e.g., poor 
recruitment). 
Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, 
including DSMB recommendations, in writing to the study Lead Investigator. Study safety 
information will be submitted to participating IRBs. 
D. Quality Assurance (QA) Monitoring 
Monitoring of study sites will be conducted on a regular basis using a combination of NIDA CCC 
contract monitors, the local node site managers, and lead node staff. The purpose of these visits 
is to assess compliance with GCP requirements and to document the integrity of the trial progress. 
Areas of particular concern will be the review of inclusion/exclusion criteria, participant informed 
consent forms, protocol adherence, safety monitoring, IRB reviews and approvals, regulatory 
documents, participant records, study drug accountability, and Principal Investigator supervision 
and involvement in the trial. The Monitors will interact with the site staff to identify issues and re-
train the site staff as needed to enhance research quality. 
QA Site Visit Reports will be prepared by the NIDA CCC contract monitors following each site 
visit. These reports will be forwarded to the site Principal Investigator, the study Lead Investigator 
and NIDA. 
E. Management of Risks to Participants 
Confidentiality 
Confidentiality of participant records will be secured by using study codes for identifying 
participants on CRFs, secure storage of any documents that have participant identifiers, and 
secure computing procedures for entering and transferring electronic data. All study data will be 
stored in a secure location with limited access. Only research staff will have access to the study 
records. Other parties with access to study data, such as local or central IRBs, will be specified 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
73 
to the participants per HIPAA regulations. No identifying information will be disclosed in reports, 
publications or presentations. 
Participants’ information will not be released without their written permission, except as necessary 
for monitoring or suspected abuse or violence. The Lead Investigator (LI) will apply for a Certificate 
of Confidentiality that will cover all sites participating in the study. By participating in this protocol, 
the local site investigator agrees that within local regulatory restrictions and ethical considerations, 
any regulatory agency may consult and/or copy study documents to verify study data. 
By participating in this protocol, the local site investigator affirms that information furnished to the 
investigator by the Lead Investigator will be maintained in confidence and such information will 
be divulged to the IRB, Ethical Review Committee, or similar expert committees, affiliated 
institutions, and employees only under an appropriate understanding of confidentiality with such 
boards or committees, affiliated institutions, and employees. 
Information Meeting Reporting Requirements 
The consent form will specifically state the types of information that are required to be reported 
and the fact that the information will be reported as required. These include suspected or known 
sexual or physical abuse of a child or elders, or threatened violence to self and/or others. 
Participant Protection 
The study physician will evaluate all pertinent screening and baseline assessments prior to 
participant randomization to ensure that the participant is eligible and safe to enter the study. 
Adverse events (AEs) and concomitant medications will be assessed and documented at each 
clinic visit. Individuals who experience an AE that compromises safe participation will be 
discontinued from further medication administration and provided referrals for other treatment or 
to specialized care. Study personnel will request that the participant complete an end-of-
medication visit to assure safety and to document end-of-medication outcomes. 
Pregnancy 
Pregnancy is an exclusion criterion for study participation. A positive pregnancy test post-
enrollment will result in the cessation of study medication. Participants who discontinue 
medications will be expected to continue with study visits. Pregnancy test results and related 
outcome information will be collected on a Pregnancy and Outcome CRF. The site staff will follow 
the participant until an outcome of the pregnancy is known. 
Expected Risks of the Study Medication 
For anyone who has opioids in their system, naloxone and naltrexone may cause opioid 
withdrawal symptoms. As with any study drug, there is also the possibility of an allergic reaction. 
Participants will be monitored for at least 30 minutes following the naloxone challenge, and at 
least 15 minutes following each medication induction (co-administration of injectable and oral 
study medications). 
BUPROPION Extended Release: Possible side effects include elevated blood pressure, agitation, 
irritability, restlessness, sleeplessness, dry mouth, headache/migraine, nausea, vomiting, 
constipation, and shakiness. At doses of 450 mg daily, there is 1 chance in 1000 that a participant 
taking bupropion will experience a seizure. Individuals with a history of epilepsy or seizure 
disorder, current eating disorder, or who are taking certain medications will not be allowed to 
participate. Although bupropion is used to treat depression, a small percentage of people who 
take antidepressants have increased thoughts of suicide, particularly during the early weeks of 
medication. 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
74 
NALTREXONE for Extended Release (Vivitrol®): Possible side effects include nausea, vomiting, 
headaches, dizziness, insomnia, dry mouth, and depressed mood. In rare cases people who 
received naltrexone developed suicidal thoughts, or a type of pneumonia (lung inflammation) 
caused by an excess of a certain type of white blood cells in the lungs. The most serious side 
effect of naltrexone is liver (hepatocellular) injury, which has almost always occurred with oral 
doses of 1400 to 2100 mg per week. Recent study findings show that no evidence of liver injury 
was found in people receiving once-monthly Vivitrol® injections. For safety, participants with acute 
symptomatic hepatitis or liver failure will not be allowed to participate. 
Vivitrol® injections may cause pain, tenderness, hardening or damage of body tissues, swelling, 
redness, bruising, itching, or infection at the injection site. Such injection site reactions have been 
the most common side effects associated with Vivitrol®. The injection site will be monitored after 
each injection. Participants will be instructed to report any injection site reactions immediately to 
the study team. Any participants showing signs of injection site reactions such as a localized 
infection (abscess), skin infection (cellulitis), body tissue damage, or extensive swelling will be 
monitored by the study medical staff and treated accordingly. 
Data Management Procedures 
This protocol will utilize a centralized Data and Statistics Center (DSC). A web-based distributed 
data entry model will be implemented. This electronic data capture system (Advantage eClinical) 
will be developed to ensure that guidelines and regulations surrounding the use of computerized 
systems in clinical trials are upheld. 
Data and Statistics Center Responsibilities 
The DSC will: 1) develop and apply data management procedures to ensure the collection of 
accurate and good-quality data, 2) provide Case Report Forms in electronic (eCRF) and paper 
(CRF) format, and Participant Reported Outcome forms in electronic (ePRO) and paper (PRO) 
format for the collection of all data required by the study, 3) develop data dictionaries for each 
CRF and PRO form that will comprehensively define each data element, 4) prepare instructions 
for the use of Advantage eClinical and for the completion of forms, 5) conduct ongoing data 
validation and cleaning activities on study data collected from all participating sites, and 6) perform 
data validation and cleaning activities prior to any interim analyses and prior to the final study 
database lock. 
Data Collection and Entry 
Data will be collected at the study sites on source documents and entered by the site on the form 
in Advantage eClinical, or will be collected via direct entry into the eCRF by the site or direct entry 
into the ePRO by the participant. In the event that Advantage eClinical is not available, the DSC 
will provide the sites with paper source documents and completion instructions. Data will be 
entered into Advantage eClinical in accordance with the instructions provided during project-
specific training and guidelines established by the DSC. Data entry into the forms shall be 
performed by authorized individuals. Selected eCRFs may also require the site investigator’s 
electronic signature. 
The principal investigator at the site is responsible for maintaining accurate, complete and up-to-
date research records. In addition, the site investigator is responsible for ensuring the timely 
completion of forms for each research participant. 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
75 
Data Monitoring, Cleaning and Editing 
Data will be entered into the DSC automated data acquisition and management system 
(Advantage eClinical). Forms will be monitored for completeness and accuracy throughout the 
study. Dynamic reports listing missing values and forms will be available to sites at all times in 
Advantage eClinical. These reports will be monitored regularly by the DSC. In addition, the DSC 
will identify inconsistencies within forms and between forms and post data clarification requests 
or queries in Advantage eClinical on a scheduled basis. Sites will resolve data inconsistencies 
and errors by entering all corrections and changes directly into Advantage eClinical. 
The CCC will conduct regular visits to sites, during which audits comparing source documents to 
the data entered will be performed. Any discrepancies identified between the source document 
and the eCRF or ePRO will be corrected by the site. 
Trial progress and data status reports, which provide information on recruitment, availability of 
primary outcome, treatment exposure, attendance at follow-up visits, regulatory status, and data 
quality, will be generated routinely and posted to a secure website. These reports will be available 
to the site, the corresponding Local Node, the Lead Investigator, the coordinating centers, and 
NIDA, to monitor the sites’ progress on the study. 
Data Lock and Transfer 
At the conclusion of data collection for the study, the DSC will perform final data cleaning activities 
and will “lock” the study database from further modification. The final analysis dataset will be 
returned to the Lead Investigator and NIDA, as requested, for storage and archive. 
 
 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
76 
18.0 APPENDIX C - SMARTPHONE APP-BASED MEDICATION 
ADHERENCE PROCEDURES 
The smartphone app will be provided by AiCure and will be referred to as the “app” or 
“study app.” 
Technology Training 
After eligibility has been established and the participant has been randomized, staff will provide 
training on the use of the medication adherence app that will monitor and encourage adherence. 
The AiCure app will be downloaded onto the participant’s personal smartphone or, if unable to be 
downloaded, a study provided smartphone device will be provided with the app pre-loaded on it. 
Training will include using the app features and capabilities, security features (e.g., encryption), 
and taking practice dosing videos.  
Medication Adherence App on Participant Personal Smartphone 
Participants who choose to use their own smartphone must own a device that is camera-equipped 
and capable of SMS text messaging and taking videos. Participants who download the app on 
their personal smartphone devices will be provided an additional $10 at the beginning of each 
study month to offset the costs for additional data services needed due to use of the app. 
Participants who require a study provided smartphone device at any point during the study may 
be provided one. However, to ensure that participants are compensated equitably, no participant 
will receive more than $10 per study month for using either the app or a study provided 
smartphone device.  
Study Provided Smartphone Device 
Participants who do not have a personal device or are unable to download the AiCure app will be 
provided with a smartphone device (and battery charger). Service plans will be included to allow 
participants to receive text messages and reminders from study staff through the study app and to 
take dosing videos. The smartphone device equipment will be retained by participants through the 
end of their participation in the study. A replacement device may be available in the event of 
unintentional damage or loss. Sites are encouraged to consult with the Lead Team when 
considering providing replacement study devices for participants who are withdrawn from study 
medications. If the participant does not require a replacement smartphone device during the course 
of the study, the participant will be provided up to $40 payment (i.e., $10 for each study month) for 
the safe return of the smartphone device and, ideally, all accompanying accessories (e.g., charger, 
carrying case). Replacement smartphone devices will be returned at the end of study participation, 
but no payment will be provided to those participants requiring a replacement device.  
Set-up and Maintenance of App (and Smartphone Device, if applicable) 
Study staff will activate the AiCure app on participant smartphones or prepare the study provided 
smartphone for the participant. If a participant is using a study provided smartphone device, study 
staff will provide appropriate training on how to use the device.  
Smartphone Device-Based Procedures and Compensation 
Prior to randomization, study personnel will request a signed agreement from participants 
regarding the use of the smartphone app or study provided device for the purposes of the study. 
Participants will be informed of the medication adherence procedures, including the requirement 
to take daily videos of oral study medication ingestion. If a participant fails to bring his/her oral 
study medication to the clinic so that self-administration of the dose can be observed and a video 


NIDA CTN-0068 
Version 6.0 
ADAPT-2 
January 31, 2019 
 
77 
can be taken, the participant will be asked to take a video of him/herself taking the dose for that 
day at home (if the dose has not already been taken). Participants will be compensated $5 for 
each dosing video taken on non-clinic days, including the taper in week 13. “Red Alerts” are 
triggered by AiCure when there is a pattern of problematic behaviors observed during video 
dosing. AiCure staff will guide site staff in how to re-train participants to appropriately use the app. 
If a pattern of recurring Red Alerts are triggered by AiCure, this indicates repeated problematic 
dosing behaviors are occurring, indicating non-adherence to oral study medication. Recurring 
Red Alerts may result in a participant not being compensated for dosing videos; sites should 
consult with the Lead Team when repeated Red Alerts occur.  
Lost/Stolen/Inoperable Smartphone Devices 
The purpose of providing a study smartphone device (to participants unable to use their own) is 
to monitor and improve medication adherence on non-clinic days as well as provide a means of 
study staff contacting participants. Participants will be notified that study provided devices will 
have a tracking tag on the back which allows for lost or stolen devices to be retrieved via a 
nationwide network and that removal of the tracking tag reveals a “stolen property” embossing on 
the device. Study provided smartphone devices are operational for study purposes only and are 
locked down to any other use. A one-time replacement of a lost, stolen, or inoperable study 
provided smartphone device may be permitted. Study staff should consult with the Lead Team 
should a second loss/theft of a study smartphone device occur. 
Protection of Participant Privacy 
Participants will be advised on how to secure their devices with passwords and how the software 
application will be used to transmit dosing videos to the secure server as an encrypted file. 
Research staff will only access smartphone device settings as needed to help troubleshoot a 
problem with the AiCure app and when requested by the participant.  
Staff-to-Participant Contact 
Staff will send texts from a list of pre-determined messages to participants through the app 
regarding reminders for clinic visits or dosing requirements. If a participant has not taken the 
dosing video by an agreed upon time on a take-home dosing day, study staff will contact the 
participant to ask the participant to take his/her study medication dose via the app as soon as 
possible.  

SAP_001.pdf: 
 
 
NCT03078075 
 
STATISTICAL ANALYSIS PLAN for 
 
Title: NIDA CTN-0068 Accelerated Development of 
Additive Pharmacotherapy Treatment (ADAPT-2) for 
Methamphetamine Use Disorder 
Version 3.0 
Date: September 13, 2019 
 


 
 
Statistical Analysis Plan 
for 
NIDA CTN-0068 Protocol 
Accelerated Development of Additive 
Pharmacotherapy Treatment (ADAPT-2) 
for Methamphetamine Use Disorder 
Lead Investigator: Madhukar Trivedi, MD 
Version 3.0 
September 13, 2019 
Prepared by: 
NIDA CTN Data and Statistics Center 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
i 
TABLE OF CONTENTS 
1.0 
SUMMARY OF STUDY DESIGN AND PROCESS .......................................................... 1 
1.1 
Study Objective ........................................................................................................... 1 
1.2 
Study Design and Procedures ..................................................................................... 1 
1.2.1 
Study Design ....................................................................................................... 1 
1.2.2 
Study Procedures ................................................................................................ 1 
1.2.3 
Randomization ..................................................................................................... 2 
1.3 
Inclusion and Exclusion Criteria .................................................................................. 2 
1.3.1 
Inclusion Criteria .................................................................................................. 2 
1.3.2 
Exclusion Criteria ................................................................................................. 3 
2.0 
GENERAL DEFINITIONS AND PROCEDURES ............................................................. 4 
2.1 
Pre-screened Population ............................................................................................. 4 
2.2 
Screened Population ................................................................................................... 4 
2.3 
Randomized Population .............................................................................................. 4 
2.4 
Intent-to-Treat Population ............................................................................................ 4 
2.5 
Per Protocol Population............................................................................................... 4 
2.6 
Safety Population ........................................................................................................ 4 
2.7 
Study Day Definition .................................................................................................... 4 
2.8 
First Dose Date ........................................................................................................... 5 
2.9 
Last Dose Date ........................................................................................................... 5 
2.10 
Treatment Period ........................................................................................................ 5 
2.11 
Follow-up Period ......................................................................................................... 5 
2.12 
Safety Window ............................................................................................................ 5 
2.13 
Treatment Emergence ................................................................................................ 5 
2.14 
Summary Table Conventions ...................................................................................... 5 
2.15 
Data and Statistics Center Responsibilities ................................................................. 5 
3.0 
ENROLLMENT, PARTICIPANT DISPOSITION, AND FOLLOW-UP .............................. 6 
4.0 
ANALYSIS OF PARTICIPANT CHARACTERISTICS ..................................................... 6 
5.0 
CONCOMITANT MEDICATIONS .................................................................................... 6 
6.0 
STUDY MEDICATION ADHERENCE ............................................................................. 7 
6.1 
Early Medication Terminations .................................................................................... 7 
6.2 
Treatment Exposure .................................................................................................... 7 
6.3 
Video Confirmed Oral Medication Dosing .................................................................... 7 
6.4 
Oral Medication Blood Levels ...................................................................................... 8 
7.0 
ANALYSIS OF EFFICACY OUTCOME MEASURES ...................................................... 8 
7.1 
Definition of Primary Outcome Measure ...................................................................... 8 
7.2 
Analysis of Primary Outcome Measure ....................................................................... 8 
7.3 
Supportive Analyses of Primary Outcome Measure .................................................... 9 
7.4 
Secondary Outcome Measures ................................................................................. 10 
7.5 
Secondary Outcome Analyses .................................................................................. 11 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
ii 
8.0 
OTHER STATISTICAL CONSIDERATIONS ................................................................. 13 
8.1 
Handling Missing Data .............................................................................................. 13 
8.2 
Significance Testing .................................................................................................. 13 
8.3 
Sample Size and Power Calculations ........................................................................ 13 
8.4 
Interim Analyses ....................................................................................................... 16 
8.4.1 
Sample Size Re-Estimation ............................................................................... 16 
8.4.1.1 
Sample Size Re-Estimation Results ............................................................... 17 
8.4.2 
Interim Monitoring of Primary Efficacy Endpoint ................................................. 18 
8.4.3 
Safety Interim Analyses ..................................................................................... 19 
8.4.4 
Conditional Power and Futility ............................................................................ 20 
8.4.5 
Results of Interim Monitoring for Efficacy and Safety ......................................... 20 
8.5 
Software to be Used for Analyses ............................................................................. 20 
9.0 
ANALYSIS OF SAFETY OUTCOME MEASURES ....................................................... 20 
9.1 
Adverse Events ......................................................................................................... 20 
9.2 
Serious Adverse Events ............................................................................................ 21 
9.3 
Injection Site Abnormalities ....................................................................................... 21 
9.4 
Laboratory Values ..................................................................................................... 21 
9.5 
Electrocardiogram ..................................................................................................... 23 
9.6 
Suicide Risk .............................................................................................................. 23 
9.7 
Pregnancy ................................................................................................................. 23 
9.8 
Deaths ...................................................................................................................... 23 
10.0 
DATA QUALITY ............................................................................................................ 23 
10.1 
Data Audits ............................................................................................................... 23 
10.2 
Protocol Deviations ................................................................................................... 23 
11.0 
UPDATES TO THE STATISTICAL ANALYSIS PLAN .................................................. 23 
12.0 
REFERENCES .............................................................................................................. 24 
13.0 
LIST OF PROPOSED TABLES, FIGURES, AND LISTINGS ........................................ 25 
14.0 
APPENDICES ............................................................................................................... 28 
14.1 
Table Shells .............................................................................................................. 28 
 
TABLES 
Table 1: Secondary Outcomes by Type of Outcome for SPCD Analysis .................................... 12 
Table 2: Primary Outcome Analysis Boundary and Cumulative Alpha Spent ............................ 13 
Table 3: Sample Size Calculation ..................................................................................................... 15 
Table 4: Sample Size Re-Estimation Results .................................................................................. 18 
Table 5: Simulated Probability of Rejecting the Null Hypothesis at α = 0.025, 1-tailed ............. 19 
Table 6: Boundary to Stop Early for Efficacy and Cumulative Alpha Spent at Interim Analysis
.............................................................................................................................................................. 19 
Table 7: Normal Ranges by Site ....................................................................................................... 22 
Table 1: Summary of Pre-screens by Site ....................................................................................... 28 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
iii 
Table 2: Summary of Screen Failures by Site................................................................................. 29 
Table 3: Summary of Pre-screens, Screening, and Randomization by Site ............................... 30 
Table 4: Randomizations by Site, Stage and Treatment Arm ....................................................... 31 
Table 5: Proposed and Actual Randomizations by Site ................................................................ 35 
Table 6: Summary of Disposition by Site ........................................................................................ 36 
Table 7: Summary of Disposition by Treatment Arm in Stage 1 .................................................. 37 
Table 8: Summary of Disposition by Treatment Arm in Stage 2 .................................................. 38 
Table 9: Summary of Disposition by Treatment Arm in Follow-up Period .................................. 39 
Table 10: Summary of Attendance at Treatment Period Visits by Treatment Arm in Stage 1 .. 41 
Table 11: Summary of Attendance at Treatment Period Visits by Treatment Arm in Stage 2 .. 42 
Table 12: Summary of Attendance at Follow-up Visits by Treatment Arm ................................. 42 
Table 13: Summary of Missed Visits by Treatment Arm in Stage 1 ............................................. 43 
Table 14: Summary of Missed Visits by Treatment Arm in Stage 2 ............................................. 44 
Table 15: Summary of Missed Visits by Treatment Arm in Follow-up Period ............................ 45 
Table 16: Summary of Baseline Characteristics by Site ............................................................... 46 
Table 17: Summary of Baseline Characteristics by Stage and Treatment Arm .......................... 50 
Table 18: Summary of Concomitant Medications by Treatment Arm1 ......................................... 54 
Table 19: Summary of Early Medication Terminations by Site ..................................................... 57 
Table 20: Summary of Early Medication Terminations by Treatment Arm in Stage 1 ............... 59 
Table 21: Summary of Early Medication Terminations by Treatment Arm in Stage 2 ............... 60 
Table 22: Summary of Treatment Exposure by Site ...................................................................... 61 
Table 23: Summary of Treatment Exposure by Site, Stage and Treatment Arm ........................ 62 
Table 24: Summary of Injections by Site ......................................................................................... 64 
Table 25: Summary of Injections by Stage and Treatment Arm ................................................... 64 
Table 26: Summary of Oral Medication Blood Levels by Stage AMC Participants .................... 65 
Table 27: Summary of Primary Outcome Availability by Stage and Treatment Arm ITT 
Population ........................................................................................................................................... 65 
Table 28: Summary of Primary Outcome Analysis by Stage and Treatment Arm ITT Population
.............................................................................................................................................................. 66 
Table 29: Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm 
ITT Population .................................................................................................................................... 68 
Table 30: Summary of Primary Outcome Availability by Stage and Site ITT Population .......... 69 
Table 31: Summary of Primary Outcome by Site, Stage, and Treatment Arm ITT Population . 70 
Table 32: Summary of Primary Outcome by Sex, Stage, and Treatment Arm ITT Population .. 70 
Table 33: Summary of Primary Outcome by Race, Stage, and Treatment Arm ITT Population 71 
Table 34: Summary of Primary Outcome by Ethnicity, Stage, and Treatment Arm ITT 
Population ........................................................................................................................................... 71 
Table 35: Summary of Primary Outcome by Age, Stage, and Treatment Arm ITT Population . 72 
Table 36: Primary Outcome Covariate Adjusted Analysis Results1 ITT Population .................. 72 
Table 37: Summary of UDS Availability1 by Stage and Treatment Arm Randomized Population
.............................................................................................................................................................. 73 
Table 38: Summary of Methamphetamine Negative UDS Results by Treatment Arm in Stage 1 
Randomized Population .................................................................................................................... 74 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
iv 
Table 39: Summary of Methamphetamine Negative UDS Results by Treatment Arm in Stage 2 
Randomized Population .................................................................................................................... 75 
Table 40: Summary of Methamphetamine Negative UDS Results by Treatment Arm in Follow-
up Period Randomized Population .................................................................................................. 76 
Table 41: Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm 
Randomized Population .................................................................................................................... 77 
Table 42: Summary of Primary Outcome by Stage and Treatment Arm Per Protocol 
Populations ......................................................................................................................................... 79 
Table 43: Summary of Treatment Emergent Adverse Events by Treatment Arm in Stage 1 .... 80 
Table 44: Summary of Treatment Emergent Adverse Events by Treatment Arm in Stage 2 .... 81 
Table 45: Summary of Treatment Emergent MedDRA Coded Adverse Events by Treatment 
Arm in Stage 1 .................................................................................................................................... 82 
Table 46: Summary of Treatment Emergent MedDRA Coded Adverse Events by Treatment 
Arm in Stage 2 .................................................................................................................................... 85 
Table 47: Summary of Treatment Emergent Serious Adverse Events by Treatment Arm in 
Stage 1 ................................................................................................................................................. 97 
Table 48: Summary of Treatment Emergent Serious Adverse Events by Treatment Arm in 
Stage 2 ................................................................................................................................................. 98 
Table 49: Summary of Treatment Emergent MedDRA Coded Serious Adverse Events by 
Treatment Arm in Stage 1 ................................................................................................................. 99 
Table 50: Summary of Treatment Emergent MedDRA Coded Serious Adverse Events by 
Treatment Arm in Stage 2 ............................................................................................................... 100 
Table 51: Summary of Injection Site Abnormalities by Treatment Arm in Stage 1 .................. 104 
Table 52: Summary of Injection Site Abnormalities by Treatment Arm in Stage 2 .................. 105 
Table 53: Summary of Elevated QTc Intervals by Treatment Arm ............................................. 116 
Table 54: Summary of Suicide Risk by Treatment Arm in Stage 1 ............................................ 120 
Table 55: Summary of Suicide Risk by Treatment Arm in Stage 2 ............................................ 120 
Table 56: Summary of Suicide Risk by Treatment Arm in Follow-up Period ............................ 120 
Table 57: Summary of Data Audits ................................................................................................ 133 
Table 58: Summary of Protocol Deviations .................................................................................. 134 
 
FIGURES 
Figure 1: SPCD: Defining the Outcome ............................................................................................. 8 
Figure 2: Completed Stage 1 and Fraction of Target Enrollment for Proposed Sample Size Re-
Estimation Based on Months from Start of Enrollment ................................................................. 17 
Figure 1: Expected versus Actual Randomizations Overall ......................................................... 32 
Figure 2: Expected versus Actual Randomizations by Site .......................................................... 33 
Figure 2: Expected versus Actual Randomizations by Site (cont.) .............................................. 34 
Figure 3: CONSORT Flow Diagram .................................................................................................. 40 
Figure 4: Methamphetamine Negative UDS Results by Stage and Treatment Arm ITT 
Population ........................................................................................................................................... 67 
Figure 5: Methamphetamine Negative UDS Results by Stage and Treatment Arm Randomized 
Population ........................................................................................................................................... 78 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
v 
LISTINGS 
Listing 1: Treatment Emergent Adverse Events by Treatment Arm ............................................ 88 
Listing 2: Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment 
Arm ...................................................................................................................................................... 92 
Listing 3: Non-Treatment Emergent Adverse Events in Screen Failure Participants ................ 96 
Listing 4: Serious Adverse Events by Treatment Arm ................................................................ 101 
Listing 5: Injection Site Abnormalities by Treatment Arm .......................................................... 106 
Listing 6: Elevated LFTs by Treatment Arm ................................................................................. 110 
Listing 7: Decreased Platelets by Treatment Arm ........................................................................ 114 
Listing 8: AV Block ECG Abnormalities by Treatment Arm ........................................................ 118 
Listing 9: Suicide Risk by Treatment Arm .................................................................................... 121 
Listing 10: Pregnancies by Treatment Arm .................................................................................. 125 
Listing 11: Deaths by Treatment Arm ............................................................................................ 129 
Listing 12: Listing of Protocol Deviations ..................................................................................... 135 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
vi 
LIST OF ABBREVIATIONS 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Aminotransferase 
AMC 
Active Medication Combination 
ATC 
Anatomical Therapeutic Chemical 
CCTN 
Center for Clinical Trials Network 
CHRT 
Concise Health Risk Tracking 
DSC 
Data and Statistics Center 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
DSMB 
Data and Safety Monitoring Board 
ECG 
Electrocardiogram 
EOM 
End of Medication form 
FSR 
Final Study Report 
IN2 
Injection Administration 2 form 
ITT 
Intent-to-Treat 
LFT 
Liver Function Test 
NIDA 
National Institute on Drug Abuse 
NNT 
Number Needed to Treat 
ODL 
Oral Study Medication Dosing Log form 
PHQ-9 
Patient Health Questionnaire-9 
PLB 
Placebo 
QOL 
Quality of Life 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SOC 
System Organ Class 
SPCD 
Sequential Parallel Comparison Design 
STC 
Study Completion form 
TEA 
Treatment Effectiveness Assessment 
TES 
Treatment Effectiveness Score 
TLFB 
TimeLine Followback 
UDS 
Urine Drug Screen 
VAS 
Visual Analog Craving Scale 
WHO 
World Health Organization 
XR-NTX 
Extended-Release Naltrexone (as Vivitrol®) 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
1 
1.0 
SUMMARY OF STUDY DESIGN AND PROCESS 
1.1 
Study Objective 
The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus 
bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary 
objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy 
of the combination pharmacotherapy on other substance use outcomes, on depression symptom 
scores, and on quality of life ratings. 
1.2 
Study Design and Procedures 
1.2.1 Study Design 
This is a double-blind, placebo-controlled, adaptive randomized clinical trial in which 400 
individuals with moderate or severe methamphetamine use disorder will be randomly assigned to 
either 1) active medication combination (AMC) arm in which injections of extended-release 
naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended-release bupropion tablets or the 
2) matching Placebo (PLB) arm in which injections of placebo and once daily oral placebo tablets 
will be provided during a 12 week medication phase. 
This protocol will utilize a two-stage sequential parallel comparison design (SPCD), originally 
proposed by Fava et al. (2003), and later revised by Chen et al. (2011). Participants will be 
randomized to Placebo:AMC in the ratio of 0.74:0.26 in Stage 1 of the study and only Stage 1 
placebo non-responders will be re-randomized at the beginning of Stage 2 in a 1:1 ratio. The 12-
week medication phase is divided into two stages of approximately equal treatment duration. 
The original designed sample size for this study was 370. After the pre-specified sample size re-
estimation, the Center for Clinical Trials Network (CCTN) approved the increase of the sample 
size to 400 participants (See Section 8.4.1.1). 
1.2.2 Study Procedures 
Participants randomized to the AMC arm will receive injections of extended-release naltrexone 
(Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets while participants 
randomized to the Placebo arm will receive placebo injections plus once-daily oral placebo 
tablets. Injectable study medications will be administered every three weeks (Weeks 1, 4, 7, and 
10). Take-home oral study medication will be dispensed once weekly for daily dosing. Once 
weekly medical management sessions with the study medical clinician will be provided. 
Medication adherence procedures will include smartphone app-confirmation of daily oral study 
medication dosing using AiCure. Participants will be asked to attend clinic twice weekly for 
observed oral study medication dosing, collection of urine drug screening samples, and self-report 
assessments. Compensation will be provided for visit attendance and dosing via AiCure. 
Screening/baseline assessments include safety and medical measures including a medical and 
psychiatric history, a physical examination, clinical lab tests (blood chemistry, hematology, and 
urinalysis), 12-lead electrocardiogram, vital signs, and pregnancy tests (for females). 
Screening/baseline assessments also include psychological and drug use measures. 
Methamphetamine use outcome assessments include Urine Drug Screens (UDS), self-reported 
use via the Timeline Followback (TLFB), and Visual Analog Scale (VAS) craving scores. Other 
outcome assessments include UDS and TLFB (i.e., alcohol, tobacco, and/or illicit drugs), 
depression (Patient Health Questionnaire-9), quality of life (QOL), functioning (Treatment 
Effectiveness Assessment), and clinic attendance. Safety measures include monitoring vital 
signs, adverse events (AEs), concomitant medications, clinical lab results, and assessments of 
suicidality. Oral study medication adherence will be assessed by self-report, quantitative blood 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
2 
levels of bupropion and its primary metabolite, and smartphone device-based dosing confirmation 
procedures. A blood sample for genetic analysis will be collected from participants who consent 
to this procedure and the deidentified sample will be sent to a cell and DNA repository. 
At the end of the 12-week medication phase, participants will complete a follow-up phase, 
including an oral medication taper. Post-medication phase follow-up visits will occur during Weeks 
13 and 16. Participants may be withdrawn from study medication for safety reasons due to the 
discretion of medical clinician. The participant will terminate study medication if there is an 
increase in liver function tests or a decrease in platelet test results. Refer to Protocol Section 7.2.5 
for further information. 
1.2.3 Randomization 
Eligible participants will be randomized in Stage 1 of the medication phase in a 0.74:0.26 fashion 
following the SPCD, which is approximately 296:104 participants to the Placebo and AMC 
treatment arms, respectively (total target N = 400), stratifying by site. Participants who have not 
been withdrawn from study medication by medical staff will remain eligible to participate in Stage 
2. Eligible Stage 1 participants assigned to Placebo and who did not meet the specified definition 
of responder (i.e., Placebo non-responders) and who attend a visit in the re-randomization window 
will be re-randomized in a 1:1 ratio to either the Placebo or AMC arm in Stage 2, stratifying by 
site. All other eligible Stage 1 participants, including participants who did not attend a visit during 
the re-randomization window, Placebo responders, and AMC participants, will remain in the same 
treatment arm during Stage 2 as was assigned in Stage 1. 
The window for re-randomization opens on Week 7 Day 1 and closes on Week 8 Day 2. If a 
participant does not attend a visit on or between Week 7 Day 1 and Week 8 Day 2, the participant 
will not be re-randomized in Stage 2 and will continue receiving the treatment assigned in Stage 
1. Re-randomization at Stage 2 helps ensure treatment balance in the two treatment groups within 
the Stage 2 population. 
1.3 
Inclusion and Exclusion Criteria 
1.3.1 Inclusion Criteria 
1. 18 to 65 years of age. 
2. Interested in reducing or stopping methamphetamine use. 
3. Able to speak English sufficiently to understand the study procedures and provide 
written informed consent to participate in the study. 
4. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder (4 or 
more criteria.) 
5. Self-report methamphetamine use on 18 or more days in the 30-day period prior to 
consent on TLFB. 
6. Provide at least 2 urine samples positive for methamphetamine out of a possible 3 
tests to occur within a 10-day period during which clinic visits occur with at least 2 
days between visits. 
7. If female, agree to use acceptable birth control methods and have periodic urine 
pregnancy testing done during participation in the study unless documentation of 
hysterectomy provided. 
8. Meet subjective and objective measures of being opioid-free prior to naltrexone 
induction per study medical clinician’s determination. 
9. Willing to comply with all study procedures and medication instructions. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
3 
10. Agree to use a smartphone app (downloaded for free to own device or on a study 
provided smartphone device) to take daily videos of medication dosing. 
1.3.2 Exclusion Criteria 
1. Have an acute medical or psychiatric disorder that would, in the judgment of the 
study medical clinician, make participation difficult or unsafe. 
2. Have suicidal or homicidal ideation that requires immediate attention. 
3. Have a history of epilepsy, seizure disorder, or head trauma with neurological 
sequelae (e.g., loss of consciousness that required hospitalization); current anorexia 
nervosa or bulimia; or any other conditions that increase seizure risk in the opinion 
of the study medical clinician. 
4. Have evidence of second- or third-degree heart block, atrial fibrillation, atrial flutter, 
prolongation of the QTc, or any other finding on the screening electrocardiogram 
(ECG) that, in the opinion of the study medical clinician, would preclude safe 
participation in the study. 
5. Have Stage 2 hypertension as determined by the study medical clinician (e.g., 
greater than or equal to 160/100 in 2 out of 3 readings during screening.) 
6. Have any elevated bilirubin test value per laboratory criteria OR any other liver 
function test (LFT) value > 5 times the upper limit of normal per laboratory criteria. 
7. Have a platelet count < 100 x 103/μL. 
8. Have a body habitus that precludes gluteal intramuscular injection of XR-NTX in 
accordance with the administration equipment (needle) and procedures. 
9. Have a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG 
(polyactide-co-glycolide), carboxymethylcellulose or any other component of the XR-
NTX diluents. 
10. Have been in a prior study of pharmacological or behavioral treatment for 
methamphetamine use disorder within 6 months of study consent. 
11. Have taken an investigational drug in another study within 30 days of study consent. 
12. Have been prescribed and taken naltrexone or bupropion within 30 days of study 
consent. 
13. Concurrently enrolled in formal behavioral or pharmacological addiction treatment 
services. 
14. Receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., 
theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, 
chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, 
etc.), or any medication that, in the judgment of the study medical clinician, could 
interact adversely with study medications. 
15. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use 
which would preclude safe participation in the study as determined by the study 
medical clinician. 
16. Require treatment with opioid-containing medications (e.g., opioid analgesics) 
during the study period. 
17. Have a surgery planned or scheduled during the study period. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
4 
18. Are currently in jail, prison or any inpatient overnight facility as required by court of 
law or have pending legal action or other situation (e.g., unstable living 
arrangements) that could prevent participation in the study or in any study activities. 
19. If female, be currently pregnant, breastfeeding, or planning on conception. 
2.0 
GENERAL DEFINITIONS AND PROCEDURES 
2.1 
Pre-screened Population 
The pre-screened population consists of all participants who provided verbal consent for the pre-
screen process. 
2.2 
Screened Population 
The screened population consists of all participants who provided informed consent at the 
initiation of the screening process. 
2.3 
Randomized Population 
The Randomized population consists of all participants randomized in Stage 1. 
2.4 
Intent-to-Treat Population 
The Intent-to-Treat (ITT) population consists of all randomized participants in Stage 1. For Stage 
2, the ITT population includes all participants who were re-randomized. 
2.5 
Per Protocol Population 
The Per Protocol (PP) population is a subgroup of the ITT population. The PP population consists 
of participants who have not taken bupropion outside of the study medication, have not taken the 
incorrect treatment assignment, do not terminate study medication early, meet all entry criteria, 
complete the treatment period as defined in Section 2.10, and meet treatment exposure 
requirements. Four PP populations will be defined using the following treatment exposure criteria: 
1. For each stage, participants who have greater than or equal to 75% treatment 
exposure for oral study medication and receive 2 injections. Each stage will have its 
own PP population. 
2. For each stage, participants who have greater than or equal to 50% treatment 
exposure for oral study medication and receive at least one injection during the 
stage. Each stage will have its own PP population. 
3. For each stage, participants who are greater than or equal to 50% compliant to oral 
study medication using AiCure confirmed dosing. 
4. Participants randomized to AMC in Stage 1 who have 2 oral medication blood levels 
collected during Stage 1 which indicate bupropion dosing, as defined in Section 6.4, 
and participants re-randomized to AMC in Stage 2 who have 2 oral medication blood 
levels collected which indicate bupropion dosing. Each stage will have its own PP 
population. 
2.6 
Safety Population 
The safety population includes all participants who completed informed consent during the 
screening visit. 
2.7 
Study Day Definition 
Study Day 1 is defined as the day of randomization. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
5 
2.8 
First Dose Date 
The first dose date for oral study medication is the first date on the Oral Study Medication Dosing 
Log (ODL) on which it is indicated that tablets were taken. The first dose for injectable study 
medication is the first date an injection was administered on the Injection Administration 2 (IN2) 
form. 
2.9 
Last Dose Date 
The last dose date for oral study medication is the last day on the ODL form on which it is indicated 
that tablets were taken. The last dose for injectable study medication is the last date an injection 
was administered on the IN2 form. 
2.10 
Treatment Period 
The treatment period consists of Study Days 1-84, coinciding with the 12-week medication phase. 
2.11 
Follow-up Period 
The follow-up period consists of two study visits during the post-medication phase occurring at 
Week 13 and Week 16. 
2.12 
Safety Window 
The safety window begins at the first dose date of either oral or injectable study medication, 
whichever comes first, and ends either 7 days after the last oral medication dose or 28 days after 
the last injectable medication, whichever comes last. 
2.13 
Treatment Emergence 
Treatment emergent AEs are defined as AEs with a start date during the safety window. 
2.14 
Summary Table Conventions 
All analyses described in this document for the intent-to-treat population will be summarized over 
all randomized participants by stages (Stage 1 and 2) and treatment arm. Additionally, some 
analyses for the intent-to-treat population will also be summarized by site. For all summaries of 
ITT population, participants will be analyzed according to the treatment arm to which they were 
randomized regardless of the subsequent sequence of events regarding study drug exposure. 
Descriptive summaries of the distribution of continuous variables will be presented with 
percentiles (median, 25th and 75th percentiles), and with mean, standard deviation, minimum and 
maximum. Categorical variables will be summarized in terms of frequencies and/or percentages. 
Listings presented by treatment arm will include groups for non-re-randomized Placebo and AMC 
participants, and re-randomized Placebo and AMC participants (Placebo, Placebo/Placebo, 
Placebo/AMC, AMC). 
2.15 
Data and Statistics Center Responsibilities 
The CTN’s DSC will conduct analyses for the Final Study Report, including those related to the 
primary outcome measure and the supportive analyses listed in Section 7.3, and the analysis for 
the primary outcome paper, as discussed by and decided upon by the Lead Node, DSC, and 
Center for Clinical Trials Network (CCTN). The Lead Node will be responsible for the all secondary 
outcomes and analyses, the AiCure app-confirmed oral medication dosing described in Section 
6.3, and the Per Protocol Population definition #3 detailed in Section 2.5 which uses AiCure 
treatment exposure information. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
6 
3.0 
ENROLLMENT, PARTICIPANT DISPOSITION, AND FOLLOW-UP 
The number of pre-screens and screens completed and the reasons for ineligibility on pre-
screening and screening will be summarized by site. Note that participants might be screened 
twice. For participants who were screened twice, they will only be considered for the second 
screening. 
The distribution of treatment assignments by site and stage will be presented. The trajectory of 
actual randomizations versus the expected number of randomizations according to the first date 
of randomization and under the assumption that three participants are expected to be randomized 
per month per site will be graphed by site and overall. Proposed versus actual randomizations 
will be summarized by site in a tabular fashion. 
Participants are defined as study completers if the Week 16 Follow-up Visit is completed as 
indicated on the Study Completion (STC) form, and are considered as early study terminations if 
this visit is not completed. Participant disposition will be summarized by site, treatment arm, and 
stage for the number of participants completing the study, the number of participants early 
terminating from the study, and the reasons for early study termination. Early study terminations, 
using the date of last data collection or date of withdrawn consent on the STC form, will be 
attributed to Stage 1 if the termination occurred prior to the end of Week 6 (Day 42). Study 
terminations occurring from Day 43 to Day 84 will be considered to occur in Stage 2, and study 
terminations occurring after Day 84 will be considered to occur during follow-up. 
The CONSORT flow diagram will be generated (Moher et al., 2010). 
The number and percentage of participants who attend the bi-weekly treatment period study visits 
during Weeks 1-12 will be presented by treatment arm and stage, and the Week 13 and 16 follow-
up visits will be presented by treatment arm. Information on missed visits during the treatment 
period and the follow-up period will be presented by treatment arm and stage, including the 
number of missed visits, the number of participants with at least one missed visit, and the reasons 
for the missed visits. The expected number of visits during the treatment period is calculated 
based on the general rule that two visits per week are expected per participant for a total of 12 
expected visits per stage, and two visits are expected during the follow-up period. The average 
number of missed visits per participant will be calculated by dividing the number of missed visits 
by the number of participants. For early study terminations, visits are only considered missed 
during active study participation if they occur before the study termination date. 
4.0 
ANALYSIS OF PARTICIPANT CHARACTERISTICS 
Baseline demographics and characteristics including sex, age, ethnicity, race, education level, 
marital status, employment status, and the number of methamphetamine use days in the 30 days 
prior to informed consent reported on TLFB will be summarized by site, treatment arm, and stage. 
Because randomization is expected to produce balance at baseline between the two arms of the 
trial, statistical comparisons of treatment groups with respect to baseline characteristics will be 
informal. If differences between treatments arms are suspected, statistical testing will be 
performed. 
5.0 
CONCOMITANT MEDICATIONS 
Concomitant medications taken during the treatment period will be coded using the WHO Drug 
Dictionary. Summaries by treatment arm will be presented by Anatomical Therapeutic Chemical 
(ATC) Class level 1 and ATC Class level 2 and will include the number and percentage of 
participants receiving each drug class during the safety window defined in Section 2.12. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
7 
6.0 
STUDY MEDICATION ADHERENCE 
Exposure to study medication will be assessed by oral medication dosing, including self-report 
and AiCure app-confirmed dosing, injection administration, and medication blood levels. 
6.1 
Early Medication Terminations 
Participants may terminate early from either oral study medication or injectable study medication, 
or from both study medications. Participants will be considered early oral medication terminations 
as of the date of last oral medication dose entered on the End of Medication (EOM) form. For 
injectable study medication the date of early medication termination is not collected, and 
participants will be considered to terminate from the medication for the injection number after the 
last injection administered on the IN2 form. Early injection termination participants receiving no 
injections or injection #1 only will be considered early injection terminations in Stage 1, and 
participants last receiving injection #2 or #3 will be considered early injection terminations in Stage 
2. Note there is one exception that participants terminating the study or terminating both study 
medications on or before Day 42 (end of Week 6) who received both injection #1 and #2 will be 
considered as early injectable study medication terminations in Stage 1. Early oral study 
medication terminations occurring before the date of re-randomization or Day 43 for participants 
who are not re-randomized are considered to occur in Stage 1, and early oral study medications 
occurring on or after the date of re-randomization are assigned to Stage 2. 
The number of participants terminating early from each study medications and the reasons for 
termination will be presented by site and by stage and treatment arm. 
6.2 
Treatment Exposure 
During the treatment period (Days 1-84), 3 tablets per study day are expected and 4 injections 
should be administered. Oral study medication dosing is recorded on the ODL form and injection 
administration is recorded on the IN2 form. Treatment exposure is defined as the average of the 
percentage of expected oral study medication taken and the percentage of expected injections 
received. Oral medication taken after the end of the treatment period Day 84 will not be 
considered. Treatment exposure will be summarized by site, and by site, treatment arm and stage. 
Oral medication expected to be taken before the date of re-randomization or Study Day 43 for 
non-re-randomized participants is considered Stage 1, and oral medication expected to be taken 
on or after the date of re-randomization or Study Day 43 for non-re-randomized participants is 
considered Stage 2. Injections #1 and #2 are allocated to Stage 1 and injections #3 and #4 are in 
Stage 2. 
A summary of the number of injections administered out of the 4 expected injections by site and 
by treatment arm and stage will be presented. Two injections are expected in each stage. 
6.3 
Video Confirmed Oral Medication Dosing 
Exposure to oral medication will also be calculated using information from the smartphone app-
based dosing confirmation procedures developed by AiCure. Video confirmed dosing adherence 
data is to be interpreted as an objective indicator of the lowest medication adherence rate 
participants achieve. Video confirmed adherence is defined as the percentage of expected oral 
study medication taken, with taken medication including dosing confirmed via video, confirmed 
by the site, and confirmed in the clinic. Oral medication taken after the end of the treatment period 
Day 84 will not be considered. Video confirmed adherence will be summarized by site and by 
treatment arm and stage. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
8 
6.4 
Oral Medication Blood Levels 
Exposure to bupropion will be assessed at Weeks 4, 7, 10, and 12 for participants randomized to 
AMC and Weeks 10 and 12 for participants re-randomized to AMC by examining quantitative 
blood levels of bupropion and its primary metabolite hydroxybupropion. Bupropion blood levels 
greater than 0.500 ng/mL (limit of detection) and hydroxybupropion blood levels greater than 1.00 
ng/mL (limit of detection) will indicate adherence to oral bupropion dosing. A summary table of 
AMC participants adherent to bupropion dosing by stage will be provided. 
7.0 
ANALYSIS OF EFFICACY OUTCOME MEASURES 
7.1 
Definition of Primary Outcome Measure 
The evaluation period is the final two weeks of the medication phase in Stage 1 (Weeks 5-6) for 
all participants and Stage 2 (Weeks 11-12) for participants that have been re-randomized. The 
primary efficacy outcome is a measurement of treatment response at a specified threshold (3 of 
4 UDS negative for methamphetamine during the two-week period). Thus, a participant will meet 
responder criterion by providing 3 or 4 methamphetamine-negative UDS tests during the final two 
weeks of each stage of the treatment period. All other participants without 3 or 4 
methamphetamine-negative UDS will be considered non-responders. 
It is hypothesized that the AMC arm will be associated with a greater number of responders, 
relative to the Placebo arm. The treatment groups will be compared as to the proportion of 
responders in Stage 1 and Stage 2. The treatment effect will be defined as a weighted 
combination of the response rates in the two stages. The weight was chosen to optimize the test 
under the alternative hypothesis as described below. In addition, clinically it is expected that a 
larger treatment effect will be observed in Stage 2 due to the exclusion of placebo responders 
from Stage 1. All treatment comparisons will be performed under the Intent-to-Treat (ITT) criteria. 
7.2 
Analysis of Primary Outcome Measure 
Figure 1 shows the design parameters of the SPCD. 
Figure 1: SPCD: Defining the Outcome 
R
A
N
D
O
M
I
Z
E
Stage 1
Stage 2
PLB
AMC
q1
p1
Non-
Responder
R
A
N
D
O
M
I
Z
E
Continued to Stage 2
(non-dropout)
PLB
AMC
p2
q2
s
 
Let p1, q1 be the response rates for AMC and Placebo in Stage 1; and p2, q2 be the response 
rates of AMC and Placebo in Stage 2, that is, among Placebo non-responders. Assume that s is 
the rate of continuation into Stage 2 among Placebo non-responders, (i.e., 1-s is the Stage 1 
drop-out rate). The primary analysis alternative hypothesis is that the AMC group has higher 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
9 
response rate than Placebo in the full population (Stage 1) OR in the sub-population of Placebo 
non-responders (Stage 2). The following null (H0) vs alternate hypothesis (H1) will be tested: 
𝐻0: 𝑝1 ≤ 𝑞1 AND 𝑝2 ≤ 𝑞2 
𝐻1: 𝑝1 > 𝑞1 OR 𝑝2 > 𝑞2 
The randomization fraction, a and the weight, w are the parameters of the SPCD that are chosen 
to maximize the power of the test, based on the alternative hypothesis. Fava (2003) recommends 
that both a and w be chosen a priori based on the alternative hypothesis of interest. For the 
alternative hypothesis of this study, it is assumed p1=0.24, q1=0.15 (response rates for AMC and 
Placebo, respectively, in Stage 1) and p2=0.24, q2=0.10 (response rates for AMC and Placebo, 
respectively, in Stage 2), and s=0.85 (rate of continuation into Stage 2 of the trial among Placebo 
non-responders). These assumptions lead to the conclusion that the randomization fraction, 
a=0.37 and the weight, w=0.43 will maximize the power of the test. The primary outcome analysis 
will be performed as described in Tamura and Huang (2007) using the Wald type test statistic Z 
= h/se(h), where 
ℎ=  𝑤(𝑝1,𝑜𝑏𝑠−𝑞1,𝑜𝑏𝑠) + (1 −𝑤)(𝑝2,𝑜𝑏𝑠−𝑞2,𝑜𝑏𝑠) 
 
 
𝑣𝑎𝑟(ℎ) = 𝑤2𝑝1,𝑜𝑏𝑠(1 −𝑝1,𝑜𝑏𝑠)
𝑛(1 −2𝑎)
+
((𝑤2
4 )𝑞1,𝑜𝑏𝑠(1 −𝑞1,𝑜𝑏𝑠) + (1 −𝑤)2𝑞2,𝑜𝑏𝑠(1 −𝑞2,𝑜𝑏𝑠)
𝑠𝑜𝑏𝑠(1 −𝑞1,𝑜𝑏𝑠)
)
𝑛𝑎
+ 
((𝑤2
4 ) 𝑞1,𝑜𝑏𝑠(1 −𝑞1,𝑜𝑏𝑠) + (1 −𝑤)2𝑝2,𝑜𝑏𝑠(1 −𝑝2,𝑜𝑏𝑠)
𝑠𝑜𝑏𝑠(1 −𝑞1,𝑜𝑏𝑠)
)
𝑛𝑎
 
 
and 𝑠𝑒(ℎ) = √𝑣𝑎𝑟(ℎ) 
Note that Schoenfeld corrected the Tamura and Huang formula for the variance. 
In the above test statistic both a and w are chosen a priori as 0.37 and 0.43; n is the sample size 
and the quantities p1,obs, q1,obs, sobs, p2,obs and q2,obs will be estimated from the data. The null 
hypothesis will be rejected if Z > boundary (one-sided), where the boundary for interim and final 
analysis is defined as the O’Brien-Fleming boundary as described in Section 8.4.2. A one-sided 
p-value for the test of primary outcome will be presented. One-sided lower bound confidence limit 
for the responder rate will be calculated using h – boundary x se(h). See Section 8.2 for the 
boundary and cumulative alpha spent to be used at interim analysis and final analysis. 
The Number Needed to Treat (NNT) will be calculated as 1/h. UDS availability and results in the 
evaluation periods will be summarized by treatment arm and stage. A graph of the percentage of 
negative methamphetamine UDS results during the treatment and follow-up periods will be 
presented. 
7.3 
Supportive Analyses of Primary Outcome Measure 
The analysis will be repeated with the inclusion of selected covariates, for example, age of onset 
of methamphetamine use, baseline number of methamphetamine use days self-reported on 
Timeline Followback (TLFB) in the 30 days prior to informed consent, severity of 
methamphetamine use (presence or absence of using methamphetamine via injection route of 
administration on TLFB in the 30 days prior to informed consent; number of DSM-5 criteria met 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
10 
during screening), tobacco use (number of days using cigarettes or e-cigarette on TLFB during 
30 days prior to informed consent),Treatment Effectiveness Assessment score at screening, 
average of all Visual Analog Craving scale scores collected during screening, and site. A 
generalized linear mixed effect model will be used to assess the covariate adjusted treatment 
effects to use in the equation in Section 7.2 to compute h. 
Subgroup analysis for sex, race, ethnicity and age will be performed as required by the NIH (NIH, 
2016). A generalized linear mixed effect model will be used to assess the subgroup-by-stage-by-
treatment interaction. A contrast will be written using the pre-specified weight (w=0.43) to test the 
difference in the primary hypothesis by subgroup. 
The primary hypothesis is the difference in the weighted treatment effect in Stage 1 and 2. For 
example, the difference in the primary hypothesis by sex (Female = F, Male = M) is obtained by 
a contrast using the weighted treatment effects within males (hM) and females (hF) which are given 
by the following equations: 
ℎ𝑀= {𝑤(𝑝1,𝑀−𝑞1,𝑀) + (1 −𝑤)(𝑝2,𝑀−𝑞2,𝑀)} 
ℎ𝐹= {𝑤(𝑝1,𝐹−𝑞1,𝐹) + (1 −𝑤)(𝑝2,𝐹−𝑞2,𝐹)} 
The estimates for the responder rate and standard error for males and females will be obtained 
using an LSMESTIMATE statement and the p-value for the comparison will be obtained using a 
CONTRAST statement in the SAS code below. 
proc glimmix data=final method=quad; 
  class sex stage trt patid; 
  model responder = sex*stage*trt/noint solution; 
  random intercept /subject=patid; 
  contrast "MvsF" sex*stage*trt -.43 .43 -.57 .57 .43 -.43 .57 -.57; 
  lsmestimate sex*stage*trt "Male" -.43 .43 -.57 .57; 
  lsmestimate sex*stage*trt "Female" 0 0 0 0 -.43 .43 -.57 .57; 
run; 
Similarly, the subgroup analysis for site, race, ethnicity, and age will be conducted. If there are 
more than 2 levels of a subgroup e.g. race (black, white and other) an overall p-value will be 
reported and appropriate post-hoc testing will be conducted. Summary tables of primary outcome 
results by site and in the subgroups for sex, race, ethnicity, and age will be provided by treatment 
arm. 
Responder rates in the Randomized Population and the Per Protocol Populations will be 
presented by treatment arm. 
A sensitivity analysis using w=0.5 will be performed for the ITT Population. 
7.4 
Secondary Outcome Measures 
Secondary outcome measures for the impact of the AMC, relative to the Placebo arm, on other 
substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, 
and medication adherence will be evaluated as follows. 
1. Alternate measures and composites of methamphetamine use including: 
a) The Treatment Effectiveness Score (TES) (Ling et al., 1997), as measured by UDS 
results, during the treatment period. The TES is the percentage of the expected urine 
drug screens that were negative for each drug. Twelve urine drug screens are 
expected within each stage. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
11 
b) Methamphetamine use, as measured by UDS, during the treatment period. 
Outcomes include UDS results in the pre-evaluation period (Weeks 1-4 for Stage 1 
and Weeks 7-10 in Stage 2), the maximum number of consecutive negative UDS 
(missing and positive UDS will reset the count to zero), and number of study weeks 
during the treatment period with two methamphetamine-negative UDS. 
c) Frequency of methamphetamine use, as measured by self-report on TLFB, during 
the treatment period. The self-reported number of days abstinent from 
methamphetamine use will be assessed during the evaluation periods during Stage 
1 and Stage 2 and over the entire treatment period. 
d) Severity of methamphetamine craving, as measured by Visual Analog Craving 
Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 
100 (most intense craving possible). The VAS is completed at screening, once a 
week during the treatment period, and at the follow-up visits. 
e) Methamphetamine use as measured by UDS and methamphetamine use self-
reported on TLFB during the follow-up period. UDS results and the self-reported 
number of days abstinent from methamphetamine use during the follow-up will be 
assessed. 
2. Other substance use, as measured by UDS, during the treatment period. Opioid use will 
also be assessed using the Opioid 2000 ng tests on the UDS. 
3. Quantity and frequency of alcohol, quantity and frequency of cigarettes, frequency of e-
cigarettes, and frequency of other drug use, as measured by self-report on TLFB during 
the treatment period. 
4. Depressive symptoms, as measured by the PHQ-9, during the treatment period. The 
PHQ-9 is collected at screening, once a week during the treatment period, and at the 
follow-up visits. 
5. Quality of life (QoL), as measured by the PhenX Core Tier 1 instrument and collected on 
the Quality of Life (QLP) form, during the treatment period. Ratings of general health, 
physical health, and mental health during the past 30 days at screening, mid-treatment 
(Week 6 Visit 2), and end-of-treatment (Week 12 Visit 2) are collected. 
6. Overall functioning, as measured by the Treatment Effectiveness Assessment (TEA), 
during the treatment period. The Treatment Effectiveness Assessment (Ling, 2012) is a 
4-item self-administered assessment that uses a Likert scale (1-10) to document changes 
in four life domains: substance use, health, lifestyle, and community and is collected at 
screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2). 
7. Percentage of participants who completed a visit in Week 12. 
8. Ratings of participant and staff satisfaction with study procedures, including use of the 
medication adherence app, compensation, and medication. 
The Lead Node will provide summary tables by treatment arm and stage for the above secondary 
outcomes. 
7.5 
Secondary Outcome Analyses 
All secondary analyses described below will be conducted by the Lead Node. The secondary 
outcomes listed in Section 7.4 are classified in Table 1. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
12 
Table 1: Secondary Outcomes by Type of Outcome for SPCD Analysis 
Type of 
Outcome 
Frequency of 
Measurement 
Outcomes 
Binary Cross-
Sectional 
one 
measurement per 
stage 
Meth use from UDS (1.b, 1.e) 
Other substance use from UDS (2) 
Ordinal 
one 
measurement 
Ratings of participant and staff satisfaction (8) 
Ordinal Cross-
Sectional 
one 
measurement per 
stage 
QOL (general health) (5) 
Count 
one 
measurement per 
stage 
Number of weeks with meth-negative UDS (1.b) 
Number of consecutive meth-negative UDS (1.b) 
Number of meth-abstinent TLFB days (1.c, 1.e) 
Number of alcohol, cigarettes, e-cigarettes, and other substance 
use TLFB days (3) 
Continuous 
one 
measurement 
Treatment completion (7) 
Continuous 
Cross-
Sectional 
one 
measurement per 
stage 
TES (1.a) 
Quantity of alcohol and cigarettes used from TLFB (3) 
QOL (physical health, mental health) (5) 
TEA (substance use, health, lifestyle, community) (6) 
Continuous 
Repeated 
Measures 
multiple 
measurements 
per stage 
Severity of meth craving measured by VAS (1.d) 
PHQ-9 (4) 
Binary cross-sectional outcomes will be analyzed using the same model as for the primary 
outcome. All repeated measures will be analyzed using the method of Doros et al, 2012. The 
mixed effects repeated measures models will control for baseline methamphetamine use days 
self-reported on TLFB and other key demographic and participant variables such as severity of 
methamphetamine use, tobacco use history, and visual analog craving scale. Nonparametric 
analyses will be used if the assumptions of the mixed effects analysis cannot be met. Participant 
and staff satisfaction ratings will be summarized. Analyses of secondary outcomes will be 
primarily performed on all individuals who are in the ITT population and inducted onto both study 
medications. 
The analysis approach described in Doros et al, 2012 is preferred, however the approach defined 
in Chen (2011) may also be used, as appropriate (i.e., for continuous outcome ordinary least 
squares and mixed effects models for repeated measures (MMRM). Logistic regression may also 
be used for binary outcomes. The same weights as primary outcome will be used to calculate the 
weighted combination of the estimated treatment effects in the two stages for the secondary 
analyses. 
Secondary analyses of outcomes not specified in Section 7.4 will also be performed. Adherence 
to oral study medication dosing will be measured by smartphone app-confirmation of daily oral 
study medication dosing and as recorded on the dosing log (ODL). In addition, per protocol 
analyses will be conducted using the Per Protocol population definitions in Section 2.5. Because 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
13 
per protocol analyses may be biased (Sheiner and Rubin, 1995), an unbiased complier-adjusted 
causal effects analysis (Stuart and Jo, 2015) may also be used to adjust for adherence. 
Additionally, methamphetamine and other substance use outcomes may be assessed for 
responders, non-responders, and other subgroups. 
8.0 
OTHER STATISTICAL CONSIDERATIONS 
8.1 
Handling Missing Data 
Any participant who drops out before the last week in each evaluation period is, by definition, a 
non-responder. Therefore, any participant who drops out before Week 6 is a Stage 1 non-
responder. In the SPCD design, Stage 1 Placebo non-responders are to be randomized again in 
Stage 2, but re-randomization is impossible if the participant has dropped out. Thus, Stage 1 
dropouts will not contribute to the analysis in Stage 2. In Stage 2, dropouts (i.e., any participant 
who drops out before Week 12) are again considered to be non-responders by definition, and this 
causes no further complication in the SPCD computation. 
It is unknown a priori how many participants will drop out in Stage 1 of the study, thus the 15% 
attrition rate (s=0.85) was chosen as a conservative estimate. Also, as described above, an 
assumption was made that participants who dropped out early in a given stage will be considered 
as non-responders in that stage. Therefore, it is important to assess the impact of these missing 
data assumptions on the primary outcome analysis of the study. A series of sensitivity analyses 
will be performed to determine how the missing data affects the primary results. Analysis by 
imputing missing UDS as negative will be conducted, as well as a complete case analysis which 
includes all participants who have 4 UDS collected in the evaluation period for each stage. Based 
on the literature review on novel missing data methodology for SPCD, additional secondary 
analysis may be performed to support the primary outcome analysis. 
8.2 
Significance Testing 
The primary outcome will be evaluated using a one-sided test with a type I error rate of α=0.025, 
adjusted based on O’Brien-Fleming boundaries for the interim analysis as described in Section 
8.4.2. The boundary and the cumulative alpha spent used for interim and final analysis are noted 
below in Table 2. 
Table 2: Primary Outcome Analysis Boundary and Cumulative Alpha Spent 
Timepoint 
Boundary for Declaring 
Statistical Significance 
Alpha Level 
(Cumulative alpha spent) 
Interim analysis 
2.9626 
0.00153 
Final analysis 
1.9686 
0.025 
The secondary outcomes will use a two-sided test with 5% error rate. There are several secondary 
outcomes; however, multiple testing will not be adjusted for in the secondary analyses, since 
these are not part of the study’s primary objective. When multiple tests are conducted, the chance 
of finding a significant difference in one of the tests, when in fact no difference exists, is greater 
than the stated type I error rate. The investigators are aware of the issues associated with multiple 
testing and will interpret results with caution. 
8.3 
Sample Size and Power Calculations 
The sample size calculation was conducted as described in Tamura and Huang (2007), with the 
randomization ratio for Placebo:AMC defined as 2a:(1-2a), where a is defined as the 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
14 
randomization fraction. Table 2 shows the impact of various design assumptions on the 
parameters of the SPCD, the randomization fraction a, and the weight w on the sample size. It is 
important to note that when the rate of discontinuation is 0% (s=1), the sample size calculation 
based on Tamura and Huang (2007) gives the same results as Fava et al. (2003) SPCD sample 
size calculations. 
As described in Section 7.2 for the alternate hypothesis, it is assumed p1=0.24, q1=0.15 
(response rates for AMC and Placebo, respectively, in Stage 1) and p2=0.24, q2=0.10 (response 
rates for AMC and Placebo, respectively, in Stage 2), and s=0.85 (rate of continuation into Stage 
2 of the trial among placebo non-responders). Corresponding to these, the randomization fraction 
a=0.37 and the weight w=0.43 would maximize the power of the test (Table 3). A sample size of 
370 is chosen for this study and will provide 90% power to detect the weighted difference between 
the two treatment arms. In Stage 1, the random allocation to Placebo:AMC would be 274:96. 
Based on the above assumptions, it would be expected that: 
 
Of the 274 assigned to PLB, 15% (q1=0.15) would be Placebo responders while 85% (or 
233) would be Placebo non-responders. 
 
198 (85% of 233, s=0.85) participants would continue to Stage 2. 
 
In Stage 2, the random allocation to Placebo:AMC would be 99:99. 
 
During the course of the entire study 195 participants will receive the AMC, with 96 in 
Stage 1 and 99 in Stage 2. 
See Section 8.4.1.1 for an update to the sample size after the sample size re-estimation was 
conducted. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
15 
Table 3: Sample Size Calculation 
SPCD Design Assumptions 
Impact of Assumptions on 
Response Rates 
Rate of 
Continuation 
in Stage 2 
AMC 
PLB 
 
Parameters 
Sample Size for 
Stage 1 
(p1) 
Stage 2 
(p2) 
Stage 1 
(q1) 
Stage 2 
(q2) 
s 
a 
w 
80% 
Power 
90% 
Power 
0.29 
0.29 
0.15 
0.15 
1 
0.28 
0.67 
187 
250 
0.29 
0.29 
0.15 
0.10 
1 
0.35 
0.46 
134 
179 
0.29 
0.29 
0.10 
0.15 
1 
0.23 
0.8 
105 
141 
0.29 
0.29 
0.10 
0.10 
1 
0.26 
0.68 
89 
119 
0.29 
0.24 
0.15 
0.15 
1 
0.24 
0.78 
225 
301 
0.29 
0.24 
0.15 
0.10 
1 
0.29 
0.61 
174 
232 
0.29 
0.24 
0.10 
0.10 
1 
0.23 
0.75 
102 
136 
0.24 
0.29 
0.15 
0.15 
1 
0.36 
0.45 
283 
379 
0.24 
0.29 
0.10 
0.15 
1 
0.25 
0.73 
160 
214 
0.24 
0.29 
0.10 
0.10 
1 
0.32 
0.54 
120 
161 
0.24 
0.24 
0.15 
0.15 
1 
0.28 
0.67 
417 
558 
0.24 
0.24 
0.15 
0.10 
1 
0.4 
0.33 
246 
329 
0.24 
0.24 
0.10 
0.15 
1 
0.23 
0.82 
187 
250 
0.24 
0.24 
0.10 
0.10 
1 
0.27 
0.67 
151 
201 
0.29 
0.29 
0.15 
0.15 
0.85 
0.27 
0.72 
196 
262 
0.29 
0.29 
0.15 
0.10 
0.85 
0.33 
0.54 
147 
196 
0.29 
0.29 
0.10 
0.15 
0.85 
0.22 
0.82 
108 
144 
0.29 
0.29 
0.10 
0.10 
0.85 
0.25 
0.72 
94 
125 
0.29 
0.24 
0.15 
0.15 
0.85 
0.24 
0.81 
230 
308 
0.29 
0.24 
0.15 
0.10 
0.85 
0.28 
0.66 
184 
246 
0.29 
0.24 
0.10 
0.10 
0.85 
0.23 
0.79 
105 
140 
0.24 
0.29 
0.15 
0.15 
0.85 
0.34 
0.54 
313 
419 
0.24 
0.29 
0.10 
0.15 
0.85 
0.25 
0.77 
167 
223 
0.24 
0.29 
0.10 
0.10 
0.85 
0.3 
0.61 
131 
175 
0.24 
0.24 
0.15 
0.15 
0.85 
0.27 
0.71 
439 
587 
0.24 
0.24 
0.15 
0.10 
0.85 
0.37 
0.43 
276 
370 
0.24 
0.24 
0.10 
0.15 
0.85 
0.22 
0.84 
190 
254 
0.24 
0.24 
0.10 
0.10 
0.85 
0.26 
0.72 
158 
212 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
16 
8.4 
Interim Analyses 
8.4.1 Sample Size Re-Estimation 
Sample size re-estimation analysis will be conducted when approximately half of the participants 
have been enrolled and have passed the last day available for re-randomization, Week 8 Day 2, 
and will focus on the nuisance parameter s (rate of continuation into Stage 2 of the trial among 
Placebo non-responders). This analysis will not reveal the treatment effect observed in the trial at 
the time of this interim analysis. Fava (2003) suggested that both a and w be a priori chosen to 
maximize the power of the test based on the alternative hypothesis of interest, and therefore a 
and w will not be re-estimated. Under the design assumptions of p1=0.24, q1=0.15, p2=0.24, 
q2=0.10, the randomization fraction a=0.37, and the weight w=0.43, a sample size re-estimation 
will be performed using the estimated parameter s, keeping the other parameters fixed, to assess 
the adequacy of the projected study sample size and whether a sample size increase is 
warranted. 
The timing of the sample size re-estimation is based on a number of factors: recruitment rate, 
timing of the primary outcome, amount of loss to follow-up, and time to perform the sample size 
re-estimation. ADAPT-2 will use the graphical tool presented in Figure 2 to assist in assessing 
the appropriate timing of sample size re-estimation. To illustrate, Figure 2 shows the timing of re-
estimation when 50% of the participants have completed Stage 1 in the study (0.5 on the red line), 
assuming enrollment (blue line) in ADAPT-2 of 370 participants over an 18-month period. The 
time point to perform the sample size re-estimation corresponds to 10.7 months (9 months to 
enroll 50% participants plus completion of end of re-randomization window at Week 8 Day 2) after 
enrollment into ADAPT-2 has started, at which point, the study will have enrolled about 58% of 
the target sample size. If recruitment takes more or less time than expected, modifications can be 
made to the timing of the sample size re-estimation. The sample size re-estimation will be done 
only once and done before any interim analysis of the primary outcome is performed. The results 
of the sample size re-estimation analysis would be presented in a closed session of the DSMB, 
who will then provide a recommendation to the NIDA CCTN regarding whether the target sample 
size should be modified. A decision regarding any such modification would be made subsequently 
by the CCTN, taking into consideration the recommendation of the DSMB. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
17 
Figure 2: Completed Stage 1 and Fraction of Target Enrollment for Proposed Sample Size 
Re-Estimation Based on Months from Start of Enrollment 
 
8.4.1.1 Sample Size Re-Estimation Results 
The NIDA CTN DSMB reviewed the sample size re-estimation report dated July 23, 2018, 
prepared by the DSC. In this report, the sample size re-estimation was presented under the design 
assumptions of p1=0.24, q1=0.15, p2=0.24, q2=0.10, the randomization fraction a=0.37, the 
weight w=0.43, and using the estimated parameter s=0.75758, keeping the other parameters 
fixed. The s parameter was estimated using the first 185 participants randomized. Table 4 shows 
the results of the sample size re-estimation. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
18 
Table 4: Sample Size Re-Estimation Results 
Sample Size Calculation 
s 
N 
Power 
Original design 
0.85 
276 
80% 
0.85 
370 
90% 
Power with current 
sample size and updated 
s parameter 
0.75758 
276 
76.8% 
0.75758 
370 
87.7% 
Maintaining original 
power with increased 
sample size using 
updated s parameter 
0.75758 
298 
80% 
0.75758 
399 
90% 
Based on the above results, the DSMB and NIDA CCTN concurred that although the loss of power 
compared to the original power calculations was negligible, the dropout rate that will occur in 
Stage 2 of the study is also unknown and recommended increasing the sample size by 30 
additional participants (N = 400) to maintain the targeted 90% power. The CCTN approved the 
increase the sample size to 400 participants in a letter to the Lead Investigator dated August 13, 
2018. 
8.4.2 Interim Monitoring of Primary Efficacy Endpoint 
Interim monitoring for efficacy will be performed of the primary alternative hypothesis that the 
AMC, relative to the Placebo, is associated with greater methamphetamine non-use. There will 
be no interim efficacy monitoring before a sample size re-estimation is performed (or a 
determination that re-estimation is not needed) because sample size re-estimation could change 
the target sample size, affecting the alpha spending function used in the interim efficacy 
monitoring. After sample size re-estimation, interim efficacy monitoring will be performed only 
once during the recruitment period. Because the Lan-DeMets approach (DeMets and Lan, 1994) 
requires an independent increments process, care must be taken in defining the population that 
will be used in the interim analysis. For example, including participants in an interim look who 
completed 6 weeks of Stage 1 and are Placebo non-responders, but have not yet had the 
opportunity to contribute Stage 2 responses, violates the independent-increments requirement. 
To avoid this, the following rule will be obeyed: 
 
For a look at study time t months, include only those participants who were randomized to 
Stage I no later than t-3 months (i.e., have the opportunity to complete the 12 weeks (or 3 
months) on study at the time of the analysis). The size of that sample, when divided by the 
target sample size, becomes the information fraction for the look at calendar time t. 
Based on the above rule and using designed parameters, the Lan-DeMets alpha-spending 
approach to interim monitoring for SPCD trials was investigated by simulation. Enrollment was 
assumed to be constant over an 18–month period. Under the null hypothesis, (p1, p2) are set 
equal to (q1, q2) = (0.15, 0.10), while under the alternative, (p1, p2) = (0.24, 0.24) a 2-look 
scenario, in which information fraction = (0.5, 1.0), was simulated. 
Table 5 gives the simulated probability of rejecting the null hypothesis at alpha = 0.025, 1-tailed, 
for each of these scenarios. More specifically, 10,000 time series of SPCD z-values were 
simulated, each with 2 values (when there are 2 looks) for each scenario. In each scenario, the 
proportion of time series that ever cross the relevant boundary is presented in Table 6. It shows 
that after using the O’Brien-Fleming-type boundaries the test size under the null and power under 
the alternative are as desired. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
19 
Table 5: Simulated Probability of Rejecting the Null 
Hypothesis at α = 0.025, 1-tailed 
 
Null Hypothesis 
Alternative 
Hypothesis 
O’Brien-Fleming type 
0.0237 
0.90 
All interim monitoring will use an O’Brien-Fleming-type boundary with information fraction equal 
to the proportion of the target sample size with primary outcome, and alpha = 0.025, one-tailed. 
This approach spends very little alpha at the interim look, therefore the impact of an interim 
monitoring on the sample size is negligible. Table 6 shows an example of boundary (Z-score) to 
stop early for efficacy and cumulative alpha spent at interim analysis with 0.5 information fraction. 
Table 6: Boundary to Stop Early for Efficacy and Cumulative Alpha 
Spent at Interim Analysis 
Information Fraction 
Boundary 
Alpha Spent 
Cumulative Alpha Spent 
0.5 (Half-way) 
2.9626 
0.00153 
0.00153 
1 (End of study) 
1.9686 
0.02347 
0.025 
In addition, the observed parameters and number of participants assigned to each treatment arm 
in the two stages will be monitored against the designed parameters (p1=0.24, q1=0.15, p2=0.24, 
q2=0.10, s=0.85) and expected assignment. The only criterion for early stopping for efficacy will 
be based on Z-scores and its relation to O’Brien-Fleming-type boundary. 
Before recommending early termination, the DSMB should consider: 
 
Internal consistency of primary and secondary results. 
 
Internal consistency of primary and secondary results by subgroups defined by baseline 
characteristics (e.g., number of baseline MA use days on TLFB, severity of MA use, 
tobacco use history, treatment effectiveness assessment and visual analog craving scale). 
 
Distribution of baseline prognostic factors among the two groups. 
 
Consistency of primary and secondary results across clinical sites and among clinical sites 
enrolling larger numbers of participants. 
 
Possible impact of missing data from missed participant visits for assessment of the 
primary and secondary response variables. 
 
Possible differences in concomitant interventions or medications. 
8.4.3 Safety Interim Analyses 
Safety interim looks will be performed for the regular DSMB meetings or at unscheduled times 
per the DSMB’s request. These will include analysis of adverse events and narrative report on 
serious adverse events. 
Further, because the primary outcome analysis is a one-sided test to assess whether AMC is 
more efficacious than Placebo, simultaneous with primary interim efficacy monitoring analysis, a 
poor efficacy statistic will be calculated to assess whether the AMC, relative to the Placebo, is 
associated with greater methamphetamine use i.e., whether compared to AMC, the response rate 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
20 
is greater in Placebo in both stages. This analysis will be conducted after the sample size re-
estimation. If the poor efficacy of AMC statistic crosses its boundary, defined by the minimum of 
q1 – p1 and q2 – p2 being greater than 10%, the DSMB will consider whether to stop the trial 
early because of poor efficacy of AMC relative to Placebo. When reporting results of the trial, the 
one-sided superiority test will be considered the primary outcome, with the other tail considered 
as part of the poor efficacy analysis intended for the DSMB to monitor for safety. That is, as in a 
more usual trial design, the possibility of exit in the safety/poor efficacy tail will not be considered 
as possibly affecting the type I or type II error of the primary outcome statistical test. 
8.4.4 Conditional Power and Futility 
Unless otherwise requested, a futility/conditional power calculation will be performed when interim 
monitoring is performed. If at any DSMB meeting the conditional power falls below 0.3 (when 
hypothetical future observations are generated under the design alternative (p1=0.24, q1=0.15, 
p2=0.24, q2=0.10) but tested under the null), this will stimulate a discussion among the DSMB 
members about whether the trial should stop for futility. 
8.4.5 Results of Interim Monitoring for Efficacy and Safety 
The NIDA CTN DSMB met on October 24, 2018 to review the interim efficacy and safety analyses 
prepared by the DSC using the first 200 enrollment participants. The DSMB recommended the 
study should continue until 400 participants complete as determined by the sample size re-
estimation. 
8.5 
Software to be Used for Analyses 
The O’Brien-Fleming boundaries and the p-value for the primary outcome will be calculated in 
WinLD (Reboussin 2000). The interim analyses for sample size re-estimation and conditional 
power will be conducted in R Versions 3.4.2 and 3.5.1. All other analyses performed by the DSC 
and the Lead Node will use SAS Version 9.4 software, including the calculation of the Wald type 
test statistic Z for the primary outcome. The Lead Node may also conduct analyses using R 
Versions 3.4.2 and 3.5.1. 
9.0 
ANALYSIS OF SAFETY OUTCOME MEASURES 
9.1 
Adverse Events 
Treatment emergent adverse events (AEs) as defined in Section 2.13 will be summarized by 
presenting the number of events, number of participants experiencing AEs, and the severity and 
relatedness of adverse events by treatment arm and stage. Stage 1 events include AEs occurring 
before the date of re-randomization for re-randomized participants and in Weeks 1-6 for non-re-
randomized participants, and Stage 2 AEs include events occurring on or after the date of re-
randomization for re-randomized participants and in Weeks 7 or greater for non-re-randomized 
participants. 
All adverse events will be coded using MedDRA® dictionary version 22.0 and higher and the 
number of participants experiencing each treatment emergent AE and the incidence rate will be 
provided by treatment arm and stage. Treatment emergent adverse event incidence rates will be 
summarized by System Organ Class (SOC) and Preferred Term (PT). The incidence rate of an 
AE is calculated as the number of participants who experience the event at least once during the 
safety window divided by the number of participants at risk times 100. Incidence rates will be 
calculated at the preferred term level, at the SOC level, and for participants with at least one 
treatment emergent adverse event. If a participant experiences multiple episodes of an event, 
then the event is only counted once. Detailed listings of treatment emergent adverse events and 
non-treatment emergent events in the safety population by treatment arm will be provided. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
21 
Treatment arm differences will be monitored by the DSMB. 
9.2 
Serious Adverse Events 
Treatment emergent Serious Adverse Events (SAEs) will be summarized by presenting the 
number of events, number of participants experiencing SAEs, and the relatedness and type of 
SAEs by treatment arm and stage. SAEs will be presented by stage as described in Section 9.1. 
A summary of treatment emergent MedDRA® coded serious adverse events using incidence rates 
will be provided by treatment arm and stage. Incidence rates, as defined in Section 9.1, will be 
calculated at the preferred term level, at the SOC level, and for participants with at least one 
treatment emergent serious adverse event. A detailed listing of SAEs, including treatment 
emergent SAEs and non-treatment emergent SAEs, will be provided by treatment arm. Narratives 
for all serious adverse events will be included in the Final Study Report. 
9.3 
Injection Site Abnormalities 
The injection site is examined by medical personnel at the next study visit following the injection 
administration. Injections #1 and #2 occur in Stage 1 and injections #3 and #4 occur in Stage 2. 
Injection site abnormalities will be summarized by presenting the number of abnormalities, 
number of participants experiencing abnormalities, type of abnormality, and the severity of the 
abnormality by treatment arm and stage. A detailed listing of injection site abnormalities for 
injections by treatment arm will be provided. 
9.4 
Laboratory Values 
Laboratory values are collected at Screening, Week 6, and Week 12. Elevated liver function tests 
(LFTs) consisting of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total 
bilirubin and decreased platelets are monitored by the safety and medical monitors at the CCC. 
There are multiple site- and sex-based normal ranges amongst the eight sites for the ALT, AST 
and total Bilirubin parameters. For practicality, the safety team reviewed these parameters and 
generated a global threshold for each: ALT and AST 250 IU/L, total bilirubin 2.2 mg/dL, and 
platelets below 75 x 103/µL. Table 7 provides the normal ranges for all study sites for LFTs and 
platelets. 
Listings of elevated LFTs and decreased platelets will be presented by treatment arm. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
22 
Table 7: Normal Ranges by Site 
Lab 
SC BHS 
WS CODA, Inc.  
GNY SURC - 
Columbia 
NS Hennepin 
County 
WS SURU - 
SFDPH 
TX UCLA 
CBAM 
TX UT Health 
CNRA 
TX 
UTSW 
ALT 
female 14-54 
IU/L 
male 17-63 IU/L 
Female 16-19 yrs 5-
32 U/L 
Female 20+ yrs 6-
29 U/L 
Male 16-19 yrs 8-46 
U/L 
Male 20+ yrs 9-46 
U/L 
Female 1-31 IU/L 
Male 1-40 IU/L 
Female up to 33 
U/L 
Male up to 41 
U/L 
Female 7-35 U/L 
Male 10-40 U/L 
8-64 units/L 
Female 0-32 
IU/L 
Male 0-44 IU/L 
9-46 U/L 
AST 
15-41 IU/L 
Female 7-19 yrs 12-
32 U/L 
Female 20-49 yrs 
10-30 U/L 
Female 50+ yrs 10-
35 U/L 
Male 7-19 yrs 12-32 
U/L 
Male 20-49 yrs 10-
40 U/L 
Male 50+ yrs 10-35 
U/L 
Female 1-31 IU/L 
Male 1-37 IU/L 
5-40 U/L 
2-60 yrs 10-41 U/L 
60-90 yrs 10-48 
U/L 
13-47 units/L 
0-40 IU/L 
10-40 
U/L 
Total 
Bilirubin 
0.3-1.2 mg/dL 
Female 10-19 yrs 
0.2-1.1 mg/dL 
Female 20+ yrs 0.2-
1.2 mg/dL 
Male 10-19 yrs 0.2-
1.1 mg/dL 
Male 20+ yrs 0.2-1.2 
mg/dL 
0.1-1.1 mg/dL 
0.0-1.2 mg/dL 
0-60 years 0.1-1.2 
mg/dL 
60-90 yrs 0.1-1.1 
mg/dL 
0.1-1.2 
mg/dL 
0.0-1.2 mg/dL 
0.2-1.2 
mg/dL 
Platelets 
130-450 x 
thousand 
cells/µL 
140-400 
thousand/µL 
130-400 K/mm3 
150-400 x 103 
µL 
150,000-
400,000/mcL 
143-398 x 
103/µL 
150-379 x 
103/µL 
140-400 
x103 µL 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
23 
9.5 
Electrocardiogram 
Electrocardiograms (ECG) are conducted at screening and at Week 12. A summary table 
displaying the count and frequency of participants with elevated QTc intervals greater than and 
equal to 500 milliseconds and changes from baseline will be presented by treatment arm. 
Participants experiencing second or third degree AV block at Week 12 will be listed by treatment 
arm. 
9.6 
Suicide Risk 
The Concise Health Risk Tracking (CHRT) and Patient Health Questionnaire-9 (PHQ-9) surveys 
are conducted at screening, weekly during the treatment period, and at follow-up visits to assess 
suicide risk. A summary table of participants endorsing suicidality on either assessment during 
the treatment period will be presented by treatment arm and stage. A listing of visits where 
suicidality was endorsed by a participant will be generated. 
Endorsement for the CHRT is defined as answering agree or strongly agree to any of the 
following: (1) I have been having thoughts of killing myself, (2) I have thoughts about how I might 
kill myself, or (3) I have a plan to kill myself. On the PHQ-9, a participant is considered to have 
endorsed suicidality if they indicate several days, more than half the days, and nearly every day 
having thoughts they are better off dead or of hurting themselves. 
9.7 
Pregnancy 
A listing of pregnancies and pregnancy outcomes in randomized participants will be generated. 
Narratives will also be provided. 
9.8 
Deaths 
A listing of deaths and narratives of deaths will be provided. 
10.0 DATA QUALITY 
10.1 
Data Audits 
A summary of data audit results from site interim monitoring visits conducted by CCC monitors 
will be presented by site. 
10.2 
Protocol Deviations 
Protocol deviations will be summarized by site and will include the number of deviations reported, 
the number of participants each deviation affects, frequencies for the types of protocol deviations, 
and information on whether the protocol deviation was deemed minor or major. A detailed listing 
of protocol deviations by deviation category will be provided. 
11.0 UPDATES TO THE STATISTICAL ANALYSIS PLAN 
The Statistical Analysis Plan (SAP) Version 0.1 was reviewed by the IRB and DSMB prior to the 
initiation of the study and contains unblinded information on the study design not included in the 
protocol. SAP Version 1.0 was updated to include all information necessary for interim analyses 
to be conducted and was finalized on July 5, 2018. SAP Version 2.0, which included a correction 
to the formula for standard error for the primary outcome analysis, was finalized on September 6, 
2018 before interim analyses were conducted for the October 24, 2018 DSMB meeting. SAP 
Version 3.0 was finalized prior to data lock to include the remaining information necessary to 
analyze the study. 
SAP Version 0.1 is included in Appendix 14.2 and a detailed Change Log from SAP Version 0.1 
to SAP Version 2.0 is located in Appendix 14.3. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
24 
12.0 REFERENCES 
Chen, Y. F., Yang, Y., Hung, H. M., & Wang, S. J. (2011). Evaluation of performance of some 
enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin 
Trials, 32(4), 592-604. doi:10.1016/j.cct.2011.04.006. 
DeMets DL, Lan KK. (1994). Interim analysis: the alpha spending function approach. Stat 
Med,13:1341-1356. 
Doros, G., Pencina, M., Rybin, D., Meisner, A., Fava, M. (2013). A repeated measures model for 
analysis of continuous outcomes in sequential parallel comparison design studies, Statistics in 
Medicine, 32:2767-2789. 
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo 
response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study 
design approach. Psychother Psychosom, 72(3), 115-127. doi:69738. 
Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M., & Klett, C. J. (1997). Treatment 
effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr, 175, 208-220. 
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, 
Altman DG. (2010). CONSORT 2010 explanation and elaboration: updated guidelines for 
reporting parallel group randomised trials. J Clin Epi, 63(8): e1-e37. 
National Institutes of Health (NIH). (2016). Guidelines for the Review of Inclusion on the Basis of 
Sex/Gender, 
Race, 
Ethnicity, 
and 
Age 
in 
Clinical 
Research. 
https://grants.nih.gov/grants/peer/guidelines_general/Review_Human_subjects_Inclusion.pdf. 
Reboussin DM, DeMets DL, Kim KM, Lan KK. (2000). Computations for group sequential 
boundaries using the Lan-DeMets spending function method. Control Clin Trials, 2000 
Jun;21(3):190-207. 
Schoenfeld D. Power calculator for a Sequential Parallel Comparison Design (SPCD). 
http://hedwig.mgh.harvard.edu/biostatistics/node/43 
Shiener, L.B., Rubin, D.B. (1995). Intention-to-treat analysis and the goals of clinical trials. Clinical 
Pharmacology and Therapeutics, 57(1):6-15. 
Stuart, E.A., Jo, B. (2015). Assessing the sensitivity of methods for estimating principal causal 
effects, Statistical Methods in Medical Research. 24(6) (2015) 657-674. 
Tamura, R. N., & Huang, X. (2007). An examination of the efficiency of the sequential parallel 
design in psychiatric clinical trials. Clin Trials, 4(4), 309-317. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
25 
13.0 LIST OF PROPOSED TABLES, FIGURES, AND LISTINGS 
The listing of tables below contains the tables, figures, and listings which will be provided by the 
DSC. 
Section 
Title 
Population 
Enrollment, 
Participant 
Disposition, and 
Follow-up 
Summary of Pre-screens by Site 
Pre-screened 
Summary of Screen Failures by Site 
Screened 
Summary of Pre-screens, Screening, and Randomization by Site 
Pre-screened 
Randomizations by Site, Stage and Treatment Arm 
ITT 
Figure of Expected versus Actual Randomizations Overall 
Randomized 
Figure of Expected versus Actual Randomizations by Site 
Randomized 
Proposed and Actual Randomizations by Site 
Randomized 
Summary of Disposition by Site 
Randomized 
Summary of Disposition by Treatment Arm in Stage 1 
Randomized 
Summary of Disposition by Treatment Arm in Stage 2 
Randomized 
Summary of Disposition by Treatment Arm in Follow-up Period 
Randomized 
CONSORT Flow Diagram 
Pre-screened 
Summary of Attendance at Treatment Period Visits by Treatment 
Arm in Stage 1 
Randomized 
Summary of Attendance at Treatment Period Visits by Treatment 
Arm in Stage 2 
Randomized 
Summary of Attendance at Follow-up Visits by Treatment Arm 
Randomized 
Summary of Missed Visits by Treatment Arm in Stage 1 
Randomized 
Summary of Missed Visits by Treatment Arm in Stage 2 
Randomized 
Summary of Missed Visits by Treatment Arm in Follow-up Period 
Randomized 
Participant 
Characteristics at 
Baseline 
Summary of Baseline Characteristics by Site 
Randomized 
Summary of Baseline Characteristics by Stage and Treatment 
Arm 
Randomized 
Concomitant 
Medications 
Summary of Concomitant Medications by Treatment Arm 
Randomized 
Treatment Exposure 
Summary of Early Medication Terminations by Site 
Randomized 
Summary of Early Medication Terminations by Treatment Arm in 
Stage 1 
Randomized 
Summary of Early Medication Terminations by Treatment Arm in 
Stage 2 
Randomized 
Summary of Treatment Exposure by Site 
Randomized 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
26 
Section 
Title 
Population 
Summary of Treatment Exposure by Site, Stage and Treatment 
Arm 
Randomized 
Summary of Injections by Site 
Randomized 
Summary of Injections by Stage and Treatment Arm 
Randomized 
Summary of Oral Medication Blood Levels in AMC Participants by 
Stage 
Randomized 
Primary Outcome 
Summary of Primary Outcome Availability by Stage and Treatment 
Arm 
ITT 
Summary of Primary Outcome Analysis by Stage and Treatment 
Arm 
ITT 
Figure of UDS Results by Stage and Treatment Arm 
ITT 
Summary of Primary Outcome Sensitivity Analyses by Stage and 
Treatment Arm 
ITT 
Summary of Primary Outcome Availability by Stage and Site 
ITT 
Summary of Primary Outcome by Site, Stage, and Treatment Arm 
ITT 
Summary of Primary Outcome by Sex, Stage, and Treatment Arm 
ITT 
Summary of Primary Outcome by Race, Stage, and Treatment 
Arm 
ITT 
Summary of Primary Outcome by Ethnicity, Stage, and Treatment 
Arm 
ITT 
Summary of Primary Outcome by Age, Stage, and Treatment Arm 
ITT 
Primary Outcome Covariate Adjusted Analysis Results 
ITT 
Summary of UDS Availability by Stage and Treatment Arm 
Randomized 
Summary of Methamphetamine Negative UDS Results by 
Treatment Arm in Stage 1 
Randomized 
Summary of Methamphetamine Negative UDS Results by 
Treatment Arm in Stage 2 
Randomized 
Summary of Methamphetamine Negative UDS Results by 
Treatment Arm in Follow-up Period 
Randomized 
Summary of Primary Outcome Sensitivity Analyses by Stage and 
Treatment Arm in the Randomized Population 
Randomized 
Figure of UDS Results by Stage and Treatment Arm in 
Randomized Population 
Randomized 
Summary of Primary Outcome by Stage and Treatment Arm in Per 
Protocol Populations 
Per Protocol 
Safety Outcomes 
 
 
 
Summary of Treatment Emergent Adverse Events by Treatment 
Arm in Stage 1 
Safety 
Summary of Treatment Emergent Adverse Events by Treatment 
Arm in Stage 2 
Safety 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
27 
Section 
Title 
Population 
Summary of Treatment Emergent MedDRA Coded Adverse 
Events by Treatment Arm in Stage 1 
Safety 
Summary of Treatment Emergent MedDRA Coded Adverse 
Events by Treatment Arm in Stage 2 
Safety 
Listing of Treatment Emergent Adverse Events by Treatment Arm 
Safety 
Listing of Non-Treatment Emergent Adverse Events in 
Randomized Participants by Treatment Arm 
Safety 
Listing of Non-Treatment Emergent Adverse Events in Screen 
Failure Participants 
Safety 
Summary of Treatment Emergent Serious Adverse Events by 
Treatment Arm in Stage 1 
Safety 
Summary of Treatment Emergent Serious Adverse Events by 
Treatment Arm in Stage 2 
Safety 
Summary of Treatment Emergent MedDRA Coded Serious 
Adverse Events by Treatment Arm in Stage 1 
Safety 
Summary of Treatment Emergent MedDRA Coded Serious 
Adverse Events by Treatment Arm in Stage 2 
Safety 
Listing of Serious Adverse Events by Treatment Arm 
Safety 
Summary of Injection Site Abnormalities by Treatment Arm in 
Stage 1 
Safety 
Summary of Injection Site Abnormalities by Treatment Arm in 
Stage 2 
Safety 
Listing of Injection Site Abnormalities by Treatment Arm 
Safety 
Listing of Elevated LFTs by Treatment Arm  
Safety 
Listing of Decreased Platelets by Treatment Arm 
Safety 
Summary of Elevated QTc Intervals by Treatment Arm 
Safety 
Listing of AV Block ECG Abnormalities by Treatment Arm 
Safety 
Summary of Suicide Risk by Treatment Arm in Stage 1 
Safety 
Summary of Suicide Risk by Treatment Arm in Stage 2 
Safety 
Summary of Suicide Risk by Treatment Arm in Follow-up Period 
Safety 
Listing of Suicide Risk by Treatment Arm 
Safety 
Listing of Pregnancies by Treatment Arm 
Safety 
Listing of Deaths by Treatment Arm 
Safety 
Data Quality 
Summary of Data Audits 
N/A 
Protocol Deviations 
Summary of Protocol Deviations 
N/A 
Listing of Protocol Deviations 
N/A 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
28 
14.0 APPENDICES 
14.1 
Table Shells 
Table 1: Summary of Pre-screens by Site 
 
SC 
BHSPC 
WS CODA, 
Inc. 
GNY 
SURC - 
Columbia 
NS 
Hennepin 
Healthcare 
WS SURU - 
SFDPH 
TX 
UCLA 
CBAM 
TX UT 
Health 
CNRA 
TX UTSW 
Total 
Number of pre-screens 
N 
 
 
 
 
 
 
 
 
Number of ineligible pre-screens 
N (%) 
 
 
 
 
 
 
 
 
Criteria resulting in ineligibility1: 
 
 
 
 
 
 
 
 
 
Have medical/mental health conditions require 
monitoring/care/medication 
N (%) 
 
 
 
 
 
 
 
 
Taking meds for medical/mental health condition 
 
 
 
 
 
 
 
 
 
Cannot refrain from opioid use 
 
 
 
 
 
 
 
 
 
Currently enrolled in addiction treatment services 
 
 
 
 
 
 
 
 
 
Taken naltrexone/bupropion within the last 30 days 
 
 
 
 
 
 
 
 
 
Not used methamphetamine in the past 30 days 
 
 
 
 
 
 
 
 
 
Methamphetamine use days in the past 30 days (mean (SD)) 
 
 
 
 
 
 
 
 
 
Not interested in study or willing to use study meds 
 
 
 
 
 
 
 
 
 
No current methamphetamine use 
 
 
 
 
 
 
 
 
 
Not willing to attend 2x week for 12 weeks 
 
 
 
 
 
 
 
 
 
Age < 18 or Age > 65 
 
 
 
 
 
 
 
 
 
No interest in reducing/stopping methamphetamine use 
 
 
 
 
 
 
 
 
 
Unwilling to use app 
 
 
 
 
 
 
 
 
 
Currently pregnant or breastfeeding 
 
 
 
 
 
 
 
 
 
1 Percentages are calculated based on the denominator of the number of ineligibles and may exceed 100% if multiple ineligibility criteria are met for potential 
participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
29 
Table 2: Summary of Screen Failures by Site 
 
SC 
BHSPC 
WS 
CODA, 
Inc. 
GNY SURC - 
Columbia 
NS Hennepin 
Healthcare 
WS SURU - 
SFDPH 
TX UCLA 
CBAM 
TX UT 
Health 
CNRA 
TX UTSW 
Total 
Number consented 
N 
 
 
 
 
 
 
 
 
Number of screen failures 
N (%) 
 
 
 
 
 
 
 
 
Failed the following eligibility criteria¹ 
 
 
 
 
 
 
 
 
 
Meth use on 18+/30 day 
N (%) 
 
 
 
 
 
 
 
 
Comply with study procedures 
 
 
 
 
 
 
 
 
 
2/3 positive meth urine in 10 days 
 
 
 
 
 
 
 
 
 
Conditions that increase seizure risk 
 
 
 
 
 
 
 
 
 
Medical/psychiatric disorder 
 
 
 
 
 
 
 
 
 
ECG finding 
 
 
 
 
 
 
 
 
 
Stage 2 hypertension 
 
 
 
 
 
 
 
 
 
Current alcohol/benzo use 
 
 
 
 
 
 
 
 
 
Opioid-free 
 
 
 
 
 
 
 
 
 
Elevated bilirubin/LFT 5x ULN 
 
 
 
 
 
 
 
 
 
Taking contraindicated meds 
 
 
 
 
 
 
 
 
 
Pregnant/breastfeeding 
 
 
 
 
 
 
 
 
 
Agrees to use birth control and do urine pregnancy testing 
 
 
 
 
 
 
 
 
 
DSM-5 meth use disorder 
 
 
 
 
 
 
 
 
 
Agrees to record videos 
 
 
 
 
 
 
 
 
 
Platelets< 100 x 103 µL 
 
 
 
 
 
 
 
 
 
Prescribed and taken study drugs 
 
 
 
 
 
 
 
 
 
Surgery planned/scheduled 
 
 
 
 
 
 
 
 
 
Jail 
 
 
 
 
 
 
 
 
 
1 Percentages are calculated based on the denominator of the number of ineligibles and may exceed 100% if multiple ineligibility criteria are met for potential 
participants. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
30 
Table 3: Summary of Pre-screens, Screening, and Randomization by Site 
Site 
Number 
of 
Screens 
Percent of 
Eligible Pre-
Screens 
Screened 
Average 
Number of 
Days 
Between 
Pre-Screen 
and 
Scheduled 
Screening 
Appointment 
Number 
of 
Screen 
Fails 
Percent 
of 
Screens 
Who 
Screen 
Fail 
Number 
Randomized 
Percent of 
Eligible Pre-
Screens 
Randomized 
Percent of 
Screens 
Randomized 
SC BHSPC 
N 
% 
X.X 
N 
% 
N 
% 
% 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
Total 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
31 
Table 4: Randomizations by Site, Stage and Treatment Arm 
 
Stage 1 
Stage 2 
Re-randomized 
 
Placebo 
AMC 
Placebo/
Placebo 
Placebo/ 
AMC 
SC BHSPC 
N (%) 
 
 
 
WS CODA, Inc. 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
TX UTSW 
 
 
 
 
Total 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
32 
Figure 3: Expected versus Actual Randomizations Overall 
 
 
 
M ay
Jul
Sep
Nov
Jan
M ar
M ay
Jul
Sep
Nov
Jan
M ar
M ay
2017
2018
2019
Month
0
25
50
75
100
125
150
175
200
225
250
275
300
325
350
375
400
425
Number of Participants
Proposed Randomizations
Expected Number Randomized
Number Randomized


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
33 
Figure 4: Expected versus Actual Randomizations by Site 
 
 
 
 
Proposed Randomizations
Expected Number Randomized
Number Randomized
Month
Number of Participants
NS Hennepin Healthcare
GNY SURC - Columbia
WS CODA, Inc.
SC BHSPC
M ay
Sep
Jan
M ay
Sep
Jan
M ay
2017
2018
2019
M ay
Sep
Jan
M ay
Sep
Jan
M ay
2017
2018
2019
0
10
20
30
40
50
60
70
0
10
20
30
40
50
60
70


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
34 
Figure 5: Expected versus Actual Randomizations by Site (cont.) 
 
 
Proposed Randomizations
Expected Number Randomized
Number Randomized
Month
Number of Participants
TX UTSW
TX UT Health CNRA
TX UCLA CBAM
WS SURU - SFDPH
M ay
Sep
Jan
M ay
Sep
Jan
M ay
2017
2018
2019
M ay
Sep
Jan
M ay
Sep
Jan
M ay
2017
2018
2019
0
10
20
30
40
50
60
70
0
10
20
30
40
50
60
70


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
35 
Table 5: Proposed and Actual Randomizations by Site 
Site 
Proposed 
Randomization 
Date Site Opened 
for Enrollment 
Date of First 
Randomization 
Actual 
Randomizations 
Actual/ 
Proposed 
(%) 
Date of Last 
Randomization 
SC BHSPC 
N 
 
 
N 
% 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
Total 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
36 
Table 6: Summary of Disposition by Site 
 
SC 
BHSPC 
WS 
CODA, 
Inc. 
GNY 
SURC - 
Columbia 
NS 
Hennepin 
Healthcare 
WS 
SURU - 
SFDPH 
TX 
UCLA 
CBAM 
TX UT 
Health 
CNRA 
TX 
UTSW 
Total 
Number of participants randomized 
N 
 
 
 
 
 
 
 
 
Number of study completers1 
N (%) 
 
 
 
 
 
 
 
 
Number of early study terminations 
N (%) 
 
 
 
 
 
 
 
 
Reasons for early study termination 
 
 
 
 
 
 
 
 
 
     Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
 
 
 
 
     Participant stopped participation due to practical problems 
 
 
 
 
 
 
 
 
 
     Participant moved from area 
 
 
 
 
 
 
 
 
 
     Participant incarcerated 
 
 
 
 
 
 
 
 
 
     Participant terminated due to AE/SAE 
 
 
 
 
 
 
 
 
 
     Participant terminated for other clinical reasons 
 
 
 
 
 
 
 
 
 
     Participant had a significant psychiatric risk 
 
 
 
 
 
 
 
 
 
     Participant deceased 
 
 
 
 
 
 
 
 
 
     Participant terminated due to protocol deviation 
 
 
 
 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
 
 
 
 
     Participant reports use of medication that could adversely 
interact with study medication 
 
 
 
 
 
 
 
 
 
      Clinical deterioration: New onset of psychiatric or medical 
condition 
 
 
 
 
 
 
 
 
 
      Clinical deterioration: Worsening of pre-existing psychiatric 
or medical condition 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
 
 
 
 
     Participant terminated for other reason 
 
 
 
 
 
 
 
 
 
1 Participants who completed the study (Week 16) as reported on the Study Completion (STC) form. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
37 
Table 7: Summary of Disposition by Treatment Arm in Stage 1 
 
Placebo 
AMC 
Total 
Number of participants randomized 
N 
 
 
Number of participants who completed Stage 11 
N (%) 
 
 
Number of participants re-randomized at the end of Stage 1 
N (%) 
 
 
Number of early study terminations in Stage 1 
N (%) 
 
 
Reasons for early study termination in Stage 1 
 
 
 
     Participant failed to return to site and unable to contact 
N (%) 
 
 
     Participant withdrew consent/assent 
 
 
 
     Participant stopped participation due to practical problems 
 
 
 
     Participant moved from area 
 
 
 
     Participant incarcerated 
 
 
 
     Participant terminated due to AE/SAE 
 
 
 
     Participant terminated for other clinical reasons 
 
 
 
     Participant had a significant psychiatric risk 
 
 
 
     Participant deceased 
 
 
 
     Participant terminated due to protocol deviation 
 
 
 
     Participant became pregnant 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
     Participant reports use of medication that could adversely interact with study medication 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
     Participant terminated for other reason 
 
 
 
1 Participants who did not early terminate from the study in Weeks 1-6. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
38 
Table 8: Summary of Disposition by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/ 
Placebo 
Placebo/ 
AMC 
Placebo 
AMC 
Total 
Number of participants randomized 
N 
 
 
 
 
Number of participants in Stage 21 
N 
 
 
 
 
Number of participants that completed Week 122 
N (%) 
 
 
 
 
Number of early study terminations in Weeks 7-12 
N (%) 
 
 
 
 
Reasons for early study termination in Weeks 7-12 
 
 
 
 
 
     Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
     Participant stopped participation due to practical problems 
 
 
 
 
 
     Participant moved from area 
 
 
 
 
 
     Participant incarcerated 
 
 
 
 
 
     Participant terminated due to AE/SAE 
 
 
 
 
 
     Participant terminated for other clinical reasons 
 
 
 
 
 
     Participant had a significant psychiatric risk 
 
 
 
 
 
     Participant deceased 
 
 
 
 
 
     Participant terminated due to protocol deviation 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
     Participant reports use of medication that could adversely interact with study medication 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
1 Participants who completed Stage 1 (Weeks 1-6) and were re-randomized or were not re-randomized in Stage 2. 
2 Participants who did not early terminate from the study on the STC form in Weeks 7-12. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
39 
Table 9: Summary of Disposition by Treatment Arm in Follow-up Period 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/
Placebo 
Placebo/ 
AMC 
Placebo 
AMC 
Total 
Number of participants randomized 
N 
 
 
 
 
Number of participants who entered the Follow-up Period1 
 
 
 
 
 
Number of participants who completed the study 
 
 
 
 
 
Number of early study terminations in Follow-up Period2 
N (%) 
 
 
 
 
Reasons for early study termination in Follow-up Period 
 
 
 
 
 
     Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
     Participant stopped participation due to practical problems 
 
 
 
 
 
     Participant moved from area 
 
 
 
 
 
     Participant incarcerated 
 
 
 
 
 
     Participant terminated due to AE/SAE 
 
 
 
 
 
     Participant terminated for other clinical reasons 
 
 
 
 
 
     Participant had a significant psychiatric risk 
 
 
 
 
 
     Participant deceased 
 
 
 
 
 
     Participant terminated due to protocol deviation 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
     Participant reports use of medication that could adversely interact with study medication 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
     Participant terminated for other reason 
 
 
 
 
 
1 Participants who completed the treatment period (Week 12). 
2 Participants who early terminated from the study in Weeks 13-16 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
40 
Figure 6: CONSORT Flow Diagram 
 
1 X participants were re-screened. 
2 Placebo non-responders who did not attend a visit during the window for re-randomization were not re-randomized. 
Pre-screened 
(N=) 
Screened1 
(N=) 
Randomized 
(N=) 
Not Randomized at 
Stage 1 
(N=) 
Reasons not eligible: 
Not Screened 
(N=) 
Reasons not eligible: 
Placebo 
(N=) 
AMC 
(N=) 
Placebo Non-responders 
re-randomized 
(N=) 
Placebo Responders 
not re-randomized 
(N=) 
Completers 
(N=) 
Completers 
(N=) 
AMC 
(N=) 
Placebo 
(N=) 
Completers 
(N=) 
Completers 
(N=) 
Discontinued (N=) 
Discontinued (N=) 
Discontinued (N=) 
Discontinued (N=) 
Discontinued (N=) 
Placebo Non-responders2 
not re-randomized 
(N=) 
Completers 
(N=) 
Discontinued (N=) 
 
Stage 1 
Stage 2 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
41 
Table 10: Summary of Attendance at Treatment Period 
Visits by Treatment Arm in Stage 1 
Visit 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Visit 0101 
N (%) 
 
 
Visit 0102 
 
 
 
Visit 0201 
 
 
 
Visit 0202 
 
 
 
Visit 0301 
 
 
 
Visit 0302 
 
 
 
Visit 0401 
 
 
 
Visit 0402 
 
 
 
Visit 0501 
 
 
 
Visit 0502 
 
 
 
Visit 0601 
 
 
 
Visit 0602 
 
 
 
Overall 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
42 
Table 11: Summary of Attendance at Treatment Period Visits by Treatment Arm in Stage 2 
 
Re-randomized1 
Not Re-randomized 
 
Visit 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Visit 0701 
N (%) 
 
 
 
 
Visit 0702 
 
 
 
 
 
Visit 0801 
 
 
 
 
 
Visit 0802 
 
 
 
 
 
Visit 0901 
 
 
 
 
 
Visit 0902 
 
 
 
 
 
Visit 1001 
 
 
 
 
 
Visit 1002 
 
 
 
 
 
Visit 1101 
 
 
 
 
 
Visit 1102 
 
 
 
 
 
Visit 1201 
 
 
 
 
 
Visit 1202 
 
 
 
 
 
Overall 
 
 
 
 
 
1 Participants may be re-randomized at Visit 0701, 0702, or 0801. 
 
 
 
Table 12: Summary of Attendance at Follow-up Visits by Treatment Arm 
 
Re-randomized 
Not Re-randomized 
 
Visit 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Visit 1301 
N (%) 
 
 
 
 
Visit 1601 
 
 
 
 
 
Overall 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
43 
Table 13: Summary of Missed Visits by Treatment Arm in Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of expected visits in Stage 1¹ 
N 
 
 
Number of missed visits in Stage 1 due to early study termination 
N (%) 
 
 
Number of missed visits during active Stage 1 participation 
N (%) 
 
 
Number of participants with at least one missed visit during active Stage 1 participation 
N (%) 
 
 
Average number of missed visits in Stage 1 per participant 
X.X 
 
 
Reason for missed visit 
 
 
 
Participant failed to return to site and unable to contact 
N (%) 
 
 
Participant unable to attend visit 
 
 
 
Participant withdrew consent 
 
 
 
Other 
 
 
 
Site closed 
 
 
 
Participant incarcerated 
 
 
 
Participant on vacation 
 
 
 
Participant in hospital, in-patient, or residential treatment 
 
 
 
Participant illness 
 
 
 
Participant moved from area 
 
 
 
Participant deceased 
 
 
 
1 Two visits per week are expected per participant in Weeks 1-6. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
44 
Table 14: Summary of Missed Visits by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of expected visits in Stage 2¹ 
N 
 
 
 
 
Number of missed visits in Stage 2 due to early study termination 
N (%) 
 
 
 
 
Number of missed visits during active Stage 2 participation 
N (%) 
 
 
 
 
Number of participants with at least one missed visit during active Stage 2 participation 
N (%) 
 
 
 
 
Average number of missed visits in Stage 2 per participant 
X.X 
 
 
 
 
Reason for missed visit 
 
 
 
 
 
Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
Participant unable to attend visit 
 
 
 
 
 
Participant withdrew consent 
 
 
 
 
 
Other 
 
 
 
 
 
Site closed 
 
 
 
 
 
Participant incarcerated 
 
 
 
 
 
Participant on vacation 
 
 
 
 
 
Participant in hospital, in-patient, or residential treatment 
 
 
 
 
 
Participant illness 
 
 
 
 
 
Participant moved from area 
 
 
 
 
 
Participant deceased 
 
 
 
 
 
1 Two visits per week are expected per participant in Weeks 7-12. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
45 
Table 15: Summary of Missed Visits by Treatment Arm in Follow-up Period 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of expected visits in follow-up period¹ 
N 
 
 
 
 
Number of missed visits in follow-up period due to early study termination 
N (%) 
 
 
 
 
Number of missed visits during active follow-up period participation 
N (%) 
 
 
 
 
Number of participants with at least one missed visit during active follow-up period participation 
N (%) 
 
 
 
 
Average number of missed visits in follow-up period per participant 
X.X 
 
 
 
 
Reason for missed visit 
 
 
 
 
 
Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
Participant unable to attend visit 
 
 
 
 
 
Participant withdrew consent 
 
 
 
 
 
Other 
 
 
 
 
 
Site closed 
 
 
 
 
 
Participant incarcerated 
 
 
 
 
 
Participant on vacation 
 
 
 
 
 
Participant in hospital, in-patient, or residential treatment 
 
 
 
 
 
Participant illness 
 
 
 
 
 
Participant moved from area 
 
 
 
 
 
Participant deceased 
 
 
 
 
 
1 Two visits total are expected per participant in the follow-up period in Weeks 13-16. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
46 
Table 16: Summary of Baseline Characteristics by Site 
Characteristic 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS SURU - 
SFDPH 
(N=) 
TX 
UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
Sex 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      Male 
 
 
 
 
 
 
 
 
 
      Female 
 
 
 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
 
 
 
Age (Mean (SD)) 
XX (X.X) 
 
 
 
 
 
 
 
 
Age 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      < 18 
 
 
 
 
 
 
 
 
 
      18 - < 25 
 
 
 
 
 
 
 
 
 
      25 - < 35 
 
 
 
 
 
 
 
 
 
      35 - < 45 
 
 
 
 
 
 
 
 
 
      45 - < 55 
 
 
 
 
 
 
 
 
 
      55 - < 65 
 
 
 
 
 
 
 
 
 
      65 - < 75 
 
 
 
 
 
 
 
 
 
      75+ 
 
 
 
 
 
 
 
 
 
Ethnicity 
 
 
 
 
 
 
 
 
 
      Missing 
 
 
 
 
 
 
 
 
 
      Not Hispanic or Latino 
N (%) 
 
 
 
 
 
 
 
 
      Hispanic or Latino 
 
 
 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
47 
Table 16: Summary of Baseline Characteristics by Site 
Characteristic 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS SURU - 
SFDPH 
(N=) 
TX 
UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
Race 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      American Indian or Alaska Native 
 
 
 
 
 
 
 
 
 
      Asian 
 
 
 
 
 
 
 
 
 
      Black or African American 
 
 
 
 
 
 
 
 
 
      Native Hawaiian or Pacific Islander 
 
 
 
 
 
 
 
 
 
      White 
 
 
 
 
 
 
 
 
 
      Other 
 
 
 
 
 
 
 
 
 
      Multiracial 
 
 
 
 
 
 
 
 
 
      Unknown 
 
 
 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
 
 
 
Education completed 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      Less than high school diploma 
 
 
 
 
 
 
 
 
 
      High school graduate 
 
 
 
 
 
 
 
 
 
      GED or equivalent 
 
 
 
 
 
 
 
 
 
      Some college, no degree 
 
 
 
 
 
 
 
 
 
Associate's degree: occupational, technical, or 
vocational program 
 
 
 
 
 
 
 
 
 
      Associate's degree: academic program 
 
 
 
 
 
 
 
 
 
      Bachelor's degree 
 
 
 
 
 
 
 
 
 
      Master's degree 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
48 
Table 16: Summary of Baseline Characteristics by Site 
Characteristic 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS SURU - 
SFDPH 
(N=) 
TX 
UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
      Professional school degree 
 
 
 
 
 
 
 
 
 
      Doctoral degree 
 
 
 
 
 
 
 
 
 
      Don't know 
 
 
 
 
 
 
 
 
 
      Refused 
 
 
 
 
 
 
 
 
 
Marital status 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      Married 
 
 
 
 
 
 
 
 
 
      Widowed 
 
 
 
 
 
 
 
 
 
      Divorced 
 
 
 
 
 
 
 
 
 
      Separated 
 
 
 
 
 
 
 
 
 
      Never married 
 
 
 
 
 
 
 
 
 
      Living with partner 
 
 
 
 
 
 
 
 
 
      Refused 
 
 
 
 
 
 
 
 
 
      Don't know 
 
 
 
 
 
 
 
 
 
Employment 
 
 
 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
 
 
 
      Working now 
 
 
 
 
 
 
 
 
 
      Only temporarily laid off, sick leave, or maternity 
leave 
 
 
 
 
 
 
 
 
 
      Looking for work, unemployed 
 
 
 
 
 
 
 
 
 
      Retired 
 
 
 
 
 
 
 
 
 
      Disabled permanently or temporarily 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
49 
Table 16: Summary of Baseline Characteristics by Site 
Characteristic 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS SURU - 
SFDPH 
(N=) 
TX 
UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
      Keeping house 
 
 
 
 
 
 
 
 
 
      Student 
 
 
 
 
 
 
 
 
 
      Other 
 
 
 
 
 
 
 
 
 
Number of days of self-reported methamphetamine 
use in 30 days prior to informed consent 
 
 
 
 
 
 
 
 
 
      N 
 
 
 
 
 
 
 
 
 
      Mean 
 
 
 
 
 
 
 
 
 
      SD 
 
 
 
 
 
 
 
 
 
      Min 
 
 
 
 
 
 
 
 
 
      25th Percentile 
 
 
 
 
 
 
 
 
 
      Median 
 
 
 
 
 
 
 
 
 
     75th Percentile 
 
 
 
 
 
 
 
 
 
      Max 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
50 
Table 17: Summary of Baseline Characteristics by Stage and Treatment Arm 
 
Stage 1 
Stage 2 
Re-randomized 
Not Re-randomized 
Characteristic 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Sex 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      Male 
 
 
 
 
 
 
      Female 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
Age (Mean (SD)) 
XX (X.X) 
 
 
 
 
 
Age 
 
 
 
 
 
 
      < 18 
N (%) 
 
 
 
 
 
      18 - < 25 
 
 
 
 
 
 
      25 - < 35 
 
 
 
 
 
 
      35 - < 45 
 
 
 
 
 
 
      45 - < 55 
 
 
 
 
 
 
      55 - < 65 
 
 
 
 
 
 
      65 - < 75 
 
 
 
 
 
 
      75+ 
 
 
 
 
 
 
Ethnicity 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      Not Hispanic or Latino 
 
 
 
 
 
 
      Hispanic or Latino 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
51 
Table 17: Summary of Baseline Characteristics by Stage and Treatment Arm 
 
Stage 1 
Stage 2 
Re-randomized 
Not Re-randomized 
Characteristic 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
      Unknown 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
Race 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      American Indian or Alaska Native 
 
 
 
 
 
 
      Asian 
 
 
 
 
 
 
      Black or African American 
 
 
 
 
 
 
      Native Hawaiian or Pacific Islander 
 
 
 
 
 
 
      White 
 
 
 
 
 
 
      Other 
 
 
 
 
 
 
      Multiracial 
 
 
 
 
 
 
      Unknown 
 
 
 
 
 
 
      Participant chose not to answer 
 
 
 
 
 
 
Education completed 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      Less than high school diploma 
 
 
 
 
 
 
      High school graduate 
 
 
 
 
 
 
      GED or equivalent 
 
 
 
 
 
 
      Some college, no degree 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
52 
Table 17: Summary of Baseline Characteristics by Stage and Treatment Arm 
 
Stage 1 
Stage 2 
Re-randomized 
Not Re-randomized 
Characteristic 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
      Associate's degree: occupational, technical, or vocational program 
 
 
 
 
 
 
      Associate's degree: academic program 
 
 
 
 
 
 
      Bachelor's degree 
 
 
 
 
 
 
      Master's degree 
 
 
 
 
 
 
      Professional school degree 
 
 
 
 
 
 
      Doctoral degree 
 
 
 
 
 
 
Marital status 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      Married 
 
 
 
 
 
 
      Widowed 
 
 
 
 
 
 
      Divorced 
 
 
 
 
 
 
      Separated 
 
 
 
 
 
 
      Never married 
 
 
 
 
 
 
      Living with partner 
 
 
 
 
 
 
      Refused 
 
 
 
 
 
 
      Don’t know 
 
 
 
 
 
 
Employment 
 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
 
      Working now 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
53 
Table 17: Summary of Baseline Characteristics by Stage and Treatment Arm 
 
Stage 1 
Stage 2 
Re-randomized 
Not Re-randomized 
Characteristic 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
      Only temporarily laid off, sick leave, or maternity leave 
 
 
 
 
 
 
      Looking for work, unemployed 
 
 
 
 
 
 
      Retired 
 
 
 
 
 
 
      Disabled permanently or temporarily 
 
 
 
 
 
 
      Keeping house 
 
 
 
 
 
 
      Student 
 
 
 
 
 
 
      Other 
 
 
 
 
 
 
Number of days of self-reported methamphetamine use in 30 days prior to 
informed consent 
 
 
 
 
 
 
      N 
 
 
 
 
 
 
      Mean 
 
 
 
 
 
 
      SD 
 
 
 
 
 
 
      Min 
 
 
 
 
 
 
      25th Percentile 
 
 
 
 
 
 
      Median 
 
 
 
 
 
 
      75th Percentile 
 
 
 
 
 
 
      Max 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
54 
Table 18: Summary of Concomitant Medications by Treatment Arm1 
 
Re-randomized 
Not Re-randomized 
 
Anatomical Therapeutic Chemical Level 1/ 
   Anatomical Therapeutic Chemical Level 2 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Participants with at least one concomitant medication 
 
 
 
 
 
Gastrointestinal 
N (%) 
 
 
 
 
    Acid related 
N (%) 
 
 
 
 
    Antiemetics 
 
 
 
 
 
    Constipation 
 
 
 
 
 
    Antidiarrheal 
 
 
 
 
 
    Diabetes 
 
 
 
 
 
    Vitamins 
 
 
 
 
 
    Mineral 
 
 
 
 
 
    Other gastrointestinal 
 
 
 
 
 
Blood and Blood Forming Organs 
N (%) 
 
 
 
 
    Aspirin/coumadin/heparin 
N (%) 
 
 
 
 
    Anti-anemic 
 
 
 
 
 
    Blood products/iv fluids 
 
 
 
 
 
    Other blood and blood forming organs 
 
 
 
 
 
Cardiovascular System 
N (%) 
 
 
 
 
    Antihypertensives 
N (%) 
 
 
 
 
    Diuretics 
 
 
 
 
 
    Beta blocking 
 
 
 
 
 
    Calcium channel 
 
 
 
 
 
    Lipid modifying agents 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
55 
Table 18: Summary of Concomitant Medications by Treatment Arm1 
 
Re-randomized 
Not Re-randomized 
 
Anatomical Therapeutic Chemical Level 1/ 
   Anatomical Therapeutic Chemical Level 2 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
    Other cardiovascular system 
 
 
 
 
 
All Skin Creams 
N (%) 
 
 
 
 
    All skin creams 
N (%) 
 
 
 
 
Contraceptives/ED/Sex Hormones 
N (%) 
 
 
 
 
    Contraceptives/ED/sex hormones 
N (%) 
 
 
 
 
Steroids/thyroid hormones 
N (%) 
 
 
 
 
    Steroids/thyroid hormones 
N (%) 
 
 
 
 
Antibacterial/Antiviral/Antifungal/TB/Vaccines 
N (%) 
 
 
 
 
    Antibacterial/antiviral/antifungal/TB/vaccines 
N (%) 
 
 
 
 
Musculoskeletal System 
N (%) 
 
 
 
 
    Anti-inflammatory and antirheumatic 
N (%) 
 
 
 
 
    Muscle relaxants 
 
 
 
 
 
    Antigout 
 
 
 
 
 
    Other musculoskeletal system 
 
 
 
 
 
Nervous System 
N (%) 
 
 
 
 
    Analgesics including antipyretics 
N (%) 
 
 
 
 
    Antiepileptics 
 
 
 
 
 
    Anxiety/depression/sleep 
 
 
 
 
 
    Other nervous system 
 
 
 
 
 
Respiratory System 
N (%) 
 
 
 
 
    Nasal 
N (%) 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
56 
Table 18: Summary of Concomitant Medications by Treatment Arm1 
 
Re-randomized 
Not Re-randomized 
 
Anatomical Therapeutic Chemical Level 1/ 
   Anatomical Therapeutic Chemical Level 2 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
    Throat 
 
 
 
 
 
    Obstructive airway 
 
 
 
 
 
Eye and Ear Drops 
N (%) 
 
 
 
 
    Eye and ear drops 
N (%) 
 
 
 
 
Various 
N (%) 
 
 
 
 
    Allergens 
N (%) 
 
 
 
 
    All other therapeutic products 
 
 
 
 
 
    Diagnostic agents 
 
 
 
 
 
    General nutrients 
 
 
 
 
 
    All other non-therapeutic products 
 
 
 
 
 
    Contrast media 
 
 
 
 
 
    Diagnostic radiopharmaceuticals 
 
 
 
 
 
    Therapeutic radiopharmaceuticals 
 
 
 
 
 
Other 
N (%) 
 
 
 
 
1 Includes all medications taken during the safety window, which begins at the first dose date of either oral or injectable study medication, 
whichever comes first, and ends either 7 days after the last oral medication dose or 28 days after the last injectable medication, whichever 
comes last. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
57 
Table 19: Summary of Early Medication Terminations by Site 
 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY 
SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS 
SURU - 
SFDPH 
(N=) 
TX UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
Number of early study medication terminations1 
N (%) 
 
 
 
 
 
 
 
 
Number of participants who early terminated oral and 
injectable study medication 
N (%) 
 
 
 
 
 
 
 
 
Number of early oral study medication terminations 
N (%) 
 
 
 
 
 
 
 
 
Reason for early oral study medication termination 
 
 
 
 
 
 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
 
 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
 
 
 
 
 
 
      Participant feels treatment no longer necessary, not 
working 
 
 
 
 
 
 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
 
 
 
 
 
 
     Contraindicated concomitant medication 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical 
condition 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing 
psychiatric or medical condition 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use 
disorder 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
 
 
 
 
     Other 
 
 
 
 
 
 
 
 
 
Number of early injectable study medication terminations 
N (%) 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
58 
Table 19: Summary of Early Medication Terminations by Site 
 
SC 
BHSPC 
(N=) 
WS 
CODA, 
Inc. 
(N=) 
GNY 
SURC - 
Columbia 
(N=) 
NS 
Hennepin 
Healthcare 
(N=) 
WS 
SURU - 
SFDPH 
(N=) 
TX UCLA 
CBAM 
(N=) 
TX UT 
Health 
CNRA 
(N=) 
TX UTSW 
(N=) 
Total 
(N=) 
Reason for early injectable medication termination 
 
 
 
 
 
 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
 
 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
 
 
 
 
 
 
      Participant feels treatment no longer necessary, not 
working 
 
 
 
 
 
 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
 
 
 
 
 
 
     Contraindicated concomitant medication 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical 
condition 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing 
psychiatric or medical condition 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use 
disorder 
 
 
 
 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
 
 
 
 
     Other 
 
 
 
 
 
 
 
 
 
1 Participants who early terminated either oral or injectable study medication. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
59 
Table 20: Summary of Early Medication Terminations by Treatment Arm in Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of early study medication terminations in Stage 11 
N (%) 
 
 
Number of participants who early terminated oral and injectable study medication in Stage 1 
N (%) 
 
 
Number of early oral study medication terminations in Stage 1 
N (%) 
 
 
Reason for early oral study medication termination 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
      Participant feels treatment no longer necessary, not working 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
     Contraindicated concomitant medication 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
     Participant became pregnant 
 
 
 
     Participant withdrew consent/assent 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
     Other 
 
 
 
Number of early injectable study medication terminations 
N (%) 
 
 
Reason for early injectable study medication termination 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
      Participant feels treatment no longer necessary, not working 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
     Contraindicated concomitant medication 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or medical condition 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
     Participant became pregnant 
 
 
 
     Participant withdrew consent/assent 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
     Other 
 
 
 
1 Participants who early terminated either oral study medication before the date of re-randomization or Day 43 for 
non-re-randomized participants, or early terminated injectable study medication and received no injections or only 
injection #1. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
60 
Table 21: Summary of Early Medication Terminations by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of early study medication terminations in Stage 21 
N (%) 
 
 
 
 
Number of participants who early terminated oral and injectable 
study medication in Stage 2 
N (%) 
 
 
 
 
Number of early oral study medication terminations in Stage 2 
N (%) 
 
 
 
 
Reason for early oral study medication termination 
 
 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
 
 
      Participant feels treatment no longer necessary, not working 
 
 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
 
 
     Contraindicated concomitant medication 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical 
condition 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or 
medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
     Other 
 
 
 
 
 
Number of early injectable study medication terminations 
N (%) 
 
 
 
 
Reason for early injectable study medication termination 
 
 
 
 
 
      Participant failed to return to site and unable to contact 
N (%) 
 
 
 
 
      Participant feels treatment no longer necessary, cured 
 
 
 
 
 
      Participant feels treatment no longer necessary, not working 
 
 
 
 
 
      Participant interested in seeking alternate treatment 
 
 
 
 
 
     Contraindicated concomitant medication 
 
 
 
 
 
     Clinical deterioration: New onset of psychiatric or medical 
condition 
 
 
 
 
 
     Clinical deterioration: Worsening of pre-existing psychiatric or 
medical condition 
 
 
 
 
 
     Clinical deterioration: Worsening of substance use disorder 
 
 
 
 
 
     Clinical deterioration: Overdose 
 
 
 
 
 
     Participant became pregnant 
 
 
 
 
 
     Participant withdrew consent/assent 
 
 
 
 
 
     Participant reports intolerable symptoms or side effects 
 
 
 
 
 
     Other 
 
 
 
 
 
1 Participants who early terminated either oral study medication on or after the date of re-randomization or Day 43 for 
non-re-randomized participants, or early terminated injectable study medication after last receiving injection #2 or #3. 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
61 
Table 22: Summary of Treatment Exposure by Site 
 
Tablets1 
Injections2 
Overall 
Treatment 
Exposure2 
Site 
Participants 
Randomized Taken Expected 
% 
Administered Expected 
% 
% 
SC BHSPC 
N 
N 
N 
% 
N 
N 
% 
% 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
Total 
 
 
 
 
 
 
 
 
1 Three tablets per day are expected during the 12-week treatment period. 
2 Four injections are expected during the 12-week treatment period. 
3 Overall treatment exposure percentage is an average of the percentage for tablets and percentage for injections. 
This percentage represents medication adherence across all treatment groups (i.e., Placebo, AMC, 
Placebo/Placebo, placebo/AMC). 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
62 
Table 23: Summary of Treatment Exposure by Site, Stage and Treatment Arm 
 
 
Stage 2 
 
Stage 1 
Re-randomized 
Not Re-randomized 
Site 
Treatment Exposure 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
SC BHSPC 
Tablets1 
Number Taken 
N 
 
 
 
 
 
Number Expected 
N 
 
 
 
 
 
Percent Taken 
% 
 
 
 
 
 
Injections2 
Number Administered 
N 
 
 
 
 
 
Number Expected 
N 
 
 
 
 
 
Percent Administered 
% 
 
 
 
 
 
Overall3 
Treatment Exposure 
% 
 
 
 
 
 
WS CODA, Inc. 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
GNY SURC - Columbia 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
NS Hennepin Healthcare 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
63 
Table 23: Summary of Treatment Exposure by Site, Stage and Treatment Arm 
 
 
Stage 2 
 
Stage 1 
Re-randomized 
Not Re-randomized 
Site 
Treatment Exposure 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
WS SURU - SFDPH 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
TX UCLA CBAM 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
TX UT Health CNRA 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
Total 
Tablets1 
Number Taken 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Taken 
 
 
 
 
 
 
Injections2 
Number Administered 
 
 
 
 
 
 
Number Expected 
 
 
 
 
 
 
Percent Administered 
 
 
 
 
 
 
Overall3 
Treatment Exposure 
 
 
 
 
 
 
1 Three tablets per day are expected during Stage 1 (Weeks 1-6) and Stage 2 (Weeks 7-12). 
2 Two injections are expected in each stage. 
3 Overall treatment exposure percentage is an average of the percentage for tablets and percentage for injections. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
64 
Table 24: Summary of Injections by Site 
Site 
Participants 
Randomized 
Participants 
Who 
Received 
Injection #1 
Participants 
Who 
Received 
Injection #2 
Participants 
Who 
Received 
Injection #3 
Participants 
Who 
Received 
Injection #4 
SC BHSPC 
N 
N (%) 
N (%) 
N (%) 
N (%) 
WS CODA, Inc. 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
Total 
 
 
 
 
 
 
 
 
Table 25: Summary of Injections by Stage and Treatment Arm 
 
Stage 2 
 
Stage 1 
Re-randomized 
Not Re-randomized 
 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Participants who received injection #1 
N (%) 
 
 
 
 
 
Participants who received injection #2 
N (%) 
 
 
 
 
 
Participants who received injection #3 
 
 
N (%) 
 
 
 
Participants who received injection #4 
 
 
N (%) 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
65 
Table 26: Summary of Oral Medication Blood Levels by Stage 
AMC Participants 
Stage 1 
Stage 2 
 
Re-randomized 
Not 
Re-randomized 
 
AMC 
(N=) 
Placebo/ 
AMC 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Bupropion adherence1 
 
 
 
 
    Visit 0401 
n/N (%) 
 
 
 
    Visit 0701 
 
 
 
 
    Visit 1001 
 
 
 
 
    Visit 1201 
 
 
 
 
Hydroxybupropion adherence2 
 
 
 
 
    Visit 0401 
n/N (%) 
 
 
 
    Visit 0701 
 
 
 
 
    Visit 1001 
 
 
 
 
    Visit 1201 
 
 
 
 
1 A participant is considered adherent if bupropion blood level is greater than 0.500 ng/mL. 
2 A participant is considered adherent if hydroxybupropion blood level is greater than 1.00 ng/mL. 
 
 
 
Table 27: Summary of Primary Outcome Availability by Stage and Treatment Arm 
ITT Population 
 
Re-randomized 
 
 
Stage 1 
(Weeks 5-6) 
Stage 2 
(Weeks 11-12) 
 
 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Total 
(N=) 
Number of UDS methamphetamine results collected1 
N 
 
 
 
 
Number of UDS expected2 
N 
 
 
 
 
Percentage of expected UDS methamphetamine 
results collected 
% 
 
 
 
 
1 Number of UDS with methamphetamine results collected in Weeks 5 and 6 in Stage 1 and Weeks 11 and 12 in 
Stage 2. 
2 Two UDS are expected per participant each week. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
 
66 
Table 28: Summary of Primary Outcome Analysis by Stage and Treatment Arm 
ITT Population 
Design Parameters 
Stage 1 
 
Stage 2 
Results 
Random-
ization 
fraction a 
Weight 
w 
N 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Rate of 
Continuation 
into Stage 2 
among 
Placebo Non- 
responders s 
N 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
Wald 
Type 
Test 
Statistic 
Z 
p-value1 
95% Lower 
Confidence 
Limit 
Number 
Needed 
to Treat 
(1/h) 
0.37 
0.43 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
X.XXXX 
X.XXXX 
XX 
1 The p-value was calculated adjusting for interim efficacy analysis. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
67 
Eval Period
Stage 1
Eval Period
Stage 2
0102
0201
0202
0301
0302
0401
0402
0501
0502
0601
0602
0701
0702
0801
0802
0901
0902
1001
1002
1101
1102
1201
1202
Visit Number
0
5
10
15
20
25
30
35
40
Percent Negative UDS
AM C
Placebo
Stage 1 Treatment Arm
AM C
Placebo
Stage 2 Treatment Arm
Figure 7: Methamphetamine Negative UDS Results by Stage and Treatment Arm 
ITT Population 
SAMPLE 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
68 
Table 29: Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm 
ITT Population 
 
 
Stage 1 
Stage 2 
Results 
Method 
Results 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number Re- 
randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
Protocol defined primary outcome 
Primary outcome 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
Imputation of missing UDS 
Missing UDS imputed as negative 
 
 
 
 
 
 
 
 
Missing UDS imputed as positive 
 
 
 
 
 
 
 
 
Complete cases1 
 
 
 
 
 
 
 
 
Using weight w=0.5 
Adjusted primary outcome 
 
 
 
 
 
 
 
 
1 Includes participants with all four UDS collected in the stage. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
69 
Table 30: Summary of Primary Outcome Availability by Stage and Site 
ITT Population 
 
 
Re-randomized 
 
Stage 1 
(Weeks 5-6) 
Stage 2 
(Weeks 11-12) 
Site 
N 
Number of UDS 
methamphetamine 
results collected 
Number of 
UDS 
expected1 
Percentage of 
expected UDS 
methamphetamine 
results collected 
N 
Number of UDS 
methamphetamine 
results collected 
Number of 
UDS 
expected1 
Percentage of 
expected UDS 
methamphetamine 
results collected 
Total 
SC BHSPC 
XX 
XXX 
XXX 
XX.X% 
XX 
XXX 
XXX 
XX.X% 
XX.X% 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
1 Two UDS are expected per participant in Weeks 5, 6, 11, and 12. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
70 
Table 31: Summary of Primary Outcome by Site, Stage, and Treatment Arm 
ITT Population 
 
Stage 1 
Stage 2 
Results1 
Site 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number 
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
p-value 
SC BHSPC 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
1 Results are obtained from the generalized linear mixed effects model. 
 
 
 
Table 32: Summary of Primary Outcome by Sex, Stage, and Treatment Arm 
ITT Population 
 
Stage 1 
Stage 2 
Results1 
Subgroup 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number 
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h p-value 
Male 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
Female 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
 
1 Results are obtained from a generalized linear mixed effects model. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
71 
Table 33: Summary of Primary Outcome by Race, Stage, and Treatment Arm 
ITT Population 
 
Stage 1 
Stage 2 
Results1 
Subgroup 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number  
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h p-value 
Black or African American 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
White 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
 
Other2 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
1 Results are obtained from a generalized linear mixed effects model. 
2 Includes American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, Multiracial, Other, Don’t Know, and Refused to Answer. 
 
 
 
Table 34: Summary of Primary Outcome by Ethnicity, Stage, and Treatment Arm 
ITT Population 
 
Stage 1 
Stage 2 
Results1 
Subgroup 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number  
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
p-value 
Hispanic or Latino 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
Not Hispanic or Latino/Other2 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
 
1 Results are obtained from a generalized linear mixed effects model. 
2 Includes Not Hispanic or Latino, Don’t Know, and Refused to Answer. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
72 
Table 35: Summary of Primary Outcome by Age, Stage, and Treatment Arm 
ITT Population 
 
Stage 1 
Stage 2 
Results1 
Subgroup 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number  
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
p-value 
 40 years 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
X.XXXX 
> 40 years 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
X.XXXX 
X.XXXX 
 
1 Results are obtained from a generalized linear mixed effects model. 
 
 
 
Table 36: Primary Outcome Covariate Adjusted Analysis Results1 
ITT Population 
Model Results 
Treatment 
Effect h 
Standard 
Error of h 
p-value 
Treatment Effect 
X.XXXX 
X.XXXX 
X.XXXX 
Other Covariates in the Model 
  Site 
 
X.XXXX 
  Age at onset of methamphetamine use 
 
X.XXXX 
  Baseline number of methamphetamine use days self-reported 
X.XXXX 
  Baseline IV methamphetamine use self-reported 
X.XXXX 
  Number of DSM-5 criteria met during screening 
X.XXXX 
  Baseline number of days of cigarette or e-cigarette use self-reported 
X.XXXX 
  Baseline Treatment Effectiveness Assessment Score 
X.XXXX 
  Baseline average Visual Analog Craving Scale Score 
X.XXXX 
1 Results are obtained from a generalized linear mixed effects model. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
73 
Table 37: Summary of UDS Availability1 by Stage and Treatment Arm 
Randomized Population 
 
 
Stage 2 
 
Stage 1 
Re-randomized 
Not Re-randomized 
Weeks 
Placebo 
(N=) 
AMC 
(N=) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
1-2 
n/N (%) 
 
 
 
 
 
3-4 
 
 
 
 
 
 
5-62 
 
 
 
 
 
 
7-8 
 
 
 
 
 
 
9-10 
 
 
 
 
 
 
11-122 
 
 
 
 
 
 
133 
 
 
 
 
 
 
163 
 
 
 
 
 
 
1 UDS Availability is presented as number of collected UDS over number of expected UDS. Two  
UDS per participant are expected each week, with the exception of one UDS expected during  
Week 1. A UDS is considered collected if the UDS has a methamphetamine result. 
2 Weeks 5-6 and 11-12 are the primary outcome evaluation period. 
3 Week 13 and Week 16 occur during the Follow-up Period. One UDS per participant per visit is 
expected at Week 13 and at Week 16. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
74 
Table 38: Summary of Methamphetamine Negative 
UDS Results by Treatment Arm in Stage 1 
Randomized Population 
Visit 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
0101 
n/N (%) 
 
 
0102 
 
 
 
0201 
 
 
 
0202 
 
 
 
0301 
 
 
 
0302 
 
 
 
0401 
 
 
 
0402 
 
 
 
0501 
 
 
 
0502 
 
 
 
0601 
 
 
 
0602 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
75 
Table 39: Summary of Methamphetamine Negative 
UDS Results by Treatment Arm in Stage 2 
Randomized Population 
 
Re-randomized 
Not Re-randomized 
 
Visit 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
0701 
n/N (%) 
 
 
 
 
0702 
 
 
 
 
 
0801 
 
 
 
 
 
0802 
 
 
 
 
 
0901 
 
 
 
 
 
0902 
 
 
 
 
 
1001 
 
 
 
 
 
1002 
 
 
 
 
 
1101 
 
 
 
 
 
1102 
 
 
 
 
 
1201 
 
 
 
 
 
1202 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
76 
Table 40: Summary of Methamphetamine Negative 
UDS Results by Treatment Arm in Follow-up Period 
Randomized Population 
 
Re-randomized 
Not Re-randomized 
 
Visit 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
1301 
n/N (%) 
 
 
 
 
1601 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
77 
Table 41: Summary of Primary Outcome Sensitivity Analyses by Stage and Treatment Arm 
Randomized Population 
 
 
Stage 1 
Stage 2 
 
 
 
Re-randomized 
Not Re-randomized 
Method 
Results 
N 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
N 
Placebo/ 
Placebo 
Responder 
Rate q2 
Placebo/ 
AMC 
Responder 
Rate p2 
N 
Placebo 
Responder 
Rate 
AMC 
Responder 
Rate 
Protocol defined primary outcome 
Primary outcome 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
N 
X/X (X.X%) 
X/X (X.X%) 
Imputation of missing UDS 
Missing UDS imputed as negative 
 
 
 
 
 
 
 
 
 
Missing UDS imputed as positive 
 
 
 
 
 
 
 
 
 
Complete cases1 
 
 
 
 
 
 
 
 
 
1 Includes participants with all four UDS collected in the stage. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
78 
Figure 8: Methamphetamine Negative UDS Results by Stage and Treatment Arm 
Randomized Population 
 
 
Eval Period
Stage 1
Eval Period
Stage 2
Baseline
0102
0201
0202
0301
0302
0401
0402
0501
0502
0601
0602
0701
0702
0801
0802
0901
0902
1001
1002
1101
1102
1201
1202
1301
1601
Visit Number
0
5
10
15
20
25
30
35
40
Percent Negative UDS
Placebo/AM C
Placebo/Placebo
AM C
Placebo
Treatment Arm


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
79 
Table 42: Summary of Primary Outcome by Stage and Treatment Arm 
Per Protocol Populations 
 
Stage 1 
Stage 2 
Results 
Per Protocol Population 
Number 
Randomized 
Placebo 
Responder 
Rate q1 
AMC 
Responder 
Rate p1 
Number  
Re-randomized 
Placebo 
Responder 
Rate q2 
AMC 
Responder 
Rate p2 
Treatment 
Effect h 
Standard 
Error of h 
Definition 1 
N 
X.X (X.X%) 
X.X (X.X%) 
N 
X.X (X.X%) 
X.X (X.X%) 
X.XXXX 
X.XXXX 
Definition 2 
N 
X.X (X.X%) 
X.X (X.X%) 
N 
X.X (X.X%) 
X.X (X.X%) 
X.XXXX 
X.XXXX 
Definition 4 
N 
 
X.X (X.X%) 
N 
 
X.X (X.X%) 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
80 
Table 43: Summary of Treatment Emergent Adverse Events by Treatment Arm in 
Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with treatment emergent adverse events in Stage 11 
N (%) 
 
 
Number of treatment emergent adverse events 
N 
 
 
Severity of adverse event 
 
 
 
      Missing 
N (%) 
 
 
      Grade 1 - Mild 
 
 
 
      Grade 2 - Moderate 
 
 
 
      Grade 3 - Severe 
 
 
 
Relationship of treatment emergent adverse event to oral study medication 
 
 
 
      Missing 
N (%) 
 
 
      No 
 
 
 
      Yes 
 
 
 
Relationship of treatment emergent adverse event to injectable study medication 
 
 
 
      Missing 
N (%) 
 
 
      No 
 
 
 
      Yes 
 
 
 
1 Stage 1 AEs include adverse events occurring before the date of re-randomization for re-randomized 
participants and in Weeks 1-6 for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
81 
Table 44: Summary of Treatment Emergent Adverse Events by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with treatment emergent adverse events 
in Stage 21 
N (%) 
 
 
 
 
Number of treatment emergent adverse events 
N 
 
 
 
 
Severity of adverse event 
 
 
 
 
 
      Missing 
N (%) 
 
 
 
 
      Grade 1 - Mild 
 
 
 
 
 
      Grade 2 - Moderate 
 
 
 
 
 
      Grade 3 - Severe 
 
 
 
 
 
Relationship of treatment emergent adverse event to oral study 
medication 
 
 
 
 
 
      No 
N (%) 
 
 
 
 
      Yes 
 
 
 
 
 
Relationship of treatment emergent adverse event to injectable 
study medication 
 
 
 
 
 
      No 
N (%) 
 
 
 
 
      Yes 
 
 
 
 
 
1 Stage 2 AEs include adverse events occurring on or after the date of re-randomization for re-randomized 
participants and in Weeks 7 or greater for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
82 
Table 45: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 1 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Participants with at least one adverse event in Stage 11 
N (%) 
 
 
Gastrointestinal disorders 
N (%) 
 
 
     Nausea 
N (%) 
 
 
     Diarrhoea 
 
 
 
     Constipation 
 
 
 
     Vomiting 
 
 
 
     Dry mouth 
 
 
 
     Toothache 
 
 
 
     Abdominal discomfort 
 
 
 
     Abdominal pain upper 
 
 
 
     Abdominal pain 
 
 
 
     Dyspepsia 
 
 
 
     Chapped lips 
 
 
 
     Breath odour 
 
 
 
     Abdominal pain lower 
 
 
 
     Vomiting projectile 
 
 
 
     Stomatitis 
 
 
 
     Rectal haemorrhage 
 
 
 
     Abdominal distension 
 
 
 
     Pancreatitis 
 
 
 
     Oral disorder 
 
 
 
     Melaena 
 
 
 
     Loose tooth 
 
 
 
     Gastrooesophageal reflux disease 
 
 
 
     Gastrointestinal pain 
 
 
 
     Gastritis 
 
 
 
     Food poisoning 
 
 
 
Psychiatric disorders 
N (%) 
 
 
     Anxiety 
N (%) 
 
 
     Insomnia 
 
 
 
     Irritability 
 
 
 
     Affect lability 
 
 
 
     Abnormal dreams 
 
 
 
     Depression 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
83 
Table 45: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 1 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
     Depressed mood 
 
 
 
     Libido decreased 
 
 
 
Nervous system disorders 
N (%) 
 
 
     Headache 
N (%) 
 
 
     Dizziness 
 
 
 
     Somnolence 
 
 
 
     Lethargy 
 
 
 
     Tremor 
 
 
 
     Dysgeusia 
 
 
 
     Cognitive disorder 
 
 
 
     Hypersomnia 
 
 
 
     Head discomfort 
 
 
 
     Loss of consciousness 
 
 
 
     Hypoaesthesia 
 
 
 
     Disturbance in attention 
 
 
 
     Depressed level of consciousness 
 
 
 
     Syncope 
 
 
 
     Restless legs syndrome 
 
 
 
     Parosmia 
 
 
 
     Nerve compression 
 
 
 
     Migraine 
 
 
 
Infections and infestations 
N (%) 
 
 
     Upper respiratory tract infection 
N (%) 
 
 
     Nasopharyngitis 
 
 
 
     Cellulitis 
 
 
 
     Gonorrhoea 
 
 
 
     Gastroenteritis 
 
 
 
     Urinary tract infection 
 
 
 
     Syphilis 
 
 
 
     Abscess 
 
 
 
     Viral infection 
 
 
 
     Abscess limb 
 
 
 
     Pharyngitis 
 
 
 
     Influenza 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
84 
Table 45: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 1 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
     Gastroenteritis viral 
 
 
 
     Furuncle 
 
 
 
     Ear infection 
 
 
 
     Cystitis 
 
 
 
General disorders and administration site conditions 
N (%) 
 
 
     Fatigue 
N (%) 
 
 
     Pain 
 
 
 
     Feeling jittery 
 
 
 
Injury, poisoning and procedural complications 
N (%) 
 
 
     Laceration 
N (%) 
 
 
     Contusion 
 
 
 
     Skin abrasion 
 
 
 
     Thermal burn 
 
 
 
     Road traffic accident 
 
 
 
     Ligament sprain 
 
 
 
     Injection site pain 
 
 
 
Skin and subcutaneous tissue disorders 
N (%) 
 
 
     Hyperhidrosis 
N (%) 
 
 
     Rash 
 
 
 
     Acne 
 
 
 
     Ecchymosis 
 
 
 
     Eczema 
 
 
 
     Blister 
 
 
 
     Laceration 
 
 
 
     Erythema 
 
 
 
Musculoskeletal and connective tissue disorders 
N (%) 
 
 
     Myalgia 
N (%) 
 
 
     Arthralgia 
 
 
 
     Back pain 
 
 
 
1 Stage 1 AEs include adverse events occurring before the date of re-randomization for re-randomized 
participants and in Weeks 1-6 for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
85 
Table 46: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Participants with at least one adverse event in Stage 21 
N (%) 
 
 
 
 
Infections and infestations 
N (%) 
 
 
 
 
     Nasopharyngitis 
N (%) 
 
 
 
 
     Upper respiratory tract infection 
 
 
 
 
 
     Cellulitis 
 
 
 
 
 
     Paronychia 
 
 
 
 
 
     Oral herpes 
 
 
 
 
 
     Abscess 
 
 
 
 
 
     Viral infection 
 
 
 
 
 
     Pneumonia 
 
 
 
 
 
     Influenza 
 
 
 
 
 
     Herpes virus infection 
 
 
 
 
 
     Gastroenteritis viral 
 
 
 
 
 
     Epididymitis 
 
 
 
 
 
     Chlamydial infection 
 
 
 
 
 
     Breast abscess 
 
 
 
 
 
     Body tinea 
 
 
 
 
 
     Urosepsis 
 
 
 
 
 
     Urinary tract infection 
 
 
 
 
 
     Appendicitis 
 
 
 
 
 
     Tooth abscess 
 
 
 
 
 
     Tinea infection 
 
 
 
 
 
     Syphilis 
 
 
 
 
 
     Pharyngitis 
 
 
 
 
 
     Infectious mononucleosis 
 
 
 
 
 
Gastrointestinal disorders 
N (%) 
 
 
 
 
     Nausea 
N (%) 
 
 
 
 
     Vomiting 
 
 
 
 
 
     Abdominal pain upper 
 
 
 
 
 
     Diarrhoea 
 
 
 
 
 
     Constipation 
 
 
 
 
 
     Dyspepsia 
 
 
 
 
 
     Abdominal discomfort 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
86 
Table 46: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
     Toothache 
 
 
 
 
 
     Gastritis 
 
 
 
 
 
     Flatulence 
 
 
 
 
 
     Dry mouth 
 
 
 
 
 
     Abdominal pain 
 
 
 
 
 
     Glossodynia 
 
 
 
 
 
General disorders and administration site conditions 
N (%) 
 
 
 
 
     Fatigue 
N (%) 
 
 
 
 
     Pain 
 
 
 
 
 
     Influenza like illness 
 
 
 
 
 
     Chest pain 
 
 
 
 
 
     Pyrexia 
 
 
 
 
 
     Asthenia 
 
 
 
 
 
     Injection site swelling 
 
 
 
 
 
     Injection site haematoma 
 
 
 
 
 
     Injection site discomfort 
 
 
 
 
 
     Drug withdrawal syndrome 
 
 
 
 
 
     Vessel puncture site bruise 
 
 
 
 
 
     Peripheral swelling 
 
 
 
 
 
Injury, poisoning and procedural complications 
N (%) 
 
 
 
 
     Laceration 
N (%) 
 
 
 
 
     Joint injury 
 
 
 
 
 
     Arthropod bite 
 
 
 
 
 
     Muscle strain 
 
 
 
 
 
     Eye injury 
 
 
 
 
 
     Contusion 
 
 
 
 
 
     Thermal burn 
 
 
 
 
 
     Road traffic accident 
 
 
 
 
 
     Procedural nausea 
 
 
 
 
 
     Limb injury 
 
 
 
 
 
     Ligament sprain 
 
 
 
 
 
     Skin abrasion 
 
 
 
 
 
Nervous system disorders 
N (%) 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
87 
Table 46: Summary of Treatment Emergent MedDRA Coded Adverse Events 
by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
     Headache 
N (%) 
 
 
 
 
     Dizziness 
 
 
 
 
 
     Dysgeusia 
 
 
 
 
 
     Tremor 
 
 
 
 
 
     Nerve compression 
 
 
 
 
 
     Migraine 
 
 
 
 
 
Psychiatric disorders 
N (%) 
 
 
 
 
     Depression 
N (%) 
 
 
 
 
     Anxiety 
 
 
 
 
 
     Paranoia 
 
 
 
 
 
     Insomnia 
 
 
 
 
 
     Homicidal ideation 
 
 
 
 
 
     Hallucination 
 
 
 
 
 
     Feeling guilty 
 
 
 
 
 
     Disorientation 
 
 
 
 
 
     Anhedonia 
 
 
 
 
 
Musculoskeletal and connective tissue disorders 
N (%) 
 
 
 
 
     Myalgia 
N (%) 
 
 
 
 
     Pain in extremity 
 
 
 
 
 
     Back pain 
 
 
 
 
 
     Musculoskeletal pain 
 
 
 
 
 
     Neck pain 
 
 
 
 
 
     Musculoskeletal chest pain 
 
 
 
 
 
     Muscular weakness 
 
 
 
 
 
     Joint stiffness 
 
 
 
 
 
     Arthralgia 
 
 
 
 
 
     Pain in jaw 
 
 
 
 
 
1 Stage 2 AEs include adverse events occurring on or after the date of re-randomization for re-randomized participants 
and in Weeks 7 or greater for non-re-randomized participants. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
88 
Listing 1: Treatment Emergent Adverse Events by Treatment Arm 
Treatment Arm = Placebo 
 
MedDRA v22.0 
Site 
Participant ID 
Random- 
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
89 
Listing 1: Treatment Emergent Adverse Events by Treatment Arm 
Treatment Arm = Placebo/Placebo 
 
MedDRA v22.0 
Site 
Participant ID 
Random- 
ization 
Date 
Re-ran- 
domi- 
-zation 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associ- 
ated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS 
Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT 
Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
90 
Listing 1: Treatment Emergent Adverse Events by Treatment Arm 
Treatment Arm = Placebo/AMC 
 
MedDRA v22.0 and 
higher 
Site 
Participant ID 
Random- 
ization 
Date 
Re-ran- 
domi- 
zation 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associ- 
ated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS 
Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT 
Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
91 
Listing 1: Treatment Emergent Adverse Events by Treatment Arm 
Treatment Arm = AMC 
 
MedDRA v22.0 and 
higher 
Site 
Participant ID 
Random- 
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related 
-ness 
to Oral 
Study 
Drug 
Related 
-ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
92 
Listing 2: Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment Arm 
Treatment Arm = Placebo 
 
MedDRA v22.0 
Site 
Participant ID 
Random- 
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
93 
Listing 2: Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment Arm 
Treatment Arm = Placebo/Placebo 
 
MedDRA v22.0 
Site 
Participant ID 
Random- 
ization 
Date 
Re-ran- 
domi- 
zation 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associ- 
ated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS 
Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT 
Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
94 
Listing 2: Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment Arm 
Treatment Arm = Placebo/AMC 
 
MedDRA v22.0 
Site 
Participant ID 
Random- 
ization 
Date 
Re-ran- 
domi- 
zation- 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associ- 
ated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS 
Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT 
Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
95 
Listing 2: Non-Treatment Emergent Adverse Events in Randomized Participants by Treatment Arm 
Treatment Arm = AMC 
 
MedDRA v22.0 
Site 
Participant ID 
Random-
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
96 
Listing 3: Non-Treatment Emergent Adverse Events in Screen Failure Participants 
 
MedDRA v22.0 
Site 
Participant ID 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral 
Study 
Drug 
Related- 
ness to 
Injectable 
Study 
Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
SAEs are highlighted in gray. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
97 
Table 47: Summary of Treatment Emergent Serious Adverse Events 
by Treatment Arm in Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with treatment emergent serious adverse events in Stage 11 
N (%) 
 
 
Number of treatment emergent serious adverse events 
N 
 
 
Type of treatment emergent serious adverse event 
 
 
 
      Death 
N (%) 
 
 
      Life-threatening event 
 
 
 
      Inpatient admission to hospital or prolongation of existing hospitalization 
 
 
 
      Persistent or significant incapacity 
 
 
 
      Congenital anomaly or birth defect 
 
 
 
      Important medical event that required intervention to prevent any of the above 
 
 
 
      Seizure 
 
 
 
Relationship of treatment emergent serious adverse event to oral study medication 
 
 
 
      No 
N (%) 
 
 
      Yes 
 
 
 
Relationship of treatment emergent serious adverse event to injectable study medication 
 
 
 
      No 
N (%) 
 
 
      Yes 
 
 
 
1 Stage 1 SAEs include serious adverse events occurring before the date of re-randomization for re-randomized 
participants and in Weeks 1-6 for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
98 
Table 48: Summary of Treatment Emergent Serious Adverse Events by Treatment Arm in 
Stage 2 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with treatment emergent serious adverse 
events in Stage 21 
N (%) 
 
 
 
 
Number of treatment emergent serious adverse events 
N  
 
 
 
 
Type of treatment emergent serious adverse event 
 
 
 
 
 
      Death 
N (%) 
 
 
 
 
      Life-threatening event 
 
 
 
 
 
      Inpatient admission to hospital or prolongation of existing 
hospitalization 
 
 
 
 
 
      Persistent or significant incapacity 
 
 
 
 
 
      Congenital anomaly or birth defect 
 
 
 
 
 
      Important medical event that required intervention to prevent any 
of the above 
 
 
 
 
 
      Seizure 
 
 
 
 
 
Relationship of treatment emergent serious adverse event to oral 
study medication 
 
 
 
 
 
      No 
N (%) 
 
 
 
 
      Yes 
 
 
 
 
 
Relationship of treatment emergent serious adverse event to 
injectable study medication 
 
 
 
 
 
      No 
N (%) 
 
 
 
 
      Yes 
 
 
 
 
 
1 Stage 2 SAEs include serious adverse events occurring on or after the date of re-randomization for re-randomized 
participants and in Weeks 7 or greater for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
99 
Table 49: Summary of Treatment Emergent MedDRA Coded Serious Adverse Events 
by Treatment Arm in Stage 1 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Psychiatric disorders 
N (%) 
 
 
     Suicidal ideation 
N (%) 
 
 
     Suicide attempt 
 
 
 
     Self-injurious behavior 
 
 
 
     Psychotic disorder 
 
 
 
     Depression suicidal 
 
 
 
     Depression 
 
 
 
     Delirium 
 
 
 
     Anxiety 
 
 
 
     Affective disorder 
 
 
 
Injury, poisoning and procedural complications 
N (%) 
 
 
     Overdose 
N (%) 
 
 
     Multiple fractures 
 
 
 
     Burns third degree 
 
 
 
Infections and infestations 
N (%) 
 
 
     Cellulitis 
N (%) 
 
 
     Abscess limb 
 
 
 
     Pneumonia 
 
 
 
     Influenza 
 
 
 
     Groin abscess 
 
 
 
     Gastroenteritis 
 
 
 
     Bronchitis 
 
 
 
Nervous system disorders 
N (%) 
 
 
     Syncope 
N (%) 
 
 
     Seizure 
 
 
 
     Facial paresis 
 
 
 
Respiratory, thoracic and mediastinal disorders 
N (%) 
 
 
     Respiratory depression 
N (%) 
 
 
     Asthma 
 
 
 
Musculoskeletal and connective tissue disorders 
N (%) 
 
 
     Back pain 
N (%) 
 
 
Metabolism and nutrition disorders 
N (%) 
 
 
     Dehydration 
N (%) 
 
 
1 Stage 1 SAEs include serious adverse events occurring before the date of re-randomization for re-randomized 
participants and in Weeks 1-6 for non-re-randomized participants. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
100 
Table 50: Summary of Treatment Emergent MedDRA Coded Serious Adverse Events 
by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
System Organ Class/ 
   Preferred Term (MedDRA v22.0) 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Participants with at least one serious adverse event in Stage 21 
N (%) 
 
 
 
 
Psychiatric disorders 
N (%) 
 
 
 
 
     Suicidal ideation 
N (%) 
 
 
 
 
     Suicide attempt 
 
 
 
 
 
     Self-injurious behavior 
 
 
 
 
 
     Psychotic disorder 
 
 
 
 
 
     Depression suicidal 
 
 
 
 
 
     Depression 
 
 
 
 
 
     Delirium 
 
 
 
 
 
     Anxiety 
 
 
 
 
 
     Affective disorder 
 
 
 
 
 
Injury, poisoning and procedural complications 
N (%) 
 
 
 
 
     Overdose 
N (%) 
 
 
 
 
     Multiple fractures 
 
 
 
 
 
     Burns third degree 
 
 
 
 
 
Infections and infestations 
N (%) 
 
 
 
 
     Cellulitis 
N (%) 
 
 
 
 
     Abscess limb 
 
 
 
 
 
     Pneumonia 
 
 
 
 
 
     Influenza 
 
 
 
 
 
     Groin abscess 
 
 
 
 
 
     Gastroenteritis 
 
 
 
 
 
     Bronchitis 
 
 
 
 
 
Nervous system disorders 
N (%) 
 
 
 
 
     Syncope 
N (%) 
 
 
 
 
     Seizure 
 
 
 
 
 
     Facial paresis 
 
 
 
 
 
Respiratory, thoracic and mediastinal disorders 
N (%) 
 
 
 
 
     Respiratory depression 
N (%) 
 
 
 
 
     Asthma 
 
 
 
 
 
Musculoskeletal and connective tissue disorders 
N (%) 
 
 
 
 
     Back pain 
N (%) 
 
 
 
 
1 Stage 2 AEs include adverse events occurring on or after the date of re-randomization for re-randomized participants 
and in Weeks 7 or greater for non-re-randomized participants. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
101 
Listing 4: Serious Adverse Events by Treatment Arm 
Treatment Arm = Not Randomized 
 
MedDRA v22.0 
Treatment 
Emergent 
Participant ID 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to Oral 
Study Drug 
Related- 
ness to 
Injectable 
Study Drug 
Outcome 
Resolu- 
tion 
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Listing 4: Serious Adverse Events by Treatment Arm 
Treatment Arm = Placebo 
 
MedDRA v22.0 
Treatment 
Emergent 
Participant ID 
Random- 
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to Oral 
Study Drug 
Related- 
ness to 
Injectable 
Study Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
No 
 
 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
102 
Listing 4: Serious Adverse Events by Treatment Arm 
Treatment Arm = Placebo/Placebo 
 
MedDRA v22.0 
Treatment 
Emergent 
Participant ID 
Random- 
ization 
Date 
Re-
random- 
ization 
Date 
Onset 
Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to Oral 
Study Drug 
Related- 
ness to 
Injectable 
Study Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
No 
 
 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Listing 4: Serious Adverse Events by Treatment Arm 
Treatment Arm = Placebo/AMC 
 
MedDRA v22.0 
Treatment 
Emergent 
Participant ID 
Random- 
ization 
Date 
Re-
random- 
ization 
Date 
Onset Date 
AE 
Description 
Severity 
of AE 
Related- 
ness to Oral 
Study Drug 
Related- 
ness to 
Injectable 
Study Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
No 
 
 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
103 
Listing 4: Serious Adverse Events by Treatment Arm 
Treatment Arm = AMC 
 
MedDRA v22.0 
Treatment 
Emergent 
Participant ID 
Random- 
ization 
Date 
Re-
random- 
ization 
Date 
Onset 
date 
AE 
Description 
Severity 
of AE 
Related- 
ness to 
Oral Study 
Drug 
Related- 
ness to 
Injectable 
Study Drug 
Outcome 
Resolu- 
tion  
Date 
AE 
Associated 
With 
Preferred 
Term 
System 
Organ 
Class 
No 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
104 
Table 51: Summary of Injection Site Abnormalities by Treatment Arm in 
Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with an injection site abnormality in Stage 11 
 
 
 
Number of injection site abnormalities reported 
 
 
 
Type of injection site abnormality 
 
 
 
      Pain 
 
 
 
      Tenderness 
 
 
 
      Bruising 
 
 
 
      Induration 
 
 
 
      Erythema (redness) 
 
 
 
      Hematoma 
 
 
 
      Swelling 
 
 
 
      Pruritus 
 
 
 
      Other 
 
 
 
      Cellulitis 
 
 
 
      Warmth 
 
 
 
      Nodule 
 
 
 
      Abscess 
 
 
 
      Sterile abscess 
 
 
 
      Necrosis 
 
 
 
Severity of injection site abnormality 
 
 
 
      Mild 
 
 
 
      Moderate 
 
 
 
      Severe 
 
 
 
1 Abnormalities occurring after injection #1 and injection #2 are reported in Stage 1. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
105 
Table 52: Summary of Injection Site Abnormalities by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-
randomized 
 
 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number of participants with an injection site abnormality in Stage 21 
N (%) 
 
 
 
 
Number of injection site abnormalities reported 
N 
 
 
 
 
Type of injection site abnormality 
 
 
 
 
 
      Pain 
N (%) 
 
 
 
 
      Tenderness 
 
 
 
 
 
      Bruising 
 
 
 
 
 
      Induration 
 
 
 
 
 
      Erythema (redness) 
 
 
 
 
 
      Hematoma 
 
 
 
 
 
      Swelling 
 
 
 
 
 
      Pruritus 
 
 
 
 
 
      Other 
 
 
 
 
 
      Cellulitis 
 
 
 
 
 
      Warmth 
 
 
 
 
 
      Nodule 
 
 
 
 
 
      Abscess 
 
 
 
 
 
      Sterile abscess 
 
 
 
 
 
      Necrosis 
 
 
 
 
 
Severity of injection site abnormality 
 
 
 
 
 
      Mild 
N (%) 
 
 
 
 
      Moderate 
 
 
 
 
 
      Severe 
 
 
 
 
 
1 Abnormalities occurring after injection #3 and injection #4 are reported in Stage 2. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
106 
Listing 5: Injection Site Abnormalities by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant ID 
Randomization 
Date 
Date of 
Injection 
Injection 
Number 
Event 
Start 
Date 
Event 
Resolution 
Date 
Abnormal 
Event 
Severity 
Treatment 
SC BHSPC 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
107 
Listing 5: Injection Site Abnormalities by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Injection 
Injection 
Number 
Event 
Start 
Date 
Event 
Resolution 
Date 
Abnormal 
Event 
Severity 
Treatment 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
108 
Listing 5: Injection Site Abnormalities by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Injection 
Injection 
Number 
Event 
Start 
Date 
Event 
Resolution 
Date 
Abnormal 
Event 
Severity 
Treatment 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
109 
Listing 5: Injection Site Abnormalities by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant ID 
Randomization 
Date 
Date of 
Injection 
Injection 
Number 
Event 
Start 
Date 
Event 
Resolution 
Date 
Abnormal 
Event 
Severity 
Treatment 
SC BHSPC 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
WS SURU – 
SFDPH 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
110 
Listing 6: Elevated LFTs by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant ID 
Randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Aspartate 
Aminotransferase 
(IU/L) 
Alanine 
Aminotransferase 
(IU/L) 
Total 
Bilirubin 
(mg/dL) 
SC BHSPC 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
Lab values above thresholds are highlighted in yellow. This includes ALT values higher than 250 IU/L based on 5x ULN, AST values higher 
than 250 IU/L based on 5x ULN, and total bilirubin values higher than 2.2 mg/dL based on 2x ULN. 
All visits are included for participants who experienced elevated LFTs at any visit. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
111 
Listing 6: Elevated LFTs by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Aspartate 
Aminotransferase 
(IU/L) 
Alanine 
Aminotransferase 
(IU/L) 
Total 
Bilirubin 
(mg/dL) 
SC BHSPC 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
Lab values above thresholds are highlighted in yellow. This includes ALT values higher than 250 IU/L based on 5x ULN, AST values higher than 250 
IU/L based on 5x ULN, and total bilirubin values higher than 2.2 mg/dL based on 2x ULN. 
All visits are included for participants who experienced elevated LFTs at any visit. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
112 
Listing 6: Elevated LFTs by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Aspartate 
Aminotransferase 
(IU/L) 
Alanine 
Aminotransferase 
(IU/L) 
Total 
Bilirubin 
(mg/dL) 
SC BHSPC 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
Lab values above thresholds are highlighted in yellow. This includes ALT values higher than 250 IU/L based on 5x ULN, AST values higher than 250 
IU/L based on 5x ULN, and total bilirubin values higher than 2.2 mg/dL based on 2x ULN. 
All visits are included for participants who experienced elevated LFTs at any visit. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
113 
Listing 6: Elevated LFTs by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant ID 
Randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Aspartate 
Aminotransferase 
(IU/L) 
Alanine 
Aminotransferase 
(IU/L) 
Total 
Bilirubin 
(mg/dL) 
SC BHSPC 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
Lab values above thresholds are highlighted in yellow. This includes ALT values higher than 250 IU/L based on 5x ULN, AST values 
higher than 250 IU/L based on 5x ULN, and total bilirubin values higher than 2.2 mg/dL based on 2x ULN. 
All visits are included for participants who experienced elevated LFTs at any visit. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
114 
Listing 7: Decreased Platelets by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant ID 
Randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Platelets (µL) 
SC BHSPC 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
Platelet values under the threshold of 75x103/µL are highlighted in yellow. 
All visits are included for participants who experienced decreased platelets at any visit. 
 
 
 
Listing 7: Decreased Platelets by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Platelets (µL) 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
Platelet values under the threshold of 75x103/µL are highlighted in yellow. 
All visits are included for participants who experienced decreased platelets at any visit. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
115 
Listing 7: Decreased Platelets by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Platelets (µL) 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
Platelet values under the threshold of 75x103/µL are highlighted in yellow. 
All visits are included for participants who experienced decreased platelets at any visit. 
 
 
 
Listing 7: Decreased Platelets by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant ID 
Randomization 
Date 
Date of 
Lab 
Collection 
Visit 
Platelets (µL) 
SC BHSPC 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
Platelet values under the threshold of 75x103/µL are highlighted in yellow. 
All visits are included for participants who experienced decreased platelets at any visit. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
116 
Table 53: Summary of Elevated QTc Intervals by Treatment Arm 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Participants with elevated QTc intervals ≥ 500 ms at Week 12 
n/N (%) 
 
 
 
 
Baseline QTc interval (ms) 
 
 
 
 
 
N 
 
 
 
 
 
Mean 
 
 
 
 
 
SD 
 
 
 
 
 
Min 
 
 
 
 
 
25th percentile 
 
 
 
 
 
Median  
 
 
 
 
 
75th percentile 
 
 
 
 
 
Max 
 
 
 
 
 
Week 12 QTc interval (ms) 
 
 
 
 
 
N 
 
 
 
 
 
Mean 
 
 
 
 
 
SD 
 
 
 
 
 
Min 
 
 
 
 
 
25th percentile 
 
 
 
 
 
Median 
 
 
 
 
 
75th percentile 
 
 
 
 
 
Max 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
117 
Table 53: Summary of Elevated QTc Intervals by Treatment Arm 
 
Re-randomized 
Not Re-randomized 
 
 
Placebo/ 
Placebo 
(N=) 
Placebo/ 
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Change from baseline QTc interval (ms) at Week 12 
 
 
 
 
 
N 
 
 
 
 
 
Mean 
 
 
 
 
 
SD 
 
 
 
 
 
Min 
 
 
 
 
 
25th percentile 
 
 
 
 
 
Median 
 
 
 
 
 
75th percentile 
 
 
 
 
 
Max 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
118 
Listing 8: AV Block ECG Abnormalities by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant ID 
Randomization 
Date 
Date of 
ECG 
Week 12 Second 
Degree AV Block 
Present 
Week 12 Third 
Degree AV Block 
Present 
SC BHSPC 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
Listing 8: AV Block ECG Abnormalities by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant ID 
Randomization 
Date 
Re-
randomi-
zation Date 
Date of ECG 
Week 12 Second 
Degree AV Block 
Present 
Week 12 Third 
Degree AV Block 
Present 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
119 
Listing 8: AV Block ECG Abnormalities by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant ID 
Randomization 
Date 
Re-
randomi-
zation Date 
Date of ECG 
Week 12 Second 
Degree AV Block 
Present 
Week 12 Third 
Degree AV Block 
Present 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
Listing 8: AV Block ECG Abnormalities by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant ID 
Randomization 
Date 
Date of 
ECG 
Week 12 
Second 
Degree AV 
Block 
Present 
Week 12 Third 
Degree AV 
Block Present 
SC BHSPC 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
120 
Table 54: Summary of Suicide Risk by Treatment Arm in 
Stage 1 
 
Placebo 
(N=) 
AMC 
(N=) 
Total 
(N=) 
Number endorsing on CHRT or PHQ-9 
N (%) 
 
 
Number endorsing on CHRT only 
N (%) 
 
 
Number endorsing on PHQ-9 only 
N (%) 
 
 
Number endorsing on CHRT and PHQ-9 
N (%) 
 
 
Endorsing suicide risk on CHRT is defined as responses of Agree or Strongly 
Agree on any of CHRT questions 13, 14, or 15. Endorsing suicide risk on 
PHQ-9 is defined as responses of Several Days or More than Half the Days or 
Nearly Every Day to PHQ-9 question 9. 
 
 
Table 55: Summary of Suicide Risk by Treatment Arm in Stage 2 
 
Re-randomized 
Not Re-randomized 
 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Number endorsing on CHRT or PHQ-9 
N (%) 
 
 
 
Number endorsing on CHRT only 
N (%) 
 
 
 
Number endorsing on PHQ-9 only 
N (%) 
 
 
 
Number endorsing on CHRT and PHQ-9 
N (%) 
 
 
 
Endorsing suicide risk on CHRT is defined as responses of Agree or Strongly Agree on any 
of CHRT questions 13, 14, or 15. Endorsing suicide risk on PHQ-9 is defined as responses 
of Several Days or More than Half the Days or Nearly Every Day to PHQ-9 question 9. 
 
 
Table 56: Summary of Suicide Risk by Treatment Arm in Follow-up 
Period 
 
Re-randomized 
Not Re-randomized 
 
Placebo/
Placebo 
(N=) 
Placebo/
AMC 
(N=) 
Placebo 
(N=) 
AMC 
(N=) 
Number endorsing on CHRT or PHQ-9 
N (%) 
 
 
 
Number endorsing on CHRT only 
N (%) 
 
 
 
Number endorsing on PHQ-9 only 
N (%) 
 
 
 
Number endorsing on CHRT and PHQ-9 
N (%) 
 
 
 
Endorsing suicide risk on CHRT is defined as responses of Agree or Strongly Agree on any 
of CHRT questions 13, 14, or 15. Endorsing suicide risk on PHQ-9 is defined as responses 
of Several Days or More than Half the Days or Nearly Every Day to PHQ-9 question 9. 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
121 
Listing 9: Suicide Risk by Treatment Arm 
Treatment Arm = Placebo 
 
CHRT 
PHQ-9 
Site 
Participant ID 
Visit 
I Have Been Having 
Thoughts of Killing 
Myself 
I Have Thoughts about 
How I Might Kill 
Myself 
I Have a Plan to Kill 
Myself 
Thoughts You are 
Better Off Dead or 
of Hurting Yourself 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
All visits are included for participants who endorsed suicide risk at any visit on either CHRT or PHQ-9. 
CHRT responses of Agree are highlighted in orange and Strongly Agree are highlighted in red. PHQ-9 responses of Several Days are highlighted in yellow, 
More than Half the Days are highlighted in orange, and Nearly Every Day are highlighted in red. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
122 
Listing 9: Suicide Risk by Treatment Arm 
Treatment Arm = Placebo/Placebo 
 
CHRT 
PHQ-9 
Site 
Participant ID 
Visit 
I Have Been Having 
Thoughts of Killing 
Myself 
I Have Thoughts about 
How I Might Kill 
Myself 
I Have a Plan to Kill 
Myself 
Thoughts You are 
Better Off Dead or 
of Hurting Yourself 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
All visits are included for participants who were endorse suicide risk at any visit on either CHRT or PHQ-9. 
CHRT responses of Agree are highlighted in orange and Strongly Agree are highlighted in red. PHQ-9 responses of Several Days are highlighted in yellow, 
More than Half the Days are highlighted in orange, and Nearly Every Day are highlighted in red. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
123 
Listing 9: Suicide Risk by Treatment Arm 
Treatment Arm = Placebo/AMC 
 
CHRT 
PHQ-9 
Site 
Participant ID 
Visit 
I Have Been Having 
Thoughts of Killing 
Myself 
I Have Thoughts about 
How I Might Kill 
Myself 
I Have a Plan to Kill 
Myself 
Thoughts You are 
Better Off Dead or 
of Hurting Yourself 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
All visits are included for participants who were endorse suicide risk at any visit on either CHRT or PHQ-9. 
CHRT responses of Agree are highlighted in orange and Strongly Agree are highlighted in red. PHQ-9 responses of Several Days are highlighted in yellow, 
More than Half the Days are highlighted in orange, and Nearly Every Day are highlighted in red. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
124 
Listing 9: Suicide Risk by Treatment Arm 
Treatment Arm = AMC 
 
CHRT 
PHQ-9 
Site 
Participant ID 
Visit 
I Have Been Having 
Thoughts of Killing 
Myself 
I Have Thoughts about 
How I Might Kill 
Myself 
I Have a Plan to Kill 
Myself 
Thoughts You are 
Better Off Dead or 
of Hurting Yourself 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
All visits are included for participants who were endorse suicide risk at any visit on either CHRT or PHQ-9. 
CHRT responses of Agree are highlighted in orange and Strongly Agree are highlighted in red. PHQ-9 responses of Several Days are highlighted in yellow, 
More than Half the Days are highlighted in orange, and Nearly Every Day are highlighted in red. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
125 
Listing 10: Pregnancies by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant 
ID 
Date of 
Randomization 
Date Staff 
Aware of 
Pregnancy 
Date 
Pregnancy 
Confirmed 
Date of Last 
Dose of Oral 
Study 
Medication 
Date of Last 
Injectable Study 
Medication 
Pregnancy 
Outcome 
Date of 
Pregnancy 
Outcome 
Normal 
Infant? 
SC BHSPC 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
126 
Listing 10: Pregnancies by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant 
ID 
Date of 
Randomization 
Date of Re-
randomization 
Date Staff 
Aware of 
Pregnancy 
Date 
Pregnancy 
Confirmed 
Date of Last 
Dose of Oral 
Study 
Medication 
Date of Last 
Injectable Study 
Medication 
Pregnancy 
Outcome 
Date of 
Pregnancy 
Outcome 
Normal 
Infant? 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
127 
Listing 10: Pregnancies by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant 
ID 
Date of 
Randomization 
Date of Re-
randomization 
Date Staff 
Aware of 
Pregnancy 
Date 
Pregnancy 
Confirmed 
Date of Last 
Dose of Oral 
Study 
Medication 
Date of Last 
Injectable Study 
Medication 
Pregnancy 
Outcome 
Date of 
Pregnancy 
Outcome 
Normal 
Infant? 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
128 
Listing 10: Pregnancies by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant 
ID 
Date of 
Randomization 
Date Staff 
Aware of 
Pregnancy 
Date 
Pregnancy 
Confirmed 
Date of Last 
Dose of Oral 
Study 
Medication 
Date of Last 
Injectable Study 
Medication 
Pregnancy 
Outcome 
Date of 
Pregnancy 
Outcome 
Normal 
Infant? 
SC BHSPC 
 
 
 
 
 
 
 
 
 
WS CODA, 
Inc. 
 
 
 
 
 
 
 
 
 
GNY SURC - 
Columbia 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
WS SURU - 
SFDPH 
 
 
 
 
 
 
 
 
 
TX UCLA 
CBAM 
 
 
 
 
 
 
 
 
 
TX UT Health 
CNRA 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
129 
Listing 11: Deaths by Treatment Arm 
Treatment Arm = Placebo 
Site 
Participant ID 
Randomization 
Date 
Date of Death 
Description 
MedDRA v22.0 
Preferred 
Term 
System Organ 
Class 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
130 
Listing 11: Deaths by Treatment Arm 
Treatment Arm = Placebo/Placebo 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of Death 
Description 
MedDRA v22.0 
Preferred 
Term 
System 
Organ Class 
SC BHSPC 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
131 
Listing 11: Deaths by Treatment Arm 
Treatment Arm = Placebo/AMC 
Site 
Participant ID 
Randomization 
Date 
Re-
randomization 
Date 
Date of Death 
Description 
MedDRA v22.0 
Preferred 
Term 
System 
Organ Class 
SC BHSPC 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
132 
Listing 11: Deaths by Treatment Arm 
Treatment Arm = AMC 
Site 
Participant ID 
Randomization 
Date 
Date of Death 
Description 
MedDRA v22.0 
Preferred 
Term 
System 
Organ Class 
SC BHSPC 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
Statistical Analysis Plan 
September 13, 2019 
 
 
133 
Table 57: Summary of Data Audits 
Site 
Date of 
Audit 
Total Fields 
Audited1 
Total Data 
Discrepancies2 
Error Rate (%) 
SC BHSPC 
 
 
 
 
 
Subtotal 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
Subtotal 
 
 
 
GNY SURC - Columbia 
 
 
 
 
 
Subtotal 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
Subtotal 
 
 
 
WS SURU - SFDPH 
 
 
 
 
 
Subtotal 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
Subtotal 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
Subtotal 
 
 
 
TX UTSW 
 
 
 
 
 
Subtotal 
 
 
 
Total 
 
 
 
 
1 Fields reviewed at monitoring visit comparing the database to source documentation. 
2 Fields discrepant between database and source documentation. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
134 
Table 58: Summary of Protocol Deviations 
 
SC 
BHSPC 
WS 
CODA, 
Inc. 
GNY 
SURC - 
Columbia 
NS 
Hennepin 
Healthcare 
WS SURU 
- SFDPH 
TX UCLA 
CBAM 
TX UT 
Health 
CNRA 
TX UTSW 
Total 
Total number of protocol deviations 
N 
 
 
 
 
 
 
 
 
Number of participants impacted per protocol deviation 
 
 
 
 
 
 
 
 
 
      None 
N (%) 
 
 
 
 
 
 
 
 
      One 
 
 
 
 
 
 
 
 
 
      More than one 
 
 
 
 
 
 
 
 
 
Total number of major protocol deviations 
N 
 
 
 
 
 
 
 
 
Type of major protocol deviation 
 
 
 
 
 
 
 
 
 
      Safety assessment (e.g. labs, ECG, clinical referral to care) not 
conducted per protocol 
N (%) 
 
 
 
 
 
 
 
 
      Medication dosing errors (protocol specified dose not dispensed) 
 
 
 
 
 
 
 
 
 
Total number of minor protocol deviations 
N 
 
 
 
 
 
 
 
 
Type of minor protocol deviation 
 
 
 
 
 
 
 
 
 
      AE/SAE reported out of protocol specified reporting timeframe 
N (%) 
 
 
 
 
 
 
 
 
      Biologic specimen not collected/processed as per protocol 
 
 
 
 
 
 
 
 
 
      Study assessments not completed/followed as per protocol 
 
 
 
 
 
 
 
 
 
      Study medication management - Other 
 
 
 
 
 
 
 
 
 
      Other study procedures/assessments issues 
 
 
 
 
 
 
 
 
 
      Informed consent/assent process not properly conducted and/or 
documented 
 
 
 
 
 
 
 
 
 
      Other significant deviations issues 
 
 
 
 
 
 
 
 
 
      Protocol required visit/assessment not scheduled or conducted 
 
 
 
 
 
 
 
 
 
      Other informed consent/assent procedures issues 
 
 
 
 
 
 
 
 
 
      AE not reported 
 
 
 
 
 
 
 
 
 
      Other inclusion/exclusion criteria issues 
 
 
 
 
 
 
 
 
 
      Other study devices issues 
 
 
 
 
 
 
 
 
 
      Non IRB approved/outdated/obsolete informed consent/assent 
documents used 
 
 
 
 
 
 
 
 
 
      AE/SAE not elicited, observed and/or documented as per protocol 
 
 
 
 
 
 
 
 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
135 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Informed consent procedures 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
136 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Inclusion/exclusion criteria 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
137 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Laboratory Assessments 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
138 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Study Procedures/Assessments 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
139 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Adverse Event 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
140 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Study Medication Management 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
141 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Study Devices 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray. 
 
 


NIDA CTN-0068: ADAPT-2 
 
Version 3.0 
SAP Table Shells 
September 13, 2019 
 
 
142 
Listing 12: Listing of Protocol Deviations 
Deviation Category = Other Significant Deviations 
Site 
Related 
Participant IDs 
Date of 
Protocol 
Deviation 
Date 
Protocol 
Deviation 
Entered 
in 
eClinical 
Deviation 
Type 
Deviation 
Type (other) 
Deviation 
Description 
Resolution 
Corrective 
Action 
IRB 
Reporting 
Required? 
IRB 
Notified 
at 
Continuing 
Review? 
Expected/ 
Actual 
IRB 
Report 
date 
SC BHSPC 
 
 
 
 
 
 
 
 
 
 
WS CODA, Inc. 
 
 
 
 
 
 
 
 
 
 
GNY SURC – 
Columbia 
 
 
 
 
 
 
 
 
 
 
NS Hennepin 
Healthcare 
 
 
 
 
 
 
 
 
 
 
WS SURU – SFDPH 
 
 
 
 
 
 
 
 
 
 
TX UCLA CBAM 
 
 
 
 
 
 
 
 
 
 
TX UT Health CNRA 
 
 
 
 
 
 
 
 
 
 
TX UTSW 
 
 
 
 
 
 
 
 
 
 
Major PDs are highlighted in gray.